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Echinococcus multilocularis infection in animals 
Panel on Animal Health and Welfare 
Abstract 
The European Food Safety Authority (EFSA) was required to support the European Commission in 
preparing the review of Regulation (EU) No 1152/2011. In Europe, red fox (Vulpes vulpes) is the main 
definitive host of the Echinococcus multilocularis (EM) lifecycle. There is no evidence that any other 
carnivore species can maintain the lifecycle in the absence of red fox, and this makes it to most 
relevant target species for surveillance. Movement of infected definitive hosts is an important 
introduction pathway. The knowledge on the geographical distribution of the environmental factors for 
the persistence of the lifecycle is scarce. In areas where no suitable autochthonous wild canid hosts 
and no highly suitable intermediate hosts are present, e.g. Malta, establishment of the EM cycle is 
considered close to impossible. Such countries do not need to carry out surveillance on domestic dogs 
to substantiate absence of EM in the relevant animal population. Reconsideration of some aspects of 
the current legislation regarding surveillance activities might be relevant; for example the 
identification of epidemiologically relevant units should be independent from political borders. Studies 
to improve the knowledge on epidemiological risk factors should be encouraged to enable risk-based 
sampling. Echinococcus notification should always be done at species level in order to discriminate 
between the more severe alveolar echinococcosis and the cystic echinococcosis. Praziquantel is the 
substance of choice for the treatment of dogs. However, the treatment window should be 
reconsidered to reduce the risk of re-infection: a general rule is to treat as close as possible to entry 
into a non-infected country. There is a lack of standardization of the diagnostic methods between 
laboratories. The diagnostic sensitivity of the tests should be established in accordance to the World 
Organisation for Animal Health (OIE) standards for validation. For the time being, the diagnostic 
sensitivity can be set conservatively to 78%. 
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Summary  
Human alveolar echinococcosis (AE) is caused by the larval stage of the fox tapeworm Echinococcus 
multilocularis. It is amongst one of the most dangerous zoonoses. Naturally the parasite transmits 
between foxes or dogs and small mammals whilst humans are aberrant intermediate hosts. In 
rodents, the larval mass proliferates rapidly by exogenous budding of germinative tissue and produces 
an alveolar-like pattern of microvesicles filled with protoscolices. In humans, the larval mass 
resembles a malignancy in appearance and behavior, because it proliferates indefinitely by exogenous 
budding and invades the surrounding tissues (Moro et al., 2008). Transmission of AE to humans is by 
consumption of parasite eggs which are excreted in the faeces of foxes and dogs. Human infection 
can be through direct contact with the definitive host or indirectly through contamination of food or 
possibly water with parasite eggs (Torgerson et al., 2010). 
The Commission adopted Commission Delegated Regulation (EU) No 1152/2011 of 14 July 2011 
supplementing Regulation (EC) No 998/2003 of the European Parliament and of the Council as 
regards preventive health measures for the control of Echinococcus multilocularis (EM) infection in 
dogs. This was to ensure continuous protection of Finland, Ireland, Malta and the United Kingdom 
which claim to have remained free of EM as a result of applying national rules until 31 December 
2011. The Regulation includes certain obligations for the Member States (MSs) listed under Regulation 
(EU) No 1152/2011 to implement a pathogen-specific surveillance programme aimed at detecting the 
parasite, if present in any part of those MSs, in accordance with certain requirements regarding 
sampling, detection techniques and reporting. On 31 May 2015, Finland, Ireland, Malta and the United 
Kingdom submitted documentation supporting the evidence for the absence of EM for three 
consecutive surveillance periods in accordance with Regulation (EU) No 1152/2011, and EFSA issued 
three scientific assessments of the submitted reports analysing the sampling strategy, the data 
collected and the detection methods used in the surveillance programmes in view of verifying 
compliance with the requirements laid down in Regulation (EU) No 1152/2011. The Regulation also 
provides that the Commission should review it no later than 5 years following the date of its entry into 
force, i.e. by December 2016, in the light of scientific developments regarding EM infection in animals. 
The review shall in particular assess the proportionality and the scientific justification of the preventive 
health measures. In order to meet the aforementioned deadline, updated scientific evidence from 
EFSA is required to support the Commission in preparing the review of Regulation (EU) No 1152/2011. 
In view of the above, and in accordance with Article 29 of Regulation (EC) No 178/2002, the 
Commission asked EFSA: to describe EM infection in animals in the European Union (EU) and adjacent 
countries; to assess the current situation in the EU and adjacent countries regarding the monitoring 
and surveillance programmes of EM infection in definitive and intermediate hosts, the probability of 
detection if EM is introduced into areas where it has never been recorded and the programmes for the 
eradication of EM in wildlife host species; to describe the current situation in the European Union and 
adjacent countries regarding the risk factors associated with human alveolar echinococcosis (AE) and 
the impact of EM infection in animals on public health; to describe the efficacy of available EM drugs 
and the effectiveness of the current species-specific treatment protocols to protect domestic species 
against the parasite and to assess the laboratory techniques for the detection of EM in live and dead 
animals, in terms of sensitivity, specificity, predictive values and practicability (i.e. rapidity, large scale 
use, ease of use). 
With the objective of improving the readability of this scientific opinion, the adjective ‘free’ will be 
used hereinafter to indicate an area or a country ‘where, at present, no findings of the parasite have 
been recorded and / or reported’. Similarly, the term ‘freedom’ was used to indicate ‘absence of 
infection’. 
Until the 1990s, only a ‘core’ area consisting of Eastern France, Southern Germany and parts of 
Switzerland and Austria were known to be endemic. Since 1980, EM-infections in animals have been 
recorded in 17 countries, in Central-Eastern Europe, previously thought to be free. The observed 
prevalence of EM-infected animals as well as the abundance of host species increased in the Baltic 
areas, Denmark, Netherlands, Poland, Romania, Slovakia and Slovenia during the 1990s and have 
continued to increase since. The distribution of EM is not homogeneous, and there are areas of high 
and low prevalence of EM infection, with values ranging from close to 0% (e.g. Denmark, northeast 
Germany, Sweden), to values close to 50% (e.g. part of France, southern Germany, part of 
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Switzerland). These differences in prevalence levels in foxes, among the countries where EM has been 
reported, have been linked most frequently to the use and structure of landscape, which influences 
the species range and abundance of rodents as intermediate hosts and to the microclimatic conditions 
necessary for the transmission and establishment of the parasite. Accessible data indicate that, within 
the Russian Federation, EM-infection in animals and human Alveolar Echinoccosis (AE) are frequent in 
parts of Siberia and the Russian Far East. No scientific literature is available to conclude on the EM 
prevalence in the areas of the Russian Federation adjacent to the Eastern border of neighbouring EU 
MS. 
Due to its high population densities, high susceptibility to EM infection, high worm burden in infected 
animals, and higher infection prevalence compared to other potential definitive hosts, the red fox 
(Vulpes vulpes) is considered to be the main definitive host in temperate parts of Europe, Asia and 
(probably) North America. The prevalence of infected animals in raccoon dog populations in Eastern 
Europe and in Eastern Germany has been shown to reach levels similar to those observed in red 
foxes. Where they occur, raccoon dog (Nyctereutes procyonoides), golden jackal (Canis aureus) and 
grey wolf (Canis lupus) can act as definitive hosts, but there is no evidence that they can maintain the 
lifecycle in the absence of red foxes. 
Regarding domestic carnivores, there is no evidence that dogs and cats can maintain the lifecycle in 
the absence of red foxes. The prevalence of EM in the general dog population is very low. No 
systematic assessment has been done anywhere on the quantitative contribution of dogs to the 
infection of intermediate host populations. Living and working with dogs might be or become relevant 
as potential risk factors for AE in Europe. Cats show low susceptibility to experimental infection. 
However, natural infection of cats has been recorded in several countries. Nevertheless, current 
knowledge suggests that the contribution of cats to the EM lifecycle is low. There are currently no 
evidences to support the inclusion of cats in the scope of the legislation. 
In the EU, various vole species of the genera Microtus, Arvicola, Myodes and Lemmus are confirmed 
as suitable intermediate hosts based on field studies and/or experimental infections. The common 
vole, Microtus arvalis, is the most important intermediate host in areas such as Northeast France 
(Ardennes) and Switzerland, while water voles Arvicola spp. may maintain transmission in Hungary 
and urban areas of Central Europe. Muskrats (Ondatra zibethicus), nutria/coypu (Myocastor coypus) 
and beaver (Castor fiber) are suitable intermediate hosts, but are likely to be infrequent prey for foxes 
due to their large size and habitat specificity. In conclusion, the relative importance of different 
rodents and other small mammal species for maintenance of the lifecycle differs according to 
geographical areas, the type of environment, prevalence of infection and other parameters. This 
extreme variability does not make any of those potential IH particularly suitable for surveillance 
purposes. 
Concerning the probability of introduction, transmission and establishment it can be concluded that 
movement of definitive hosts with a pre-patent or patent infection (i.e. infected domestic and wildlife 
species involved in the E. multilocularis lifecycle) is an important introduction pathway. In principle, 
EM can be introduced also by infected intermediate hosts that carry fertile larval stages 
(metacestodes) or infectious parasitic stages, or by other items, e.g. plants, contaminated with eggs 
into free areas. It is difficult to distinguish introduction of EM from its first detection (i.e. established, 
but not detected) if no adequate surveillance had been in place in areas deemed to be free.  
Based on the model results, which do not represent any particular country as complete data are not 
available at present, the following general conclusions can be drawn: (i) the presence of the border 
compliance checks increases the number of dogs that need to pass the border by 1.75 to 4 times; (ii) 
if no border compliance check is in place for a country adjacent to an endemic area (prevalence in 
foxes equal to 16%) introduction would require 75 to 1200 times more dogs than foxes crossing the 
border. If border compliance checks are in place, the proportion increases (150 to 2550 times more 
dogs than foxes crossing the border); (iii) for a free country adjacent to an area with a very low 
prevalence in foxes (0.001%) the crossborder movement of dogs has a prominent role (1.16 to 2.31 
fewer dogs coming from an endemic area relative to migrating foxes); (iv) the degree of non-
compliance to treatment among dogs that are not checked at the border (because no border checks 
are in place or because the border checks have been evaded) plays a less important role on the 
probability of introduction of EM, compared to other parameters.; (v) despite the implementation of 
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appropriate mitigation measures, it is inevitable that infected dogs enter free countries. However, 
other factors in addition to introduction are important in establishing EM in free countries. 
In fact, for the transmission and establishment of the lifecycle, appropriate definitive and intermediate 
hosts must be present. Environmental factors influence the persistence of the lifecycle; therefore the 
probability of EM becoming established will vary from one area to another. However, the knowledge 
on the potential role of environmental factors for the persistence of the life cycle is scarce. Studies to 
improve the knowledge on the probability of transmission and establishment of new EM introduction 
in free countries should be encouraged. 
In areas where no suitable autochthonous wild canid hosts and no highly suitable intermediate hosts 
are present, e.g. Malta, establishment of the EM cycle is considered close to impossible. Such 
countries do not need to carry out surveillance on domestic dogs to substantiate EM-freedom. The 
option of making the treatment non compulsory anymore for dogs entering such country is a public 
health issue and relates to the risk of humans getting infected by the parasite by means of 
contaminated dog faeces. 
Only the countries listed under Commission Delegated Regulation (EU) No 1152/2011 are obliged to 
implement surveillance activities. The legislation lists, among the obligations for those MS, the need of 
having in place ‘an early detection system for Echinococcus multilocularis infection in host animals’. In 
order to allow early detection of EM infection, a very low design prevalence of e.g. 0.1% is required, 
as it may take many years for EM to reach a prevalence of 1% in the population. However, such a low 
design prevalence may make surveys for early detection impracticable due to the large sample size 
required. In addition, the following critical aspects have been identified: (i) the diagnostic sensitivity of 
the tests used in these EM surveillance programmes is not supported by robust scientific evidence and 
the tests are not validated according to World Organisation for Animal Health (OIE); (ii) obtaining a 
representative sample from host populations is hampered by the impossibility of implementing a 
representative random sample in wildlife and the scarcity of knowledge on the distribution of red fox 
populations at regional level. Reconsideration of some aspects of the current legislation to optimise 
the surveillance activities might be relevant. In detail: (i) the identification of epidemiologically 
relevant units should be independent from the political borders; (ii) for the purpose of demonstrating 
absence of infection, the inclusion of the concept of the Bayesian Probability of Freedom in the 
regulation, may allow a reduction of the sample size. Finally, studies to improve the knowledge on 
epidemiological risk factors, including geographical risk factors, should be encouraged to enable well-
founded risk-based sampling in geographical subpopulations of hosts to improve the detection.  
Aside from the technical aspects of the implementation of the surveillance systems, it has to be 
highlighted that the detection of the parasite is currently not notifiable in non-free MS. Occurrence 
may be reported at genus or species level. However, E. multilocularis and E. granulosus, although 
they belong to the same genus, have different lifecycles and cause completely different pathologies in 
humans. Echinococcus notifications should always be done at species level to enable an understanding 
of the actual trend and geographical distribution of these infections. In fact, considering the spatial 
and temporal heterogeneity in the EM distribution within a country, the results of local or regional 
surveys cannot be extrapolated to a whole country. 
Eradication of EM in the European wildlife could theoretically be achieved by means of baites, at least 
in small areas, where foxes are present, but the intervention needs to be perpetuated to maintain the 
status. In large areas, long term control - but not elimination - of the parasite may be possible by 
baiting. Control by baiting campains requires more knowledge about how and where to control the 
parasite in a cost-efficient way. Increased fox hunting/trapping is not considered to be effective in 
controlling the parasite. 
Concerning human AE, dog ownership, cat ownership, living in a rural area, having a kitchen garden, 
occupation (farming), haymaking in meadows not adjacent to water, going to forests for vocational 
reasons, chewing grass and handling foxes were identified as potential risk factors in Europe. 
Particular Human leukocyte antigen (HLA) types have been found to be protective against AE. 
However, the presumably very long incubation period of the human AE makes the study of risk factors 
extremely difficult which makes the uncertainty on the risk factors considerably high. In addition, the 
true number of cases of AE in Europe is not known mainly because of under-reporting. There has 
been an increase in the number of reported AE cases in new areas, such as Lithuania and Latvia, and 
an increase in the incidence of human AE in endemic countries, such as Austria, France, Poland and 
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Switzerland, which suggests a geographic spread and an increase of this disease/infection in Europe. 
If early detection does not become more effective, the European health system might face costs in 
the order of billions of euros to care for the number of AE patients expected in the next two decades. 
The public health risk associated with human cases of AE is the reason behind the EU regulation to 
control and monitor EM in animal species, it is therefore essential that notification of human AE and 
cystic echinococcosis (CE) cases be made mandatory in all MSs to enable effective and coherent 
monitoring of trends of AE and CE occurrence in humans. A re-evaluation of the case definition for 
‘echinococcosis’ in the current EU decision 2012/506/EU, differentiating alveolar from cystic 
echinococcosis, will be crucial to collect real epidemiological and clinical data to manage and trace 
back these infections. 
Regarding the available drugs for EM, due to its favorable pharmacokinetic properties and activity 
against both immature and mature stages, praziquantel is the substance of choice for the treatment of 
EM in definitive hosts, including travelling or imported dogs. In addition to treatment efficacy, the 
timing of treatment is crucial. Results of model simulations indicate that: (i) the risk of introduction / 
transmission / establishment, expressed as a function of the number of eggs deposited in a free area, 
can be reduced by treating dogs before or after entering the free area where no findings of the 
parasite have been recorded; (ii) treating dogs earlier than 24 hours, before entering a free area, 
allows the risk of reinfection before moving. Therefore, the risk of introduction / transmission / 
establishment is the lowest when treating one day prior to crossing the border; (iii) the shorter the 
visit of a dog living in an endemic area to a free area, the more effective it is to treat the dog before it 
enters this area compared to treating the dog after it has entered; (iv) the shorter the visit of a dog 
living in a free area to an endemic area, the greater is the advantage of delaying treatment until the 
dog has returned to the free area. Reconsideration of the definition of the optimal treatment window 
(presently up to 120 hours before entry), when moving dogs from infected to non-infected countries, 
might be worthwhile to reduce the risk of reinfection. A general rule is to treat as close as possible to 
entry into a free country. 
Different methodologies are available for the detection of EM. The SCT is a post mortem approach at 
necropsy considered as the reference standard for the detection of EM. The lower limit of detection of 
the SCT is high. Usually the worm burden is low and this results in a diagnostic sensitivity of less than 
100%, particularly if used in a period close to the introduction. Furthermore, the SCT is a time 
consuming approach. DNA-based methodologies for the detection of EM genetic material in faeces or 
intestinal contents may have a diagnostic sensitivity comparable to SCT. Intrinsic limitations of DNA-
based methodologies such as inhibitors, costs, small volume of sample to analyse, timing and 
sensitivity were recently overcome. However, lack of standardization of diagnostic methods detecting 
EM probably causes variation in sensitivity and specificity between labs. In addition, studies on the 
diagnostic tests for detection of EM in animals are very heterogenic, which complicates drawing any 
consistent conclusions from them. A study should be undertaken to estimate the probability of each 
relevant test to detect infection, given that the animal is truly infected (according to the definition of 
test sensitivity), using an adequate sample of specimens from endemic areas where the entire range 
of different infection stages and intensities are represented. Such a study should follow the OIE 
Terrestrial Manual, Chapter 1.1.5 (OIE, 2013), and could be coordinated by the EURL for Parasites. 
Until better documentation is available, the diagnostic sensitivity should be set conservatively to the 
lowest value, excluding the lowest 20th percentile, from the ones reported in the scientific literature 
and related to the diagnostic tests implemented by the countries listed in Annex I of the Commission 
Delegated Regulation (EU) No 1152/2011. In this case, the suggested value to be used for future 
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1. Introduction  
 Background and Terms of Reference as provided by the European 1.1.
Commission 
The Commission adopted Commission Delegated Regulation (EU) No 1152/2011 of 14 July 2011 
supplementing Regulation (EC) No 998/2003 of the European Parliament and of the Council as 
regards preventive health measures for the control of Echinococcus multilocularis infection in dogs.1 
This was in order to ensure continuous protection of Finland, Ireland, Malta and the United Kingdom 
that claim to have remained free of the parasite Echinococcus multilocularis (EM) as a result of 
applying national rules until 31 December 2011.  
The Regulation includes certain obligations for these Member States to implement a pathogen-specific 
surveillance programme aimed at detecting the parasite, if present in any part of those Member 
States, in accordance with certain requirements regarding the sampling, the detection techniques and 
the reporting. 
It also provides that the Commission is to review this Regulation no later than five years following the 
date of its entry into force, i.e. by December 2016, in the light of scientific developments regarding 
EM infection in animals and to submit the results of the review to the European Parliament and to the 
Council. The review shall in particular assess the proportionality and the scientific justification of the 
preventive health measures. 
By 31 May 2015, Finland, Ireland, Malta and the United Kingdom will have submitted documentation 
supporting the evidence of the absence of EM for three consecutive surveillance periods in accordance 
with Regulation (EU) No 1152/2011. 
By the same date and in the context of the scientific and technical assistance conferred by the 
Commission to EFSA in May 2012, EFSA will have issued three scientific assessments of the submitted 
reports analysing the sampling strategy, the data collected and the detection methods used in the 
surveillance programmes in view of verifying compliance with the requirements laid down in 
Regulation (EU) No 1152/2011. 
In order to meet the aforementioned deadline, updated scientific evidence from EFSA is required in 
order to support the Commission in preparing the review of Regulation (EU) No 1152/2011. 
1.1.1. Terms of Reference 
In view of the above, and in accordance with Article 29 of Regulation (EC) No 178/2002, the 
Commission asks EFSA: 
1. To describe Echinococcus multilocularis infection in animals in the European Union and 
adjacent countries and in particular: 
a) the geographical distribution and prevalence of Echinococcus multilocularis infection in 
the main infected domestic and wildlife species involved in the Echinococcus 
multilocularis lifecycle; 
b) the importance and role of the different host species in the life cycle of the parasite; 
c) the risk factors for and the probability of introduction and establishment of 
Echinococcus multilocularis in areas where it has never been recorded, through the 
movement of infected domestic and wildlife species involved in the Echinococcus 
multilocularis lifecycle; 
2. To assess the current situation in the European Union and adjacent countries regarding: 
a) the monitoring and surveillance programmes of Echinococcus multilocularis infection in 
definitive and intermediate hosts, and the probability of detection if Echinococcus 
multilocularis is introduced into areas where it is has never been recorded; 
                                                          
1  OJ L 296, 15.11.2011, p. 6. 
2  EFSA and ECDC (European Food Safety Authority and European Centre for Disease Prevention and Control), 2015. The 
European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2013. 
EFSA Journal 2015;13(1):3991, 162 pp. doi:10.2903/j.efsa.2015.3991 
3  The views and opinions of the authors expressed herein do not necessarily state or reflect those of the ECDC. The accuracy of 
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b) the programmes for the eradication of Echinococcus multilocularis in wildlife host 
species; 
3. To describe the current situation in the European Union and adjacent countries regarding: 
a) the risk factors associated with human alveolar echinococcosis; 
b) the impact of Echinococcus multilocularis infection in animals on public health; 
4. To describe the efficacy of available Echinococcus multilocularis drugs and the effectiveness of 
the current species-specific treatment protocols to protect domestic species against the 
parasite; 
5. To assess the laboratory techniques for the detection of Echinococcus multilocularis in live and 
dead animals, in terms of sensitivity, specificity, predictive values and practicability (i.e. 
rapidity, large scale use, ease of use). 
 Interpretation of the Terms of Reference  1.2.
This scientific opinion describes several aspects related to EM infections in animals, in particular in 
Member States (MSs) and in countries sharing a land border with MSs when information is available.  
In order to improve the readability of the present opinion, the term ‘free’ was used to indicate areas 
‘where Echinococcus multilocularis has never been found and/or detected’. Similarly, the term 
‘freedom’ was used to indicate ‘absence of infection’. By no means, for the time being, the absence of 
positive samples provided by the countries listed under Commission Delegated Regulation (EU) No 
1152/2011 can be interpreted as actual complete absence of the parasite. 
The current epidemiological situation of EM in Europe is presented, in particular for red foxes since 
there is a lack of data for the other definitive hosts (DH) and intermediate hosts (IH) species (TOR1a).  
The role of different DH and IH in the life cycle of EM is described to identify the most important 
species to target for monitoring, surveillance and eradication programmes (TOR1b). 
The current knowledge on risk factors for EM introduction, transmission and establishment in free 
areas is described. In addition, a conceptual framework is provided to compare by means of realistic 
scenarios the probability of EM introduction, transmission and establishment via movement of 
domestic animals and foxes (TOR1c). 
The monitoring and surveillance programmes on EM in the European Union and adjacent countries are 
described and the difference between assessing absence of infection and early detection is explained 
(TOR2a). 
A description of programmes for the control and eradication of EM is only provided for foxes, since 
data on other species are scarce (TOR2b). 
A description of reported human alveolar echinococcosis (AE) cases in Europe is provided, although 
the true numbers are not known. The association of risk factors reported in the scientific literature is 
assessed, differentiating those that are relevant, globally or in a particular area (TOR3a).  
An overview of published data on the burden of AE, the economic cost in humans and the economic 
cost in animals is included to give an impression of the impact of EM infections on public health 
(TOR3b). A more detailed economic analysis was considered beyond the scope of this mandate. 
Treatment protocols are mainly determined by the selection of the anthelmintic drug and the timing of 
its administration. Praziquantel is currently the most-used and most effective anthelmintic for the 
treatment of EM infections. The efficacy of praziquantel in dogs is described based on available 
literature and the relative effect of treatment protocols to prevent EM transmission and establishment 
are modelled for dogs from endemic areas visiting free areas (and vice versa). In addition, some 
scenarios are presented to quantify how much the degree of treatment compliance has to increase to 
compensate for the increased probability of EM introduction when expanding the treatment window 
from 1 day to 5 days before a dog enters a free area (TOR4).  
The most frequently used laboratory techniques for the detection of EM are reviewed and guidance is 
provided to substantiate test sensitivity estimates (TOR5). Predictive values of the tests are not 
evaluated, since these are dependent on prevalence, which varies considerably and often is unknown. 
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2. Data and Methodologies  
 Data 2.1.
Eight systematic literature reviews on questions related to the TORs of this mandate were available to 
the working group (Casulli et al., 2015). The European Summary Report (Efsa and ECDC, 2013)2 and 
the data provided by the European Centre for Disease Prevention and Control (ECDC) extracted from 
The European Surveillance System (TESSy)3 were consulted to obtain information on the EM cases in 
animals and alveolar echinococcosis (AE) cases in humans reported until 2013. In addition, EFSA’s 
Scientific Network for Risk Assessment in Animal Health and Welfare has been contacted requesting 
submission of non-published prevalence data from the period 2012–2014, data on local host 
populations, the notification status of EM cases in animals, the number of human AE cases since 2000, 
surveillance activities and data on dog movements (see Appendix E).  
 Methodologies 2.2.
A descriptive summary of the available scientific evidence and uncertainties is provided for all TORs. 
This is based on the systematic literature reviews carried out under the EFSA Grant Project 
GP/EFSA/AHAW/2012/01 (Echinococcus multilocularis infection in animals; Casulli et al., 2015) and on 
review of additional scientific papers (mainly published after the systematic review) and the data 
sources mentioned in section 2.1. 
A conceptual scenario-tree model has been generated to estimate the probabilities of EM introduction, 
transmission and establishment via movement of domestic animals and foxes (TOR1c, see 
Appendix B). Some examples regarding absence of infection assessment have been produced using a 
Bayesian approach (TOR2a) (Appendix D). A deterministic mathematical model has been used to 
calculate the average number of eggs excreted in a country where no findings of the parasite have 
been recorded by a dog exposed in an endemic area and taken into a country where no findings of 
the parasite have been recorded (TOR4, see Appendix F). This model has been used to analyze 
different treatment protocols and changing the treatment timing and considering different types of 
movements of domestic dogs. 
3. Assessment 
 Importance and role of the different host species in the life cycle of 3.1.
the parasite (linked to TOR1b)  
Human alveolar echinococcosis (AE) is caused by the larval stage of the fox tapeworm Echinococcus 
multilocularis. It is amongst the world's most dangerous zoonoses. Naturally the parasite transmits 
between foxes or dogs and small mammals whilst humans are aberrant intermediate hosts (Figure 1). 
In rodents, the larval mass proliferates rapidly by exogenous budding of germinative tissue and 
produces an alveolar-like pattern of microvesicles filled with protoscolices. In humans, the larval mass 
resembles a malignancy in appearance and behavior, because it proliferates indefinitely by exogenous 
budding and invades the surrounding tissues (Moro et al., 2008). Transmission of AE to humans is by 
consumption of parasite eggs which are excreted in the faeces of foxes and, increasingly, dogs. 
Human infection can be through direct contact with the definitive host or indirectly through 
contamination of food or possibly water with parasite eggs (Torgerson et al., 2010). 
                                                          
2  EFSA and ECDC (European Food Safety Authority and European Centre for Disease Prevention and Control), 2015. The 
European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2013. 
EFSA Journal 2015;13(1):3991, 162 pp. doi:10.2903/j.efsa.2015.3991 
3  The views and opinions of the authors expressed herein do not necessarily state or reflect those of the ECDC. The accuracy of 
the authors’ statistical analysis and the findings they report are not the responsibility of ECDC. ECDC is not responsible for 
conclusions or opinions drawn from the data provided. ECDC is not responsible for the correctness of the data and for data 
management, data merging and data collation after provision of the data. ECDC shall not be held liable for improper or 
incorrect use of the data. 
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Source: Torgerson et al., 2013. 
Figure 1:  Echinococcus multilocularis life cycle (Torgerson et al., 2010) 
3.1.1. Definitive hosts 
Definition 
Definitive hosts are animals, which contain the adult (strobilar) stage of the cestode in the small 
intestine after being infected via ingestion of metacestodes from intermediate hosts. Eggs produced 
by the adult worms pass into the environment via faeces and are the infection source for intermediate 
hosts (including accidental hosts like humans). The presence of adult worms is transient 
(approximately one month of prepatency followed by one to several months of patency) and does not 
cause disease in the definitive hosts (Figure 1).  
Wild carnivores 
Red fox: The red fox is the principal DH in temperate parts of Europe, Asia and (probably) North 
America. The assessment of the importance of the red fox is based on its high susceptibility to 
infection with EM, the high worm burden detected in foxes, the (usually) high population densities, 
and the high prevalence of infection with EM compared with other potential DHs (Table 1 and Table 2; 
see also Appendix A, tables A1, A3 and A4). For these reasons, the red fox is considered the primary 
target species for surveillance. There are no areas in Europe where EM has been found in other DHs 
while absent from the sympatrical red fox population. 
Red fox density is highly variable. Even within one country (UK) it can range between one fox per 40 
km² and 30 foxes per km², depending on abundance of food. Social group density may vary between 
0.2–5 families per km² in the suburbs and a single family per 10 km² in barren uplands. Fox density in 
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mountainous rural areas of Switzerland is 3/km², in northern boreal forests and Arctic tundra is 
0.1/km², and in Southern Ontario, Canada is 1/km² (Macdonald and Reynolds, 2008). 
In Sweden, an endemic country adjacent to a MS where no findings of the parasite have been 
recorded, the population density has been estimated in two areas, Grimsö (southern-middle part of 
Sweden, a southern boreal zone) and Revinge (most southern part of Sweden, nemoral zone). At 
Revinge the population density was estimated to be 0.8 foxes/km2. In Grimsö the population density 
was estimated to be between 0.2 and 0.4. Between Grimsö and Revinge, in the boreo-neomoral zone 
which, apart from the most southern and western parts, covers most of south Sweden, the prevalence 
was estimated to be between 0.4 and 0.8 foxes/km2. North of Grimsö, the population density was 
considered to decrease in north-western direction as the zones change from southern boreal, to 
middle boreal, north boreal and alpine zones (H. Wahlström, personal communication based on 
Schantz, 1981 and Lindström, 1982; Doctoral Thesis) 
Dispersal of juvenile foxes starts at approximately 6 months of age. Distance moved is negatively 
correlated with population density, i.e. foxes in sparsely populated areas with low food resources are 
likely to disperse over longer distances. Even in the case of foxes from the same area, dispersal 
distances vary drastically between sexes and among individuals: most do not move far and only few 
disperse over long distances. In a review covering 24 studies from Europe and North America, juvenile 
foxes showed mean dispersal distances of 2.8–43.5 km (males) and 1.8–38.6 km (females), while 
maximum dispersal was 14–346 km (males) and 4–256 km (females) (Trewhella et al., 1988). 
Arctic fox: In Europe, the Arctic fox is only relevant on Svalbard, where it maintains the EM lifecycle 
together with one vole species as intermediate host, and in parts of the tundra region of European 
Russia (Nemetsia), with lemmings and Arctic voles as intermediate hosts (Peklo, 2014). Elsewhere, 
Arctic foxes are reported as DHs in Arctic region of North America and Asia. There are no comparative 
data on susceptibility, but reported prevalence values can be high. (Table A1, Appendix A). 
Other wild canids (raccoon dog, golden jackal, wolf): Where they occur in Europe, these 
species can act as DHs in conjunction with the red fox. There is no evidence that any of these species 
can maintain the lifecycle in the absence of red foxes. Raccoon dogs (Nyctereutes procyonoides) are 
currently only frequent in the eastern part of Europe (from eastern Germany onwards), with 
introductions having been reported from Austria; Belarus; Czech Republic; Estonia; Finland; France; 
Germany; Hungary; Kazakhstan; Latvia; Lithuania; Moldova; Netherlands; Norway; Poland; Romania; 
Slovakia; Sweden; Switzerland; Ukraine (IUCN, 2008). There is only one area (Brandenburg, 
Germany) where prevalence values in red foxes and raccoon dogs have been compared based on 
large sample sizes and where prevalences of the two species were at a similar level (Schwarz et al., 
2011; see Table A4 and Appendix A). Given that this also applies for other areas, raccoon dogs could 
be considered an additional target for surveillance. However, its hibernation and defecation behaviour 
(in ‘latrines’) is considered to render the raccoon dog epidemiologically less important for transmission 
to voles, although it is highly susceptible under laboratory conditions. The Golden Jackal (Canis 
aureus) is widespread in North and north-east Africa, occurring from Senegal on the west coast of 
Africa to Egypt in the east, in a range that includes Morocco, Algeria, and Libya in the north to 
Nigeria, Chad and Tanzania in the south. They also occur in the Arabian Peninsula and have expanded 
their range into Europe, where they have a patchy distribution, being resident in the Balkans and, 
since recent times, in Hungary and south-western Ukraine (IUCN, 2008). There are no data on the 
susceptibility of golden jackals. European wolves have only been found infected in Latvia and Slovakia, 
but data from North America indicate that wolves can be frequent hosts and may play a more 
important part in the lifecycle than previously assumed (Schurer et al., 2014). There are no data on 
susceptibility of wolves, but it is considered to be similar to domestic dogs, which are highly 
susceptible (Table 1 and Table 2; see also Appendix A, Tables A1 and A3). 
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Table 1: Evidence regarding definitive host species for E. multilocularis in Europe (see Appendix A, 
Table A1 for references) 
Host species Type of evidence 
Red fox (Vulpes vulpes) Natural and experimental infection 
Arctic fox (Vulpes lagopus) Natural infection 
Raccoon dog (Nyctereutes procyonoides) Natural and experimental infection 
Wolf (Canis lupus) Natural infection 
Golden jackal (Canis aureus) Natural infection 
Domestic dog (Canis lupus familiaris) Natural and experimental infection 
Wild cat (Felis s. silvestris) Natural infection 
Domestic cat (Felis silvestrus catus) Natural and experimental infection 
Table 2: Current E. multilocularis status of EU MS and adjacent countries  
A: Endemic countries Evidence for presence (recorded host species with number of 
references) 
Austria DH: red fox (6) 
Belarus DH: fox (2) 
IH: voles (1), muskrat (1), coypu (1), other rodents (1), shrews (1) 
Belgium DH: red fox (8) 
IH: voles (1), muskrat (2) 
Bulgaria IH: voles (2) 
Czech Republic DH: red fox (3), dog (1), cat (1) 
IH: voles (1) 
Denmark DH: red fox (3), cat (1) 
Estonia DH: red fox (1), raccoon dog (1) 
France DH: red fox (17), dog (1), cat (2) 
IH: voles (13), muskrat (2), coypu (1), other rodents (2) 
Germany DH: red fox (52), raccoon dog (3), dog (2), cat (5) 
IH: voles (3), muskrat (9), coypu (2) 
Hungary DH: red fox (4), golden jackal (1) 
Italy DH: red fox (5) 
Latvia DH: red fox (1), raccoon dog (1), wolf (1) 
Liechtenstein DH: red fox (1) 
Lithuania DH: red fox (2), raccoon dog (1), dog (1) 
IH: muskrat (1), pig (1) 
Luxembourg DH: red fox (1) 
IH: muskrat (1) 
Netherlands DH: red fox (6), cat (1) 
IH: muskrat (1) 
Norway (Svalbard only) DH: arctic fox (1) 
IH: voles (1) 
Poland DH: red fox (14), raccoon dog (1) 
IH: pig (2), wild boar (1) 
Romania DH: red fox (1) 
IH: voles (1) 
Russia  DH: red fox (1), arctic fox (1) 
IH: lemming (1) 
Slovakia DH: red fox (11), raccoon dog (1), wolf (1), dog (2) 
Slovenia DH: red fox (1) 
IH: Apodemus (1) 
Sweden DH: red fox (2) 
Switzerland DH: red fox (14), dog (2), cat (1) 
IH: voles (10), pig (2) 
Turkey  Numerous human cases, mainly from Eastern Anatolia; old unverifiable 
record from one fox and (probably misdiagnosed) cases in cattle 
Ukraine DH: red fox (2) 
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B: Free countries Evidence for absence (number of references, examined host 
species) 
Finland 5 (red fox, raccoon dog, voles) 
Ireland 4 (red fox) 
Malta 2 (dog) 
Norway (mainland) 8 (red fox) 
United Kingdom 5 (red fox, dog, cat) 
C: Countries with uncertain 
endemicity status 
Reason for uncertainty 
Albania No data 
Bosnia-Herzegovina Old, unverifiable records from cattle (probably misdiagnosed) 
Croatia Border to endemic country (one negative survey of 85 foxes) 
Cyprus Insufficient data (28 dogs tested negative) 
Greece Few unverified human cases 
Iceland No data 
Macedonia (FYR) One human case reported to European Registry (under country ‘Greece’) 
Moldavia Border to endemic countries; old record from Mus musculus 
Montenegro No data 
Portugal No data 
Serbia Border to endemic countries; one negative survey of 1000 foxes); one case 
of infected beaver, probably introduced 
Spain Insufficient data (1969 foxes tested negative) 
Presence in humans is only listed for Turkey (strong, but almost exclusive evidence of presence) and countries of doubtful 
endemicity status, due to uncertainty on the origin of infection.  
DH: definitive hosts, IH: intermediate hosts (see Appendix A, Table A3 for references). 
Domestic carnivores  
Dog, cat: Dogs are highly susceptible in experimental infection-studies, but the prevalence of EM in 
the general dog population is very low (e.g. 0.2% in Germany (Dyachenko et al., 2008)). This is likely 
due to a lower exposure to infectious intermediate hosts (e.g. by feeding on voles) and probably also 
the result of deworming treatments to which domestic dogs are subjectNo systematic assessment has 
considered the quantitative contribution of dogs to the infection of intermediate host populations or 
the effect of differences in infection probability between dogs from different backgrounds (pets, sheep 
dogs, hunting dogs, etc.). Unrestrained dogs exposed to potentially infected rodents were found to be 
frequently infected in Switzerland (8.1% according to Gottstein et al., 2001), and even the rarely 
infected group of pet dogs may contribute considerably to the contamination of the urban and 
suburban environment due to their large numbers compared with red foxes (Deplazes et al., 2011). 
There is no evidence that dogs can maintain the lifecycle in the absence of red foxes. Even though 
their contribution to the lifecycle is limited, human case-control studies suggest that dogs may be an 
important source of infection in humans (Kern et al., 2004 – see also Section 3.7.). In addition, 
infected dogs that are companion animals can potentially reach any free area, e.g. when travelling 
with their owners, and may therefore be important for parasite dispersal (Davidson et al., 2012). Cats 
show a low susceptibility to experimental infection, but there are numerous records of naturally 
infected animals from several countries. Their contribution to the lifecycle is probably small, but 
additional assessment is warranted. (Table A1, Appendix A) 
3.1.2. Intermediate hosts 
Definition 
Intermediate hosts are animals containing the larval (metacestode) stage of the cestode in internal 
organs, usually the liver. Protoscolices forming in the metacestodes develop into adult worms once 
ingested by a definitive host (after preying on the intermediate host). In competent intermediate 
hosts, metacestodes probably continue to grpw for the lifetime of the host (similarly to a tumour), 
eventually leading to the host’s death due to replacement of organ tissue (alveolar echinococcosis). 
The time needed for the metacestode to reach fertility (characterised by the presence of 
protoscolices) is 2 to 3 months in some competent rodent species. After 4 months and later, many 
thousands of protoscolices can be present in metacestodes developing from one or few established 
oncospheres. Some (unsuitable) host species are known to limit the metacestode growth or even kill 
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the metacestodes through immune processes, preventing the development of protoscolices in the 
metacestode, and therefore can not transmit the parasite to a definitive host. Intermediate hosts can 
be infected only through the accidental ingestion of cestode eggs from the environment, not via 
ingestion of metacestodes from other intermediate hosts. 
Competent and epidemiologically relevant intermediate hosts 
Voles: In Europe, various species of the genera Microtus, Arvicola, Myodes and Lemmus are 
confirmed as suitable hosts based on field studies and/or experimental infections. However, the 
relative importance of individual species for the maintenance of the lifecycle, also depends on 
additional parameters such as population densities and predation rate by definitive hosts. There is 
evidence that the common vole, Microtus arvalis, is most important for the parasite in some areas, 
e.g. the Ardennes region of North-Eastern France (Guislain et al., 2008), and the southern limit of the 
parasite in Switzerland coincides with presence and absence of this species (Guerra et al., 2014). In 
other areas, water voles Arvicola spp. may maintain transmission, e.g. in Hungary and in urban areas 
of Central Europe. The transmission role of the aquatic form of the water vole may partly account for 
the association of EM presence with the vicinity of surface water e.g. in Germany and Hungary 
(Staubach et al., 2001; Tolnai et al., 2013) (Table A2, Appendix A). 
Other small mammals: various murid rodents (Mus musculus, Apodemus spp, Rattus norvegicus), 
hares and shrews have been found naturally infected, but these seem to be sporadic events and the 
importance of these rodents appears negligible (probably as a function of partial resistance to the 
parasite and/or low attractiveness as fox prey). Muskrats (Ondatra zibethicus), nutria (Myocastor 
coypus) and beaver (Castor fiber) are suitable hosts, but are likely to be infrequent prey for foxes 
due to their large size and habitat specificity; they may, however, have a role in dispersal of the 
parasite. There are two incidences when beavers intentionally translocated (for re-stocking or re-
introduction) from an endemic area (Southern Germany) to free areas (UK and Serbia) being found 
infected (Barlow et al., 2011; Cirovic et al., 2012). Muskrats, as common animals in wetlands, 
frequently show high prevalences compared to other intermediate hosts, and may have a potential as 
target species in addition to a definitive host species for surveillance in circumstances where carcasses 
are readily available. (Table A2, Appendix A). 
The relative importance of different rodent and other small mammal species for maintenance of the 
lifecycle differs according to geographical areas, the type of environment, and other parameters (e.g. 
species, population densitiy and predation behaviour of DHs). Prevalence in small rodents is highly 
variable on small scales and generally much lower than in DHs (Guislain et al., 2008, Guerra et al., 
2014, Staubach et al., 2001; Tolnai et al., 2013. Large rodents (e.g. muskrats) can show high 
prevalence, but are only present in special environments. This extreme variability does not make any 
of those potential IH particularly suitable for surveillance purposes. 
Accidental or refractory intermediate hosts: 
Ungulates: Wild boar and domestic pigs can be infected but do not develop disease and play no role 
in transmission; calcified, died out lesions (verified by PCR) are frequently seen in the livers of wild 
boar and domestic pigs kept outdoors in highly endemic areas. It is difficult for untrained persons to 
differentiate such lesions from other, more common, lesions, such as ‘white spots’, and therefore 
surveillance of suspected lesions will have to use PCR, which is likely to be too expensive to be applied 
in a monitoring programme. Furthermore, the expected prevalence in these species is very low, in 
particular in domestic pigs kept indoors. For these reasons wild boar and domestic pigs are not 
considered to be a relevant species in a monitoring programme. Extensive liver lesions appearing as 
AE have been reported from domestic ruminants, but, upon molecular examination (PCR), turned out 
to be unusual growth forms of CE (Heath et al., 2005; Adriano Casulli, ISS Rome, personal 
communication, 25 August 2015). Therefore, any finding of AE in such animals needs molecular 
confirmation. Experimental infections of large herbivores were invariably abortive, resulting in small, 
calcified liver lesions (Ohbayashi et al., 1971). (Table A2, Appendix A) 
Zoo animals: A number of unrelated mammal species from outside the parasite’s geographical range 
(e.g. wallaby, hyrax) were found accidentally infected. Interestingly, some non-human primates, both 
monkeys and apes, are highly susceptible to AE (Deplazes et al., 2001), and losses of such animals 
kept in European and Japanese zoos are not infrequent. As no primate species occurs naturally in the 
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range of EM, with the possible exception of Western China, this susceptibility has no consequence for 
transmission. (Table A2, Appendix A) 
Dogs: Lethal hepatic AE in domestic dogs is not uncommon and shows the susceptibility of dogs to 
infection with the metacestode stage of the parasite, in addition to their role as definitive hosts. So 
far, this seems to be a feature of domestic dogs only; no records of AE are known from wild canids 
(e.g. foxes). (Table A2, Appendix A) 
 Geographical distribution and prevalence of Echinococcus 3.2.
multilocularis infection (linked to TOR1a)  
 
Map based on Table 3 in Appendix A.  
Free: MS or AC (Norway) listed in Annex I of Commission Delegated Regulation (EU) No 1152/2011 of 14 July 2011; Uncertain 
endemicity: freedom not documented but no case reported. 
Figure 2:  Echinococcus multilocularis status of EU Member States and adjacent countries  
Since the 1980s, EM has been recorded in animals from 17 countries previously thought to be free 
(Davidson et al., 2012). The endemicity status of these countries is based on animal records. Human 
cases are difficult to interpret because the geographical origin of infection is unknown, and because of 
differences in notification requirements throughout the EU and adjacent countries. Whether these new 
EM records are due to range expansion or reflect an increased surveillance effort will be difficult to 
prove, since there is a general lack of (negative) baseline data from previous periods in many of these 
‘newly endemic’ countries. However, there are convincing data that EM prevalence and abundance of 
host species increased dramatically in some countries during the 1990s and since (Romig et al., 
2006a; Gottstein et al., 2015). Range increase is likely, but it cannot be excluded that the parasite had 
remained undetected due to low prevalence or presence in small transmission foci within the ‘newly 
endemic’ countries, which may have expanded in the wake of population increases of red foxes 
(Davidson et al., 2012). 
In many countries, the distribution of EM is not homogeneous, showing areas with high and low 
prevalence levels (Table 4). These differences in prevalence levels have been linked to various factors, 
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most frequently the use and structure of landscape, which influences species range and abundance of 
rodents as intermediate hosts (Romig et al., 2006b). 
Detailed information on each country with reference to the data sources is available in Table A3 and 
A4 of Appendix A. 
3.2.1. Norway, Sweden and Finland 
EM on the Norwegian arctic island of Svalbard was reported for the first time in 2001 after the 
anthropogenic introduction of a species of vole (Microtus levis) from Eastern Europe during the 
twentieth century (Henttonen et al., 2001). The parasite population using Arctic foxes as definitive 
hosts is not closely related to those on the European mainland (Knapp et al., 2012). EM has not been 
detected in mainland Norway (Wahlström et al., 2011a; 2015a). Furthermore no human cases of AE 
have been reported. Any finding of EM in animals or echinococcosis in humans is notifiable 
(Wahlström et al 2015a). In countries where no findings of the parasite have been recorded it can be 
suspected that the awareness of this disease and therefore also the sensitivity of the surveillance 
system is low. However, in Norway a total of 19 echinococcosis cases, considered to be CE, were 
notified in the period 2006-2013 and seroconversion but no lesions have been reported in two arctic 
fox field researchers from Svalbard, indicating that the surveillance detects cases of echinbococcosis 
(Wahlström et al 2015a). Mainland Norway has never recorded EM findings and was added to the list 
of countries complying with the conditions laid down in Regulation (EU) No 1152/2011 by  Decision of 
the EEA Joint Committee No 103/2012 of 15 June 2012 amending Annex I (Veterinary and 
phytosanitary matters) to the EEA Agreement. 
However, in 2012, the Norwegian Scientific Committee for Food Safety has concluded that it was likely 
that EM would be detected in mainland Norway during the next decade (VKM, 2012). They also 
highlighted that with the current surveillance program it was unlikely that E. multilocularis would be 
detected upon its first introduction. Theoretically, nearly 1,000 foxes could have become infected 
before the first case was detected since the surveillance program was designed to detect a prevalence 
level of <1% in an estimated red fox population size of 70,000–120,000. It was also highlighted that 
the paucity of border control checks is a concern with regard to the risk of importing infected dogs 
from the EU into mainland Norway (Høgåsen et al., 2012). It was considered that there was a 
moderate probability of importing EM with rehomed stray dogs from Eastern Europe. This was further 
highlighted by Hamnes et al. (2013) who found, at examination of a large number of the rehomed 
stray dogs, that they had not been given the correct anthelmintic treatment prior to and post import 
(Wahlström et al 2015b). 
Sweden was considered free until a few years ago (Osterman et al, 2011; Wahlström et al 2011a). 
However, EM since 2011 has been detected in 4 counties in south and central Sweden since 2011 
(Wahlström et al., 2015). Whether this is the result of anthropogenic introduction (e.g. via dogs), or 
the parasite has previously escaped detection due to rare occurrence, is not known.  
There are no reports of EM in animals from Finland despite considerable monitoring efforts 
(Wahlström et al 2011a, 2015a; EFSA, 2015). A risk assessment performed in 2001 (Maijala et al., 
2001) highlighted the importance of preventing introduction of EM , as the conditions for the spread 
of the parasite appear favorable, with both suitable definitive and intermediate hosts. It was 
concluded that there was a considerable risk of introduction with wildlife, but the risk was difficult to 
assess as information about the EM situation in North-Western Russia was lacking. Furthermore, the 
risk of introduction with infected pets was regarded as real. To prevent introduction, deworming of 
imported pets against cestodes was recommended. The control of fox and raccoon dog populations 
was considered as the best means to control EM spread in Finland. However, this was considered very 
difficult to perform (Wahlström et al 2015a). 
The risk of introduction by wild life from Sweden is considered negligible. The reasoning behind this is 
that only a few kilometres of the 555 km long Swedish-Finnish border is a land border, thereby 
interfereing with migration of wild life. Furthermore the closest case of EM in Sweden occurred about 
1,000 km from the Finnish border. Extensive surveillance has been performed in the nothern parts of 
Sweden (bordering Finland) without any finding of EM. 
EM in animals and echinococcosis in humans is notifiable in Finland. During 2000–2014 (until 22 
September), 22 cases of echinococcosis were reported. None of the reported cases was considered 
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autochthonous and most of them were diagnosed as caused by Echinococcus granulosus G1. No AE 
cases have been reported (Wahlström et al, 2015b). 
In conclusion, there is no indication that EM or AE is present in Finland today. The risk of introduction 
by wildlife from Sweden is considered negligible. The risk of introduction by wiild life from Russia is 
considered to be low, however due to lack of surveillance data on wildlife in the Russian area adjacent 
to Finland, this risk is not possible to estimate. However, there is a real risk of introduction by 
imported dogs that are insufficiently dewormed. 
3.2.2. Central area (France to the Baltic States and Poland, Denmark to Italy 
and Romania)  
Until the 1990s, only a ‘core’ area consisting of Eastern France, Southern Germany and parts of 
Switzerland and Austria were known to be endemic. Now the parasite has been shown to occupy most 
– if not all – of Central Europe, in the north from the Normandy region through the Netherlands, 
Denmark and Poland to Estonia, in the south to Southern Switzerland, northern Italy, Hungary and 
Romania, and in the east at least to Western Ukraine and Southern Belarus. Estimated prevalences 
within this region vary: particularly high estimates are reported from the historic ‘core’ area, but also 
from mountainous landscapes ranging from the Ardennes through central Germany into the Czech 
Republic, and in the High Tatra region of Poland and Slovakia. Range extension may have occurred in 
some parts, e.g. in Belgium and the Netherlands (Vervaeke et al., 2006), but a previously undetected 
presence in the presumed ‘new’ areas cannot be excluded. The increase in the prevalence of infected 
animals over time is likely to have taken place in most areas since the 1990s in the wake of growing 
fox populations. Such increases are best documented for Eastern France, parts of Germany, Poland 
and parts of the Baltic States, but are often anecdotal for other areas and are difficult to verify due to 
lack of previous baseline data (Romig et al., 2006a; Davidson et al., 2012; Gottstein et al., 2015). 
There is a clear trend towards the establishment of urban and peri-urban EM transmission in central 
Europe (Deplazes et al., 2004). (Tables A3 and A4, Appendix A) 
3.2.3. Spain/Portugal/France  
There are no records of animal infection or human cases. Only negative data in one fox survey in 
Spain are available (Table A3, Appendix A). Information is also lacking for the neighbouring regions of 
Western and Southern France. 
3.2.4. Italy  
So far, EM has been found consistently only in isolated foci of the northern provinces of Trentino Alto 
Adige, but not yet in regions further south and west. However, the surveys had a limited scope. 
Molecular data indicate that these north Italian foci might be ancient endemic foci rather than an 
introduction from neighbouring highly endemic Tyrol in Austria, which is supported by old records of 
human cases from the area (Casulli et al., 2009). (Tables A3 and A4, Appendix A) 
3.2.5. Balkan Peninsula (former Yugoslavia, Albania, Greece and Bulgaria) 
The most southern recent records of infected foxes come from Slovenia, southern Hungary and 
Central Romania. However, further south in Croatia and Serbia only a few fox surveys have been 
done. These did not identify infected animals. There are convincing reports of metacestodes in 
rodents in Southern Bulgaria. Several older reports of human cases in these countries are difficult to 
assess. Ecological conditions appear favourable for the parasite in many parts of this region, so 
further surveys are warranted. (Tables A3 and A4, Appendix A) 
3.2.6. Eastern Europe (Belarus, Ukraine and Russia) 
As presently confirmed, the endemic area stretches into Western Ukraine and Southern Belarus. 
Whether there is a connection to the endemic parts of Russia is unclear due to lack of surveys in the 
European part of that country. Accessible data indicate that, within the Russian Federation, EM and 
human AE are frequent in parts of Siberia and the Far East (Martynenko et al., 1988; Bessonov, 
2002). There are no records of human AE cases from the north-western parts of European Russia, 
and records from animals are restricted to a highly endemic focus in the tundra zone of the far North 
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(Nenetsia Autonomous Okrug) (Peklo, 2014). It cannot be excluded that the parasite is absent from 
Karelia and the Kola Peninsula, but its presence is highly likely in Kaliningrad (located between high 
endemic areas of Poland and Lithuania) and the region bordering Estonia to the East. Data from 
Northwestern Russia are needed to be able to estimate an introduction probability into Finland (Tables 
A3 and A4, Appendix A) 
 Risk factors for and the probability of introduction, transmission 3.3.
and establishment of E. multilocularis (linked to TOR1c)  
3.3.1. Risk factors 
Risk factors must be known to assess the probability of introduction, transmission and establishment 
of EM in areas where no findings of the parasite have been recorded. They may also serve as the 
basis for the implementation of risk-based surveillance. In fact, very few science-based estimates of 
relative risk values have been reported so far. An example is given by Ziadinov et al. (2008) and 
Antolova et al. (2009). These authors refer to the effect of ‘exposure to intermediate host’ and report 
an odds ratio (OR) of 4.28 for use of dogs for hunting vs. dogs not used for hunting, and an OR = 
0.39 for dogs being tied up at all times vs. being allowed to roam all or some of the time. A total of 50 
EM-positive out of 466 dogs were included in this study (Ziadinov et al., 2008). An OR of 6.36 for 
shepherd-use dogs vs. all other dog categories in the study, an OR of 7.05 for being fed with raw 
viscera of sheep, pigs and occasionally cattle vs. not or unknown feeding of raw viscera, and an OR of 
6.09 for catching rodents vs. not or unknown catching of rodents were identified in another study. All 
of these latter OR-values, however, have very wide confidence intervals due to only 8 EM-positive 
cases out of the 289 dogs in the entire study (Antolova et al., 2009). In addition, a careful evaluation 
of potential confounding factors should be considered. 
Several other potential risk factors are difficult to identify unambiguously due to lack of appropriate 
data or studies, such as the age of infected definitive hosts, climate and climatic changes, geographic 
location, DH population dynamics and their interaction with IH. 
Probability of introduction 
Despite a good theoretical understanding of the ways of introduction of EM into areas where no 
findings of the parasite have been recorded, there are gaps in the knowledge on which in practice are 
the most important infection routes. 
Furthermore, the true disease status of an area is often not known, for example, if surveillance has 
not been carried out or if the results are not available. 
Regarding the compliance with de-worming requirements for dogs before entry into areas where no 
findings of the parasite have been recorded, the available data are basically limited to the UK, where 
border compliance checks are implemented and records of movements/entries are kept (Roberts, 
2015. See also Appendix B). 
The knowledge on the movement of wildlife DH, including red foxes, across borders is scarce (see 
also Section 3.1.1). 
Furthermore, it is unlikely to detect a recent introduction of EM due to its slow spread and resulting 
very low prevalence, see Section 3.4.3. 
In principle, EM can be introduced by moving definitive hosts with a pre-patent or patent infection, 
infected intermediate hosts that carry fertile larval stages (metacestodes) or infectious parasitic 
stages, and plants or other items contaminated with eggs into areas where no findings of the parasite 
have been recorded. Lack of compliance with existing regulations on the treatment of dogs with a 
drug effective against EM before entry of the dog into a country where no findings of the parasite 
have been recorded also represents a potential risk factor for the introduction of EM. 
EM introduction into Svalbard has been reported (Hentonnen et al., 2001; Knapp et al., 2012), but it is 
not clear, if the introduction of the parasite has taken place into other European countries that had 
been definitely free before. In 2011, Sweden first reported the detection of parasite in foxes after 
intensive surveillance had not detected EM in the country for many years (Osterman Lind et al., 
2011). It has been argued by some authors that the parasite was detected in areas, both in Denmark 
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and Sweden, into which the dog nematode Angyostrongylus vasorum has also been introduced, 
presumably by infected dogs. Nevertheless, it cannot be ruled out completely that the parasite had 
been present before at a very low prevalence level in foxes or in small foci and has remained 
undetected for a long period of time despite the surveillance system in place. Most likely, the actual 
prevalence was lower than the target design prevalence of 1% prevalence. In some situations, EM 
was detected by more sensitive surveillance systems (Tackmann et al., 1998; Wahlström et al., 2012). 
Probability of transmission and establishment 
Introduction of the parasite into areas where no findings of the parasite have been recorded is 
necessary, but not sufficient, for the establishment of its life cycle. The latter requires transmission 
from definitive hosts to intermediate hosts and back to definitive hosts to close the life cycle of the 
parasite. Establishment is generally considered to be the ‘Perpetuation, for the foreseeable future, of a 
pest (organism or disease) within an area after entry’. It is obvious that appropriate definitive and 
intermediate hosts must exist to support the life cycle, but the knowledge on the potential role of 
environmental factors for the persistence of the life cycle is scarce. 
Hence, the probability of the infection becoming established will also vary from one area to another. 
In broad terms, it will vary depending on the exposure of intermediate hosts to a contaminated 
environment; the ingestion of infected intermediate hosts (mainly voles) by definitive hosts; and 
survival of the parasite to patent infection in the definitive host. This is determined by the presence of 
intermediate hosts and definitive hosts, geographic and environmental characteristics, presence of 
competitors to reduce likelihood of establishment and the likelihood of repeated introductions. It is 
conceivable that dogs that have eaten potentially infected intermediate hosts (i.e. small mammals) 
have a higher probability of being infected with the parasite as compared to pet dogs that feed on 
canned or other heat-treated food. For an area, where no suitable wild canid hosts and no highly 
suitable intermediate hosts (i.e. voles) exist, such as Malta, transmission and establishment is 
considered not to be possible. Therefore, it is unlikely that a dog resident in such an area, which 
never travelled to an endemic area, or was properly treated before or after leaving an endemic area, 
will be infected, unless there was anthropogenic introduction of infected small mammals on the island, 
as seen with Svalbard in 1999-2000 (Henttonen et al. 2001). 
In a Systematic Review on the risk factors for introduction, transmission and establishment of EM in 
free areas through movements of domestic and wildlife species involved in the EM lifecycle (Casulli et 
al., 2015), the only eligible publication of Stieger et al. (2002) analysed the high prevalence of EM 
reported from foxes in the city of Zurich, Switzerland. This work shows that differences in the 
prevalence, habitats and ecology of definitive and intermediate hosts may influence the risk of 
transmission and establishment of the parasite in urban and peri-urban areas. From a total of 604 
tested putative fox faecal samples, 156 (25.8%) were positive in a copro-antigen enzyme-linked 
immunosorbent assay ELISA with a distinct increase in the proportion of positive samples from the 
urban to the peri-urban zone. Furthermore, samples collected in the border zone had significantly 
more copro-antigen-positive results during winter. The prevalence of the parasite in rodent 
intermediate hosts was 9.1% (81/889) for Arvicola terrestris (with 3.5% of the animals harbouring 
between 14 and 244,400 protoscolices) and 2.4% (2/83) for Clethrionomys glareolus. EM-infected 
A. terrestris was found in 9 of 10 trapping sites in the border zone. The high infection pressure in the 
periphery of urban areas might pose a risk for infection with EM for domestic carnivores as well as for 
urban humans inhabitants. It should be noted, however, that the work was conducted in a 
surrounding area with a high prevalence of EM infection in foxes. Whether or not this is comparable to 
the situation in countries where no findings of the parasite have been recorded, is difficult to assess. 
In addition, these issues were addressed in greater detail in a systematic review of EM infections in 
domestic and wild animals (Otero-Abad and Torgerson, 2013). This review article lists studies that 
assessed potential associations between EM infection in foxes and environmental factors such as 
seasonal and spatial variations of the prevalence, altitude, average annual maximum temperature, 
precipitation, geographic areas and land-use. The authors also extracted studies that identified 
statistically significant determinants of infection of foxes with the parasite such as higher intensity of 
infection in juvenile foxes, at least under high endemic conditions. 
The role of different species as DH or IH is described in Section 3.1.2. Reports exist on the probability 
of introduction of EM by infected dogs or intermediate hosts, but there is no information regarding the 
transmission and establishment of the infection after a given introduction. As a consequence, there 
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are no data in the literature allowing a quantification of the risk for any of the species. In addition, 
there are no studies performed which systematically analysed the risk factors for animals to become 
infected with EM. 
Vegetables, mushrooms, berries, fruit or plants may become contaminated with eggs of EM on the 
ground, e.g. through contact with fecal material of infected definitive hosts. Introduction of the 
parasite into areas where the parasite has never been recorded through raw contaminated food or 
plants and the subsequent establishment of the life cycle is in principle possible. However, there are 
no data in the literature allowing a quantification of the probability and the identification of further 
potential risk factors. 
3.3.2. Conceptual model 
A conceptual model, represented in a scenario tree (Figure 3), has been developed to include and 
describe all potential pathways through which EM can be introduced from an endemic area into a free 
area by wild DH or by dogs. The scenario tree consists of the following nodes:  
x Area: the country / region from where the infected animal originates, characterised by a given 
prevalence; 
x Animal: three different alternatives are included: travelling dogs, foxes and other wild DH 
(racoon dogs, wolves); 
x Infection: the probability that the animal is infected, depending on the lenght of stay in the 
area; 
x Introduction: the probability that the parasite is introduced into the free country 
x Transmission: the probability of the life cycle initiated in the free country; 
x Establishment: probability of perpetuation (for the foreseeable future) of the EM lifecycle 
within an area after entry. It is the final step and cannot be modelled due to the uncertainty 
as expressed in earlier sections, on the factors affecting it. 
For dogs moving to a free country, introduction is conditional on the following nodes:  
x Treatment compliance: if the dog is treated correctly (24-120 hours before entry) 
x Treatment failure: probability that a treatment fails; 
x Probability of re-infection: probability of re-infection after an effective treatment and before 
entry; 
x Border checks: presence of border compliance checks 
x Evading: probability of evading the border compliance checks in place 
The scenario tree shows that there are three pathways whereby a travelling dog may enter a free 
country with different probabilities of being infected depending on the prevalence of the country of 
origin and the time spent in that country. A dog may be not treated, or treatment was not effective 
(due to drug inefficacy or dog vomiting drug soon after ingestion), or the dog is re-infected between 
treatment and entry. Each pathway leads to introduction. A second step is where exposure of 
intermediate hosts and the native definitive hosts are infected in a transmission cycle. The final step 
is establishment, where the life cycle is perpetuated for the foreseeable future in the originally free 
country. 
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The black triangles indicate a stop in the flow. 
Figure 3:  Conceptual model on the probability of introduction, transmission and establishment of 
Echinococcus multilocularis in a free country  
3.3.3. A probabilistic model to quantitatively estimate the probability of 
introduction and establishment 
Based on the conceptual model described in the previous section, a probabilistic model has been 
developed. Provided that all input data are gathered, the model can give a quantitative estimate of 
the probability of introduction and establishment in a free MS.  
The routes of introduction considered in this modelling exercise are the domestic dogs and the red 
foxes. 
The time frame considered is 1 year. 
The probabilistic model is fully described in Appendix B and may allow estimating: 
x The probability of introduction, defined as the probability that at least one infected DH (i.e. 
any DH harbouring at least one live parasite, irrespective of its stage of development) will 
successfully move from an endemic area into a free area. 
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There is information in the scientific literature about the probability of transmission of EM, however 
these data are relevant only for geographical areas that are suitable for the parasite (i.e. suitable for 
the DH, for the IH, for the survival of the eggs, etc.). Therefore, a detailed map of a given area 
reporting that information should be available in order to allow a proper quantitative assessment. 
However, those characteristics can vary at very short distances, which makes it very difficult, if not 
impossible, to draw such maps. Because that information is not available for any area in Europe, the 
quantitative assessment of the probability of establishment, defined as the probability that an 
introduction will lead to perpetuation, for the foreseeable future, of EM within a previously free area, 
was not possible. 
In general, it should be highlighted, that as complete data is not available at present, it is not possible 
for the model results to represent any particular MS. To draw conclusions for individual MSs, data for 
those MSs has to be available and the model must be run separately for each MS. 
For this reason, the model was used to better understand the relationship between the input (the 
parameters in the model) and the output (the probability of introduction) by carrying out a ‘sensitivity 
analysis’ (Saltelli et al., 2008). Three main aspects were investigated: i) the impact of the border 
compliance checks (in place / not in place) and; ii) the impact of the red fox, relative to domestic 
dogs, on the probability of introduction; iii) the impact of the degree of treatment compliance on the 
probability of introduction by dogs. 
3.3.3.1 Parameterisation 
The parameters in the model where estimated based on available scientific literature or official 
national data. When no data were available, expert estimates were used considering that the 
parameterisation is not MS specific. Different extreme scenarios were explored instead, covering the 
range of plausible estimations of the relevant parameters. The 16 explored scenarios are the outcome 
of the combination of four parameters: (i) the prevalence of infection in the dog population of the 
endemic country (0.002 and 0.01); (ii) the prevalence of infection in the fox population of the 
endemic country (0.0001 and 0.16); (iii) the probability of a dog being in compliance with the 
treatment requirements given that it is not checked at the border (because it evades or because the 
border compliance checks are not in place (0.4 and 0.8)); (iv) the reduction factor of the probability of 
being infected, as a function of the time spent in an endemic country (0.16 and 1). Table 3 reports 
the list of the relevant parameters, including the values used and their source. 
The results are reported in the following sections. 
Table 3:  Summary of the parameters used in the modelling exercise 
Notation Short description Values 
(mean if stocastic) 
Source 
𝑵𝒇𝒐𝒙𝒆𝒔 Number of foxes moving into a free 
area 
0 - 50 Independent variable 
𝑵𝒅𝒐𝒈𝒔 Number of dogs moving into a free 
area 
0 – 30,000 Independent variable 
𝝆𝑭𝑶𝑿𝒊  Prevalence of infected foxes in the i
th 
country of origin 
0.0001 T Romig(a) and H 
Wahlström(b), personal 
communication 
0.16 (stochastic) Karamon et al. (2014) 
𝝆𝑫𝑶𝑮𝒊  Prevalence of infected domestic dogs 
in the ith country of origin 
0.002 (stochastic) Dyachenko et al., (2008) 
0.01 (Worst case scenario) 
T Romig(a), personal 
communication 
𝑷𝒆𝒗 Where border compliance checks are in 
place, this is the probability that a dog 
evades the checks.  
0.09 (stocastic) H Roberts(c), personal 
communication 
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Notation Short description Values 
(mean if stocastic) 
Source 
𝑷𝒌𝒆 Given that the dog evaded the border 
compliance check in place (𝑷𝒆𝒗), this is 




H Roberts(c), personal 
communication 
𝑷𝒌𝒏𝒆 Given that the dog did not evade the 
border compliance check in place 
(1 − 𝑷𝒆𝒗), this is the probability that 
this dog is in compliance 
0.99 (stocastic) H Roberts(c), personal 
communication 
𝑷𝒌𝑵𝑩𝑪 Where no compliance checks are in 
place, this is the probability that a dog 
is in compliance. 
0.4 
0.8 
H Wahlström(b), personal 
communication 
𝑷𝒇𝒂𝒊𝒍 Probability that a deworming treatment 
was not effective (not all worms killed) 
0.08 (stocastic) Table A4 
𝑷𝒅𝒂𝒚𝟏 Probability that the treatment has been 
administered within 24 hours before 
the dog enters a free country 
0.2 H Roberts(c), personal 
communication 
𝑷𝒓𝒆𝒊𝒏𝒇 Probability that a dog gets re-infected 
following an effective deworming 
treatment administered between 24 
and 120 hours prior to entry 
0.03 R Bødker(d), personal 
communication  
(section 3.5) 
𝑭𝒊𝒏𝒇 Reduction factor of the probability of 
being infected (𝝆𝑫𝑶𝑮𝒊) as a function of 
the time spent in an endemic country 
0.16  
(2 weeks in an endemic area) 
R Bødker(d), personal 
communication  
(section 3.5) 1  
(living in an endemic area) 
(a): Universität Hohenheim, Parasitology. 
(b): National Veterinary Institute, Sweden, Uppsala. 
(c): International Disease Monitoring and Risk Analysis, APHA, Defra. 
(d): National Veterinary Institute. Section for Epidemiology. Technical University of Denmark. Bülowsvej. 
3.3.4. The probability of introduction of E. multilocularis in free areas: the model 
results 
The model results are shown in Figure 4. The lines in the Trellis plot show the probability of 
introduction dependent on the number of animals (dogs / foxes) moving into the free country. The 
red and the blue lines refer to dogs (border compliance checks in place / no border compliance checks 
in place), while the green lines refer to foxes. The different scenarios are: 
Columns A and B refer to dogs living in a free country, travelling in an endemic country for two weeks 
and then coming back home (Finf=0.16), while columns C and D refer to dogs living in an endemic 
country and then entering a free country (Finf=1). 
Columns A and C consider a low-prevalence fox scenario (𝜌ிை௑೔ = 0.001), while columns B and D 
consider a high-prevalence fox scenario (worst case, 𝜌ிை௑೔ = 0.16). 
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X-axis: number of dogs/foxes; Y-axis: probability of introduction. Red line: dogs & border checks in place. Blue line: dogs & no border chacks in place. Green line: foxes. The black x-axis in each 
small plot indicates the number of dogs (blue and red lines). The green x-axis at the bottom of the figure refers to foxes (green line). Dashed lines=95% confidence bounds (where relevant). 




























www.efsa.europa.eu/efsajournal 27 EFSA Journal 2015;13(15):4373 
 
Where no border compliance checks are in place (blue line), two scenarios of compliance (𝑷𝒌𝑵𝑩𝑪 and 
𝑷𝒌𝑬𝑽) are considered: rows 1 and 2 refer to a probability of compliance equal to 40%, while rows 3 
and 4 refer to 80%. 
Rows 1 and 3 consider a low-prevalence dog scenario (𝜌஽ைீ = 0.002), while rows 2 and 4 consider a 
high-prevalence dog scenario (worst case; 𝜌஽ைீ = 0.01). 
The presence of border compliance checks always reduces the probability of introduction (Figure 4; 
comparison between red and blue line for all 16 scenarios). 
The number of animals required to introduce the parasite with a certain probability is always lower for 
foxes compared to dogs. The only exceptions are when the prevalence in foxes is very low and the 
moving dogs are resident in the endemic area (column C). For the particular probability of at least 
75% (value arbitrary chosen) the exact number of animals are read from Figure 4 and reported in 
Appendix B, Table B11. 
In the following, the impact of the parameters of the model on the probability of introduction is 
explored. This is achieved by comparing alternative scenarios in terms of number of animals that have 
to move into a free country in order to reach at least, e.g., 75% probability of introduction: 
x When border compliance checks are in place, the number of domestic dogs that need to 
be moved into the the free country is 1.75 to 4 times higher. 
x For a country adjacent to an endemic area (prevalence of foxes equal to 16%) 
introduction would require 75 to 1200 times more dogs moved, compared to foxes, in case 
no border compliance check is in place. While 150 to 2550 times more dogs moved are 
required, compared to foxes, in case border compliance checks are in place,  
x For a free country adjacent to an area with a very low prevalence in foxes (0.001%) 
the moving dogs have a prominent role (1.16 to 2.31 more foxes required, compared to 
dogs) only if they are all resident in an endemic area. 
x The degree of compliance in dogs that are not checked for compliance (because no 
border checks are in place or because they evaded) plays a less important role on the 
probability of introduction of EM, compared to other parameters. An increase from 40% to 
80% of the degree of compliance requires 1 to 1.5 more dogs to be moved, if the free 
country has border checks in place. The number of moving dogs is 1 to 2 times higher if the 
free country has no border checks in place. 
Finally, it has to be highlighted that despite the implementation of appropriate mitigation measures, it 
is inevitable that infected dogs enter free countries. However, other factors in addition to introduction 
are important in establishing EM in free countries. 
3.3.5. Probability of transmission and establishment in light of the model results 
The model results, supporting previous reports, show that introduction will take place in spite of 
existing barriers with a probability close to 100%. This outcome appears to be inconsistent with the 
field observation, that e.g. the UK and Ireland have not detected EM yet in spite of the large number 
of dogs arriving each year and the number of samples collected each year to fulfil the relevant 
legislation. It is, however, important to take account of the fact that transmission and establishment 
are prerequisites to detection, since the introductions of EM by dogs in and by themselves might not 
be detectable in the fox population. The latter yields the tested samples, and the dog-borne infections 
may not be able to spread to the foxes, e.g. due to environmental, geographical or demographic 
barriers in the transmission cycles, barriers which are poorly recognized and understood. It should be 
realized, however, that often in countries with high-risk EM-areas, other adjacent areas are found to 
have low prevalence for unknown reasons (see Table A4). 
The hypothesised environmental effects on the transmission and establishment may also contribute to 
the apparent gradient of EM prevalence within Europe between central and northern countries. The 
low-risk areas (Sweden) borders the yet free areas of Norway and Finland, so the prevailing factors 
may not be conducive to EM spread. 
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 Monitoring and surveillance programmes of E. multilocularis 3.4.
infection in EU and adjacent countries(linked to TOR2a)  
3.4.1. Mandatory surveillance for EM in countries where no findings of the 
parasite have been recorded 
Four EU MS claiming freedom from EM currently implement a surveillance programme in accordance 
with Commission Delegated Regulation (EU) No 1152/2011 on preventive health measures for the 
control of EM infection in dogs. These are the whole territories of Finland, Ireland, Malta and the UK 
(Part A of Annex I). One EEA State, mainland Norway (Svalbard excluded), has also claimed freedom 
from EM and implements a surveillance programme in line with Regulation (EU) No 1152/2011.4 No 
country or area at present has taken advantage of the use of Part B of Annex I, thereto allowing 
countries with a very low prevalence of disease/ infection with an eradication programme to continue 
to require pre-entry treatment of dogs for a limited time period of five years. Indeed, there are no 
eradication programmes for EM in any EU Member State or other affected country. For those Member 
States claiming freedom from EM (EC 1152/2011), EM infection in animals is compulsorily notifiable 
under national law. 
Annex II to Regulation (EU) No 1152/2011 stipulates the requirements for the pathogen-specific 
surveillance programmes in order for the Member States to be maintained on the list set up in Part A 
of Annex I to that Regulation. The programme shall use appropriate sampling, either risk-based or 
representative, that ensures detection of EM if present in any part of the Member State at the design 
prevalence of not more than 1% at confidence level of at least 95%, using ongoing collection of 
samples from definitive hosts during 12-month surveillance periods. 
EFSA has developed a scientific report and a technical report in 2012 (EFSA, 2012a,b) aiming at 
defining the principles and procedures established therein. Those principles have been applied in the 
assessment of each of the national surveillance reports submitted to the Commission for annual 
reporting.  
Firstly, the quality of the surveillance reports of the four Member States and Norway is assessed by 
checking the description of the surveillance system for completeness against the relevant elements. 
For each relevant element, data are provided in the surveillance report (See Tables 4 and 5). 
Secondly, the raw data on individual samples submitted by the five countries via the EFSA Data 
Collection Framework (DCF) are analysed. For the purpose, the software R5 is used to compute 
descriptive statistics. In the context of EM surveillance, the epidemiological unit is defined as the 
individual definitive host animal.  
In the context of the scientific and technical assistance conferred to EFSA by the Commission in May 
2012 and by the EFTA Surveillance Authority in 2014, the programmes for the four MSs and Norway 
are reviewed by EFSA on an annual basis. The outcomes of this review (‘Assessment of Echinococcus 
multilocularis surveillance reports submitted yearly in the context of Commission Regulation (EU) No 
1152/2011) are published each year in October by EFSA (EFSA 2013, 2014, 2015a and 2015b). In 
these five countries, no positive case of EM has been detected by the surveillance programmes in the 
period 2012–2014. However, the required design prevalence of 1% with 95% confidence was not 
achieved by the surveillance programmes of Norway (in 2013) and Malta (in 2014) due to insufficient 
sample size.  
The current EM surveillance programme is output-based, providing flexibility about the level of 
sampling required, the use of risk-based or representative strategies and the combination of tests (see 
Section 3.9) which can be used to achieve the required confidence.6 However, there is a lack of 
specific data to obtain sensitivity estimates at country level of the diagnostic tests (see Section 3.9), 
                                                          
4  Decision of the EEA Joint Committee No 103/2012 of 15 June 2012. 
5  R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. URL: http://www.R-project.org/ 
6  Annex II of Commission Delegated Regulation 1152/2011 
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which means that comparing results between countries, between species, or from one year to the 
next when different tests are used, is difficult. 
Other sampling issues exist around the host characteristics and the timing of the sampling. The 
objective is to obtain a representative sample, but in practice, the final sample collected by the 
countries, may be biased by several factors. As an example, hunted and trapped animals make up 
convenience samples, which may not be considered representative samples. Hunting is often carried 
out in areas where the animals are considered pests and therefore the animals are selected and may 
not compose a representative sample. For welfare reasons there is a moratorium in most countries on 
hunting at certain times of the year, so the samples are not evenly spread throughout the year. Young 
animals may harbour higher parasite burdens than adults (although there is little or no evidence of 
acquired immunity (Millner-Gulland et al, 2004)), but the age of the animals when tested is not 
known/recorded. Estimates of the population size for each country use different methodology or old 
estimates, so these values should be taken with caution.  
The reason for the temporal distribution of sampling was the aim to avoid culling adult female foxes 
with fox cubs dependant on their dam fox for food. It is reported that collection of samples during the 
winter months only would not adversely affect the sensitivity of the survey, based on a study from an 
endemic urban area in Switzerland, which found a greater prevalence of E. multilocularis in foxes in 
winter months (Hofer et al., 2000). The impact of the sampling distribution over time on the 
interpretation of the outcome has been assessed (EFSA, 2013), suggesting that concentrating the 
samples in the second half of the sampling period, in a Freedom from Disease framework, could be 
more effective when a quantitative evaluation has not been performed on this subject. 
Table 4: List of the parameters extracted from the raw data submitted by the Member States via 
the Data Collection Framework 
 
  
 Parameter Description 
1 Theoretical Sampling 
period 
The twelve-months sampling period. It may go from January to December, but 
this is not a restriction: the reporting period can include twelve months over 2 
years. 
2 Actual Sampling 
Period 
Number of days from the first sampling collection date to the last sample date 
within the theoretical sampling period 
3 Sampling activity 
over time 
Number of samples collected each month within the theoretical sampling 
period 
4 Number of samples Total number of samples collected during the theoretical sampling period 
5 Number of test 
results 
Total number of test results. If the number of test results is equal to the 
number of samples, none of the latter required further investigations (i.e. were 
negative at the first test).  
6 Laboratory test 
completion 
Comparison between the year when the samples are collected and the year 
when the test was completed 
7 Host Target population size (N); additional information on the host species 
8 Sampling Strategy 
and Design 
As reported (e.g. representative sample – risk based sample) 
9 Sampling point Activity adopted for the sample collection (e.g. hunting, veterinary activity, …) 
10 Sampling Area  Number of NUTS 3 regions covered by the sampling, number of samples per 
NUTS 3 region, number of samples per 1000 Km2 
11 ASe Area Sensitivity: level of confidence when stating that the actual prevalence is 
below the threshold foreseen in the relevant legislation (0.01). The area 
sensitivity was calculated using the RiBESS tool (EFSA, 2012b) 
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Table 5: Summary of current Echinococcus multilocularis surveillance in EU Member States and 
Norway under Commission Regulation (EU) No 1152/2011 (see also Appendix D) 
Country Single 
Epidemiological unit 
Estimates of the definitive 
host population sampled 
Diagnostic test used Risk 
Based 
Finland Yes Red Fox (150,000) and 
Raccoon Dog (230,000) 
SCT and MC-PCR  
(Isaksson et al., 2014) 
No 
Ireland Yes Red Fox (150,000) SCT No 
Malta Yes Domestic Dog [hunting 
(10,000), stray (2,000), rural 
(4,500)] 
Sieving/Flotation followed 
by Copro-DNA detection 
with PCR 
Yes 
Norway(a) Yes Red Fox (70,000) MC-PCR  No 
UK No – two geographical 
units 
Red Fox in GB (250,000) Copro-DNA detection with 
PCR (GB) 
No 
Red Fox in NI (14,000) SCT (NI) 
(a): Mainland. 
At present, the sampling strategy does not take account of results from previous surveillance activities 
(i.e. the prior probability of infection absence); rather each year is treated independently. This differs 
from the common epidemiological concept of ‘documenting freedom from disease’, which makes use 
of accumulating negative test results over a period of several years, while discounting the weight of 
the evidence by correcting for an estimated annual probability of introduction (Martin et al. 2007). 
x In Finland, two definitive wild host species are sampled, the red fox and the raccoon dog. The 
red fox has a higher population density in the southwest, while the raccoon dog has a higher 
density in the Southeast (particularly along the Russian border). 
x On the British Isles the red fox is the only wild DH. The UK is split into two epidemiologically 
and geographically separate areas (Northern Ireland and Great Britain). The Republic of 
Ireland is considered to be a separate epidemiological area. However, the Republic of Ireland 
and Northern Ireland share a land border, which does not prevent fox migration from one 
area to the other.  
x Although Malta reports risk-based surveillance, the weights used for the risk factors have not 
been documented nor validated. Science-based estimates of relative risks, which would 
support implementing risk-based surveillance, have not been reported so far.  
x The domestic dog is reported as the only canid present in Malta, where there are no wild 
canid host species. The most suitable intermediate host species (arvicolid rodents) are not 
reported (Savona-Ventura, 2001). 
x Norway has several definitive wild host species: red foxes, wolves, arctic foxes and raccoon 
dogs. The current legislation considers the mainland of Norway, hence, excluding Svalbard 
where EM has been detected in the Arctic fox and the sibling vole (Fuglei et al., 2008). 
3.4.2. Surveillance and monitoring in EU countries where findings of the 
parasite have been recorded 
The detection of Echinococcus spp. in animals is notifiable in some MS, but there is frequently no 
requirement for notification of human cases (Table E1, Appendix E). There is no EU requirement for 
the monitoring or surveillance of EM in countries where findings have been reported in the EU. Certain 
countries have been carrying out targeted surveillance to answer specific issues such as geographic 
expansion, effectiveness of control strategies, changes in pathogenicity. For examples, see 
Appendix D. 
Notification of cases is important in order to verify whether EM is present in a country where findings 
of the parasite have been recorded and if so, in which host species. However, infection with EM in 
animals being asymptomatic, official statistics have a limited use to estimate prevalences as the data 
collected will most likely be biased and infection will be under-reported. To ensure a consistent 
prevalence estimate, repeated, randomised surveys on the healthy DH population have to be done. 
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There is considerable spatial and temporal heterogeneity in EM distribution within a country and 
across Europe (see Section 3.2). This is compounded by the nature of infection, such as the variability 
in pathogen prevalence in infected rodents or contaminated soil, having an indirect lifecycle in two 
different species of wildlife, both with variable distribution, which contributes to parasite clustering or 
aggregation. In addition, the genetic susceptibility or acquired immunity in susceptible populations has 
an unknown impact on the EM distribution. Therefore, the results of local or regional surveys cannot 
be extrapolated to a whole country.  
3.4.3. Absence of infection and early detection of introduction 
The principle used to substantiate absence of infection, (i.e. the probability that qualifies a statement 
on the presence/absence of a given disease/infection from a population (Cameron and Baldock, 
1998), is to estimate the so called surveillance system sensitivity (SSe). In probabilistic terms, the 
System Sensitivity is the probability to obtain at least one positive test, given that the infection is 
present at or above a given prevalence (the design prevalence, DP) in the target population. The test 
sensitivity and the DP are used in estimating the number of samples needed to reach the required 
level of confidence in infection absence (provided no EM-positive samples have been detected). This 
leads to an increased efficiency and flexibility when compared to input-based surveys. Appendix D 
contains a detailed description of the estimation procedures.  
In contrast, the Probability of Freedom (Pfree) is the probability that the infection is absent (i.e. DP < 
1%) given that all samples tested negative. This corresponds to the Negative Predictive Value of the 
Surveillance System. Pfree can be estimated incorporating evidence of infection absence from previous 
surveillance activities using Bayes’ theorem (Cannon, 2002). The procedure prescribed in the EM 
regulation does not take into account prior information on absence of infection based on the outcome 
of previous surveillance activities. For the purpose of demonstrating absence of infection, the inclusion 
of the Probability of Freedom concept in the regulation and its implementation in the surveillance 
activities may allow a reduction of the sample size. 
The current regulation prescribes the use of a design prevalence of < 1%. The design prevalence is a 
theoretical value, which allows the estimation of the confidence in being below 1% prevalence of EM 
given the number of tests done, all with a negative result. A sufficient number of samples examined 
with the estimated test sensitivity for the laboratory in question are needed to reach at least 95% 
confidence. The need for design prevalence has been described as follows: 
‘In populations with high levels of disease it is easy to detect infected animals, so the sensitivity of the 
surveillance system is high. When prevalence is low, disease is harder to find and sensitivity of a given 
approach is lower. It is therefore necessary to set a standard hypothetical prevalence of disease 
(design prevalence) against which to measure surveillance sensitivity’ (Cameron, 2012). 
If a single positive animal is detected, then official infection absence can no longer be conferred on 
that area. Accordingly, at least 300 animals need to be tested from an overall population of at least 
several thousand with a test of known sensitivity (Cannon and Roe, 1982). If all sampled animals test 
negative, the primary condition in the Regulation for being listed and maintained in Annex I thereto is 
fulfilled. The approach is further elaborated in Appendix D. 
The legally required design prevalence of < 1% (95% confidence) to substantiate infection absence, 
however, is unlikely to detect the introduction of infection within a short time. The time to first 
detection is likely to vary considerably across different countries. 
In fact, if the rate of spread of the infection is low, as for EM, there would be a considerable time lag 
between the introduction and the first detection, as it will take time to reach a proportion of infected 
animals greater than the design prevalence (i.e. the Limit of Detection of the surveillance system). 
In general, however, it should be expected that countries claiming absence of disease/infection can 
also substantiate their ability to detect an existing infection shortly after it developed. Documenting 
infection absence without an adequate early detection might expose the proclaimed absence-of-
infection status to criticism, because it is de facto mainly historical given the relative inability to detect 
a very low prevalence of infection caused by a recent introduction. 
Early detection requires a lower design prevalence than documenting freedom (Cameron, 2012), 
although the parameter substantiating the confidence in early detection in case of a new introduction 
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is the same as that used to substantiate absence of infection, i.e. the surveillance system sensitivity. A 
suitable surveillance system should possess the following characteristics: i) be continuous (to allow for 
early detection of an infection introduced at any time), ii) have comprehensive coverage of the 
population, and iii) be sensitive with a very low design prevalence (Cameron, 2012). 
To illustrate the two last points, assume that in an EM-free country there is a population of red foxes 
estimated at 150,000 individuals. Using the design prevalence applied in the infection absence 
estimation, i.e. 1%, up to 1,500 foxes may be infected, but the country could nevertheless document 
absence with 95% confidence, if approx. 400 foxes tested negative out of the population of 150,000 
(assuming a test sensitivity of 0.75). Waiting for 1,500 infected foxes to be present in the country 
before EM is detected would be considered far from ‘early’ detection. It may take many years for EM 
to achieve the assumed 1% population prevalence, so it might be more suitable to assume e.g. 0.1% 
(i.e. 150 infected foxes) as reasonable design prevalence for early detection. The confidence in 
detecting the infection at a design prevalence of 0.1% with the sample of 400 foxes is however only 
26%. Achieving a 95% confidence to detect an infection presence at 0.1% requires an annual sample 
of 4,000 foxes for testing, which may be neither practically nor economically feasible.  
As shown above, if the prevalence is very low then more animals would need to be tested to detect 
infected animals. For a design prevalence of < 0.1%, at least 3,000 samples are required, provided 
there is 100% test sensitivity. The case in Sweden helps understanding this issue: after nine years 
(2000 to 2009) of testing fox samples in a surveillance programme with 1% design prevalence, a 
single fox tested positive in 2010. Further testing of foxes using a design prevalence of 0.1% detected 
two more infected foxes distributed over a wider geographical area, which made it unlikely that the 
incursion had taken place recently (Wahlström et al., 2011). Denmark had reported EM in 2000 in 
foxes in the Copenhagen area, but did not carry out regular surveillance until the Swedish cases were 
reported in 2011. Between 2011 and 2013 a total of 676 wild carnivores were sampled in Denmark 
and four tested positive. All were clustered near the German border, and based on these preliminary 
data a national prevalence estimate of 0.7%, and a local estimate of 31% (95% CI: 7–55) were 
obtained (Enemark et al., 2013). 
Another option might be to perform risk-based surveillance. This approach is based on the 
identification of subpopulations with different relative risk. The subpopulations can be defined by 
individual characteristics (e.g. hunting dog vs. domestic dog) or by geographical provenience (close to 
the borders adjacent to an endemic country vs. close to the sea). If the relative risk of such sub-
populations could be documented, the number of samples required to obtain a specified probability of 
infection absence can be lowered/decreased compared to a representative sample (EFSA, 2012b). 
In summary, the inclusion of the concept of the Bayesian Probability of Freedom or the 
implementation of a risk based approach, supported by properly documented risk factors, may allow a 
reduction of the sample size. 
  




www.efsa.europa.eu/efsajournal 33 EFSA Journal 2015;13(15):4373 
 
 Efficacy of available Echinococcus multilocularis-deworming drugs 3.5.
and the effectiveness of the current species-specific treatment 
protocols to protect domestic species against the parasite (linked to 
TOR4)  
3.5.1. Drug efficacy 
Praziquantel is currently the most-used and most effective anthelmintic for the treatment of EM 
infections (EFSA, 2015). Praziquantel is a pyrazinisoquinoline derivative acting at the level of cell 
membrane permeability of cestodes and schistosomes, resulting in the killing of the parasites. 
Praziquantel is active against both immature and mature stages of EM in the intestine (Rommel et al., 
1976; Thomas and Gönnert, 1978; Sakamoto, 1977; Andersen et al., 1981; Kazacos et al., 1993 and 
1994; Schroeder et al., 2009). For use in dogs, veterinary medical products containing praziquantel 
are available for oral or parenteral administration (intramuscular, subcutaneous). For the treatment of 
EM the approved minimum recommended dose is 5mg/kg bw for single oral administration and 5.7 
mg/kg bw for single intramuscular or subcutaneous administration. After oral administration in dogs, 
praziquantel is rapidly and nearly completely (80–100%) absorbed from the gut, reaching maximum 
serum levels between 30 to 120 minutes after administration. Praziquantel is well distributed in all 
tissues with higher concentrations in the liver and duodenum. The substance is rapidly metabolized in 
the liver. Due to a pronounced first pass effect, the level of un-metabolized praziquantel in the blood 
after oral administration is lower compared to the blood levels found after parenteral administration. 
Praziquantel is re-secreted in its active form into the small intestine, thereby achieving relatively large 
quantities and, thus, is capable to reach even the juvenile stages of EM which are hidden in the 
intestinal crypts. The half-life of praziquantel is three hours in the dog. Praziquantel is mainly excreted 
via the kidneys. The efficacy of the anthelmintic treatment becomes less when the dose given is 
lower, in particular below 5 mg per kg body weight, and results may also be influenced by the 
infective dose used (EFSA, 2015).  
Six studies using the recommended treatment dose for oral and parenteral administration of 
Praziquantel were identified in the literature review and, additionally, data from two published abstract 
were used. Treatment efficacy was based on the quantification of worm load after praziquantel 
treatment. Praziquantel at a single oral dose of 5mg/kg bw resulted in five of the studies in a 100% 
reduction of worm count while the efficacy was nearly 100% (99.96 to 99.99%) in the remaining 
three studies. The studies comprised 76 dogs of which 70 were completely cleared and six had 
remaining worms after treatment and hence the average treatment efficacy at dog level was 92.1%. 
On average the worm burden was reduced by 99.95% in the 76 treated dogs (see Table A5 in 
Appendix A). 
Epsiprantel is a benzazepin analogue to praziquantel and currently marketed in veterinary medical 
products containing fixed combinations of epsiprantel and pyrantel embonate. Information in the 
scientific literature on the activity of Epsiprantel against EM is scarce and the exact mode of action is 
not known. However, due to its structural similarity to praziquantel it is assumed that epsiprantel has 
the same endpoint(s) against cestodes (i.e. increases the membranes’ permeability for calcium ions, 
resulting in disintegration of the tegumentum). In contrast to praziquantel, epsiprantel is poorly 
absorbed from the intestine, hence its efficacy is limited to lumen dwelling adult stages of EM. The 
minimum recommended single oral dose against EM and E. granulosus is 5.5 mg epsiprantel per kg 
bw in dogs. In a controlled study on dogs experimentally infected with protoscoleces of EM, a single 
oral doses of 4.9 to 5.8 mg/kg bw (mean: 5.3 mg/kg) resulted in a worm count reduction of over 
99%, however, residual worm burdens of up to 10 to 1480 worms persisted in 4 out of 8 (see Table 6 
in Appendix A).  
Most of the available studies were carried out on pre-patent infections that may not be fully 
representative for the patent stage. In addition, while systematic scientific trials can achieve a near 
100% reduction in intestinal worm load after treating dogs with 5 mg praziquantel per kilo 
bodyweight, the reduction following treatment by owners and local veterinarians may be lower. The 
owner of a dog regurgitating the drug on the way back from the veterinarian may ignore the incident 
and not have the dog retreated. Such potential reduction in treatment efficacy cannot be quantified. 
Therefore, a conservative estimate of 0.4% has been used in this scientific opinion for treatment 
failure based on an experimental trial (Eckert et al 2001).  
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3.5.2. Quantifying the relative effectiveness of treatment protocols to prevent 
establishment 
In addition to treatment efficacy, the timing of the treatment is important. Worms only live for 
approximately 90 days and the maximum worm load in a dog is therefore reached after 90 days. A 
reinfection period after treatment of even a few days will be important as reinfection takes place with 
1.1% of the maximum worm load per day (1/90). To prevent reinfection, dogs should be treated as 
close as possible to entering the country where no findings of the parasite have been recorded. 
However the narrower the treatment window the more difficult it is for dog owners to plan the 
treatment, therefore a very narrow treatment window may decrease compliance. Current legislation 
requires a treatment in a 24–120 hour period before crossing a border to a country where no findings 
of the parasite have been recorded. Prior to Regulation (EU) No 1152/2011, the treatment window 
required under national rules (in accordance with Article 16 of Regulation (EC) No 998/2003) for 
deworming treatments was 24–48 hours for Malta, the UK and Ireland, 1–10 days for Sweden, and 
not more than 30 days before entry for Finland. The new 24–120 hour window has increased the risk 
of reinfection but may on the other hand also have increased compliance. It is therefore relevant to 
investigate to what extend the increased risk of reinfection may have been been compensated for by 
a potential increase in the number of dogs in compliance. In the sections below, a model will be used 
to quantify the impact of various treatment windows and different compliance levels on the EM 
introduction/transmission/establishment probability. Modelling the impact of treatment in the following 
sections has been restricted to praziquantel.  
3.5.3. A mathematical model for optimizing treatment protocols  
This section presents the structure and assumptions for the developed mathematical model. The 
model is here used to quantify the relative effect of treatment protocols to prevent establishment. The 
model defines risk of establishment as being a function of the number of eggs deposited in the free 
country rather than a function of the number of infected dogs entering the free area. Scenarios are 
described for dogs from endemic areas visiting free areas (Section 3.5.4), dogs from free areas 
visiting endemic areas and returning to a free area (Section 3.5.5), and the relation between 
treatment window and compliance by the owners (Section 3.5.6). These different scenarios are crucial 
to understand the intimate relationship between the treatment timing and the probability of 
reinfection. The model is fully tailored to infected dogs, assuming they are the only ones representing 
a risk of introduction. 
A qualitative import risk assessment model has previously been presented by EFSA (2007), estimating 
the annual risk of importing infected dogs from an endemic area to a free country when taking into 
account the number of dogs imported, the probability of infection in the countries of origin, treatment 
efficacy and reinfection probability after treatment. This approach identified a relatively high 
probability of reinfection with large treatment windows because the drug is only effective 24 hours 
after oral intake. Praziquantel administrated 10 and 30 days prior to entering a free country therefore 
left 9 and 29 days, respectively, for the dogs to be re-infected in endemic areas. This is important 
because the lifespan of the worms is only 90 days and the maximum prevalence is therefore reached 
in a dog population after 90 days exposure in an endemic area. A reinfection period of e.g. 9 days will 
thus allow for 10% of the maximum prevalence to be reached in the period between treatment and 
crossing the border. In the worst case, the previous Swedish and the Finnish protocols only reduced 
the probability of importing an infected dog with 90% and 68% respectively. The rules for 
prophylactic treatment are now harmonized in all free countries, and allow for treatment up to 5 days 
prior to entry in a free country. 
In the previous EFSA risk assessment (2007), risk was defined as the probability of introducing a dog 
with an infection. However, EM may not be so contagious that a single infected animal crossing the 
border necessarily results in the successful establishment of the parasite. This is because a worm will 
produce a large number of eggs in its lifetime. But on average only very few of these eggs will 
manage to complete the development cycle and result in a new adult tapeworm. The real concern 
associated with import and travel of companion animals is the probability of establishment of EM in a 
free area rather than the probability of importing an infected dog. Therefore, an alternative 
deterministic mathematical model has been developed to calculate the average number of eggs 
excreted in a free country by a dog exposed in an endemic area. The model quantifies the risk as the 
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cumulative number of eggs excreted by a dog in the free country. It is assumed that the risk of 
establishing the parasite in a free area is linearly proportional to the number of eggs excreted in this 
area. In order to calculate the number of eggs excreted, the model calculates the probability that a 
dog is infected in the endemic area of exposure, and also the number of worms the dog may be 
infected with, as well as the duration of each of these worms’ remaining lifespan, together with the 
number of days the dog will spend in the free country. The model also takes into account that the 
worms undergo a 30 days immature stage before developing into a mature egg producing stage. The 
model is based on a number of simplifying assumptions e.g. that the daily egg production per worm is 
constant, that all eggs are excreted within 24 hours after treatment and that treatment efficacy of e.g. 
95% can be modeled as if 95% of worms are killed and the remaining 5% worms are completely 
unaffected. These assumptions can be violated in real life, e.g. eggs’ excretion has been reported to 
last up to 60 hours after treatment (Kazacos et al, 1994). However, a possible violation of one or 
more of these assumptions is not expected to affect the overall conclusions. In addition, the aim of 
the deterministic model is not to quantify the risk exactly but rather to identify and rank key risk 
mechanisms related to the size of treatment window, treatment before vs. after crossing the borders 
and the relation between treatment window and owners compliance and how these vary with different 
travel scenarios. A more detailed description of the model is provided in Appendix G and the following 
sections describe some selected scenarios. The model allows for treatment of dogs not only before 
moving to a free area, but also after entering the free area as this will also reduce the number of 
excreted eggs in the free area.  
The model is used to quantify the relative treatment effect (i.e. compared to a non-treated dog) for 
dogs from endemic areas imported to or visiting free areas (Section 3.5.3), for dogs from free areas 
visiting endemic areas and then returning to their free areas (Section 3.5.4) and to quantify the 
potential relationship between treatment regulations and the owners’ compliance with these 
(Section 3.5.5). 
3.5.4. Treatment of dogs from endemic areas visiting free areas 
In this section, the effect of the timing of the deworming treatment and the time spent in an endemic 
area on the risk of introduction/transmission/establishment is assessed for dogs from endemic areas 
visiting free areas for up to 90 days. 
A visit of 90 days has the same effect on the risk of establishment as permanent import since the 
lifespan of the worms is 90 days, hence, the maximum worm load is reached after 90 days. Treatment 
efficacy is assumed to be 99.6%. The number of eggs deposited in the free area in the different 
scenarios is given as percentage of the maximum egg excretion, i.e. in case a dog, living in an 
endemic area, is moved into a free area for more than 90 days without having been treated (worst 
case). In this way the calculations become independent of the exposure level in the endemic area, 
and present the relative effect of treatment given on different days compared with no treatment. 
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The number of eggs are given as percentages of the number of eggs deposited if treatment is not applied and the dog is fully 
exposed and stays in a free area for 90 days, thus that the results are presented as the relative impact of the treatment 
strategies and travel history. The five sets of data points show that the relative risk depends both on the duration of the visit 
and on which day the treatment is administered. Multiple scenarios are presented for the treatment day, ranging from 100 days 
before (day -100) up to 100 days after (day 100) entering the free area. Interpretation of the figure is explained in more detail 
in Appendix G. 
Figure 5:  Number of eggs deposited in a free country by dogs exposed for more than 90 days and 
then visiting free areas for 90, 60, 20, 10 or 5 days  
The shorter the visit to the free area the lower the probability and the more effective it is to treat 
dogs before they enter the free area compared to treating dogs after they enter the free area. For 
instance, treating a dog 11 days (day-11) prior to visiting a free area for a 60 day period will reduce 
the introduction risk to 9.8%, while postponing risk to nine days after entry at day 9 will only reduce 
risk to 16.8% (Figure 5, red arrows). This suggests that in this type of scenario (dog living in an 
endemic country and visiting an area where no findings of the parasite have been recorded) the 
timing of the treatment greatly influences the risk and it is best to treat dogs before they enter the 
free area. More precisely, the number of deposited eggs in the free area can be reduced by treating 
before or when entering the free area. The number of eggs excreted in the free area is lowest when 
treating one day prior to crossing the border (day -1). 
Short visits will always result in fewer eggs being deposited in the area where no findings of the 
parasite have been recorded. It should be noted that 20-days visits (or shorter) are so short that any 
re-infecting worms will remain in the pre-patent stage during the entire visit and eggs will only be 
deposited in case of treatment failure.  
The model shows that short visits to a free country by potentially infected dogs carry a much lower 
risk of establishment compared to longer visits or permanent import of dogs from endemic areas. 
3.5.5. Treatment of dogs from free areas visiting endemic areas before returning 
to a free area  
In this section, the relative effect of deworming treatment is assessed for dogs from free areas visiting 
endemic areas for up to 90 days before returning to a free area (e.g. dogs from the UK visiting risk 
areas for a limited period and then returning home). A visit of 90 days in the endemic area is 
equivalent to permanent import since the lifespan of the worms is 90 days, hence, the maximum 
worm load is reached after 90 days. A fixed 100% compliance and 99.6% treatment effectiveness are 
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The number of eggs are given as percentages of the number of eggs deposited if treatment is not applied and the dog is fully 
exposed and stays in a free area for 90 days, thus that the results are presented as the relative impact of the treatment 
strategies and travel history. The five set of data points show that the relative risk of establishment by dogs returning to a free 
country after being exposed for various periods depends both on the duration of exposure and on which day treatment is 
applied. Multiple scenarios are presented for the treatment day, ranging from 100 days before (day -100) until 100 days after 
(day 100) entering the free area. Interpretation of the figure is explained in more detail in Appendix G. 
Figure 6:  Number of eggs deposited in a free country by dogs exposed for 90, 60, 20, 10 or 5 days 
before moving to a free area for more than 90 days  
The shorter the exposure period in the endemic area the greater the advantage of delaying treatment 
until dogs are back in the free area (Figure 6). For instance, treating a dog 11 days (day-11) prior to 
returning to a free area after being exposed in an endemic area for 20 days will only reduce the 
number of eggs excreted in the free area (the risk) to 16.6% compared to import of untreated dogs, 
because this protocol will leave ten days for the dogs to be re-infected before returning. On the other 
hand, in order to reach the same level of reduction, the dog can be treated up to 50 days (day +50) 
after it comes back home (Figure 6, red arrows). From another perspective, delaying the treatment to 
e.g. day 10 after returning to the free area will reduce the risk to 0.1% (for a dog exposed for 20 
days). In fact, worms in a dog exposed for 20 days cannot mature before treatment is given (i.e. after 
10 days from returning), and hence the only risk (0.1%) is resulting from treatment failure. Also in 
this case, i.e. considering a dog living in a country where no findings of the parasite have been 
recorded, visiting an endemic area and then returning home, the timing of the treatment greatly 
influences the risk. However, the model suggests that the incubation period (the immature non-egg-
laying stage) makes it often safe to delay treatment until returning to the free home country and also 
treatment in the free area prevents re-infection. It is thus much safer to delay treatment until return 
to the area where no findings of the parasite have been recorded, particularly after short visits to an 
endemic area (less than 30 days). 
Treatment of dogs one day prior to entering the area where no findings of the parasite have been 
recorded always results in the lowest proportion of maximum excreted eggs in the free area. Treating 
before returning to a free area on the other hand always carries a risk of re-infection between 
treatment and entry into the free area. A treatment administered before and after entry to a non 
endemic area would be the most effective strategy. When first treatment is done prior to day -1 in the 
endemic area and second treatment is given in the free area and within 30 days after first treatment 
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and the second treatment would kill any reinfecting worms acuirred after first treatment and before 
they produce eggs. 
3.5.6. Compliance and treatment window 
As shown above in Figure 5 and Figure 6, it is optimal to apply treatment one day prior to entering a 
free area. However this is logistically difficult to administer for dog owners traveling between 
countries. Recently a treatment window requiring deworming up to 120 hours prior to entry in a free 
country was implemented in Europe (Regulation (EU) No. 1152/2011). This carries a risk of reinfection 
of the treated dogs, but does on the other hand make it easier for the dog owners to arrange for the 
dogs to be treated in the visiting endemic country, and hence, has the potential to increase 
compliance and may thus compensate for the increased risk of re-infection. Compliance is here 
defined as the proportion of dogs entering a free country that are being treated according to the 
regulations. 
In this section, an attempt is made to quantify how much compliance has to increase to compensate 
for the increased reinfection risk when expanding the treatment window from 24 hours before entry to 
48 hours, 72 hours, 96 hours, 120 hours and 144 hours before entry. Similar to above (Sections 3.5.4 
and 3.5.5), long-term exposed dogs living in endemic areas visiting free areas for short periodshave to 
be distinguished from dogs living in free areas visiting endemic areas for short durations of exposure 
before returning to the free area. The calculations are explained in last part of Appendix F. 
As the compliance levels are not known for each EU MS, with the exception of the UK, three different 
suboptimal compliance levels of 95%, 80% and 50% were explored at the optimal treatment time 
(day -1). The increase in compliance required to keep the risk at the same level as treatment on day -
1 was calculated, given a treatment administered at day -2, day -3, day -4, day -5 or day -6. As the 
re-infection risk increases as treatment is given earlier it was calculated how much compliance needed 
to increase in order to keep the risk stable. This is the break-even point, where risk is being defined 
as the number of eggs excreted in a free area. 
Table 6: Level of compliance needed (%) to counteract increase in re-infection risk as treatment 
window is increased from day -1 for long-term exposed dogs staying in the free area for 
more than 90 days (dogs)  
Day -1  
(reference) 
Day -2 Day -3 Day -4 Day -5 Day -6 
50% 51% 52% 53% 54% 54% 
80% 82% 83% 85% 86% 88% 
95% 97% 99% Not possible Not possible Not possible 
The table shows how much compliance needs to increase to counteract the increased probability that a dog is reinfected after 
treatment (when treatment is given day -2 to day -6 instead of the optimal treatment day -1), in order to prevent the ‘risk of 
establishment’ from increasing. The actual risk of establishment is not shown in the table. 
If dogs are introduced from endemic areas and the compliance is 80% when a treatment window of 
just one day (day -1) is prescribed, the re-infection risk can be held stable (Table 1) as long as 
compliance increases with a wider treatment time window. An increase in compliance up to 86% is 
necessary to fully compensate for the increased risk of re-infection due to the extension of the 
treatment window (from day -1 to day -5). If the compliance increases from 80% on day -1 to more 
than 86% on day -5 then the risk of establishment will actually decrease, resulting in a treatment 
strategy that is both more flexible for owners and carries lower risk of spreading the infection. 
However, if the level of compliance is 95% (or higher) at treatment day -1, increasing the treatment 
window to earlier than three days prior to import cannot be fully compensated by an increased 
compliance even if compliance reaches 100% (Table 6). In this case the treatment strategy will still be 
more flexible for the owners and may increase compliance, but even 100% compliance will not be 
able to prevent the risk from increasing. 
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Table 7: Level of compliance needed (%) to counteract increase in re-infection risk as treatment 
window is increased from day -1 for long-term exposed dogs visiting a free area for 60 
days  
Day -1 Day -2 Day -3 Day -4 Day -5 Day -6 
50% 51% 52% 52% 53% 54% 
80% 81% 82% 83% 84% 85% 
95% 96% 97% 97% 98% Not possible 
If the dogs are staying in the endemic area for more than 90 days (as are imported dogs) but only 
visiting a free country for 60 days then increasing a treatment window with a 95% compliance at day 
-1 to a treatment window of five days can be compensated if the compliance increases to 98% (Table 
7). And if the visit is as short as 20 days (Table 8) or even just five days (Table 9) the treatment 
window can be increased to 6 days without increasing risk even if compliance does not increase. The 
reason for this is that no re-infecting worms after treatment will be able to mature and produce eggs 
before the dog again leaves the free area since the pre-patent period is 30 days. However if 
compliance increases as the treatment window is allowed to expand this will reduce number of eggs 
excreted in the free country and thus reduce risk of establishment. 
Table 8: Compliance needed to prevent increase in re-infection risk as treatment window is 
increased from day -1 for long term exposed dogs that stay in the free area for 20 days 
(visit)  
Day -1 Day -2 Day -3 Day -4 Day -5 Day -6 
50% 50% 50% 50% 50% 50% 
80% 80% 80% 80% 80% 80% 
95% 95% 95% 95% 95% 95% 
Table 9: Level of compliance needed (%) to counteract increase in re-infection risk as treatment 
window is increased from day -1 for long term exposed dogs visiting an area where no 
findings of the parasite have been recorded for just 5 days  
Day -1 Day -2 Day -3 Day -4 Day -5 Day -6 
50% 50% 50% 50% 50% 50% 
80% 80% 80% 80% 80% 80% 
95% 95% 95% 95% 95% 95% 
 
Table 10: Level of compliance needed (%) to counteract increase in re-infection risk as treatment 
window is increased from day -1 for dogs exposed for 20 days before returning to a free 
area  
Day -1 Day -2 Day -3 Day -4 Day -5 Day -6 
50% 52% 55% 59% 63% 67% 
80% 85% 89% 93% 99% Not possible 
95% >99% Not possible Not possible Not possible Not possible 
Table 11: Level of compliance needed (%) to counteract increase in re-infection risk as treatment 
window is increased from day -1 for dogs exposed for just 5 days before returning to a 
free area  
Day -1 Day -2 Day -3 Day -4 Day -5 Day -6 
50% 63% 84% Not possible Not possible Not possible 
80% >99% Not possible Not possible Not possible Not possible 
95% Not possible Not possible Not possible Not possible Not possible 
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If dogs from a free area are exposed for a limited period in an endemic area before they return to a 
free area and stay there permanently (more than 90 days), then it is difficult to compensate for the 
increased risk of re-infection associated with treating the dogs earlier than one day before returning to 
the free area. Only a very low initial compliance of 80% at day -1 can be compensated by treating 
within two days before entry (day -2) if the compliance increases to 99% (see Table 11). This is 
because the risk of egg excretion in the free area is a result of reinfection between treatment and the 
time of returning to the free area (e.g. treatment day -2 leaves one day for reinfection while 
treatment days -3 doubles this reinfection period to two days). This doubling of reinfection risk is not 
possible to compensate with increased compliance unless the compliance at day -1 is very low.  
The level of compliance with the requirement to treat dogs entering the four Member States and 
Norway is uncertain as not always recorded. It is assumed that the knowledge of the owners about 
border compliance checks are in place in a given country increases the degree of compliance of dog, 
while knowing that no border compliance checks are in place is likely to decrease the compliance. 
While the UK data suggests that an increased treatment window from 24 hours to 120 hours has 
increased the number of dogs in compliance, as the overall number of travelling pets has also 
increased, this has had less effect on the proportion of animals in compliance. The above calculations 
demonstrate that it is possible that an increased compliance as a result of allowing earlier treatment 
may counteract the increased risk caused by re-infection between treatment and entering a free area, 
but it is only likely to be effective for dogs living in endemic areas and visiting free areas. The shorter 
time a dog from an endemic area visits the free area the more likely the risk is to break even because 
of increased compliance. If the visit is so short that the dog living in an endemic country will return 
within 30 days after being treated, then re-infection does not increase risk and therefore any 
improvement in compliance will actually reduce the overall risk of eggs being deposited in the free 
area. 
An important finding is that dogs living in free countries and visiting endemic areas for shorter periods 
before returning to their free countries constitutes a risk of egg excretion in their home countries that 
will require large increases in compliance to counteract. For shorts visits in endemic areas, e.g. 5 
days, it is unlikely that even dramatic improvements in compliance will be enough to counteract the 
increased risk resulting from an increase in treatment window from two days to five days. However, it 
must be remembered that the absolute risk from a short visit in an endemic area is lower than the 
absolute risk from a long visit, regardless of the treatment window allowed. 
While an increased treatment window may increase treatment compliance and thus reduce risk or at 
least result in the same risk for dogs from endemic areas visiting a country where no findings of the 
parasite have been recorded, this is not likely to be the case for dogs from countries where no 
findings of the parasite have been recorded returning from visits in endemic areas. For dogs returning 
to counties where no findings of the parasite have been recorded very large improvements in 
compliance is needed to prevent the risk from increasing when increasing the treatment window. 
Unfortunately, most dogs crossing the border tothe UK appear to belong to the latter group while we 
do not have data for the Malta, Ireland or the Nordic countries. But the negative effect of increased 
treatment windows is much bigger for dogs returning to a free country than are the positive effect for 
dogs from endemic areas visiting a free country, and since the absolute risk during short visits is also 
higher in dogs returning to free areas compared to dogs visiting free areas (when treatment is done 
before crossing the border). Therefore, when the treatment protocol was harmonized in the new 
legislation, the overall effect of increasing the treatment window in the case of the UK, Ireland and 
Malta from two days to five days increased the probability of introduction of the parasite into these 
countries. Whereas for Finland, the window was tightened and therefore the risk of introduction was 
reduced. 
Large treatment windows were previously in place in, e.g. Finland, extending up to 30 days prior to 
entry. Anecdotal evidence suggests the long treatment window facilitated compliance as it was easier 
for dog owners to plan the treatment. However, in some cases it lead the owners of dogs residing in 
free countries who were intending to visit endemic countries and then return to the free country to 
treat the dog before visiting the endemic area. While such a protocol from the owner’s side may 
appear to be technically legal it has no protective affect at all because treatment take place before the 
dog is exposed. In this case it would therefore be much more beneficial if owners were allowed to 
delay treatment until returning from the trip to an endemic area. This would also make it easier for 
owners to plan the deworming and thus comply and it would kill potential infections acquired on the 
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trip. Indeed, the mathematical model developed here demonstrates that even if the compliance may 
be unchanged when delaying treatment, the risk of introducing the parasite will still be lower when 
deworming takes place in the free home country. 
 Programmes for the eradication of E. multilocularis (linked to 3.6.
TOR2b)  
This section is limited to considering the control and eradication of EM in foxes as the main definitive 
host (see Section 3.1.1) and because data on other species are scarce. 
Several studies have shown that anthelmintic treatment of foxes with praziquantel decreases the 
prevalence of EM both in urban and rural areas (Table 7, Appendix A). The decrease in prevalence has 
been shown to be larger in the centre of the baiting area compared to the marginal areas, a 
difference probably caused by migrating foxes (Schelling et al., 1997). Comte et al. (2013) evaluated 
the effect of baiting in two medium size cities (< 100,000 inh.), where intervention was not done in 
the surrounding areas. The prevalence decreased in one city but not in the other, and the authors 
suggest that frequency of baiting should be adapted to the local situation (Comte et al., 2013).  
As seasonal variations of EM prevalence occur, studies lacking control areas or only having historic 
control areas cannot determine how much of a change in prevalence is caused by the control and how 
much is due to seasonal variations (Schelling et al., 1997; Tackmann et al., 2001). Furthermore, 
changes due to baiting may sometimes be smaller compared to changes over time (Tsoumada et al., 
2002). In one study where the prevalence was estimated 12 times during a four year period prior to 
baiting, the prevalence estimates varied between 12.6% to 36.6% (Tackmann et al., 2001). In 
another study, the prevalence in the control area varied during the study period from 33.3 to 60% 
(Antolova et al., 2006). 
Different baiting strategies have been used, the baiting area has varied from a few km2 (Antolova et 
al., 2006; Hegglin et al., 2003 and 2007) to 5000 km2 (Tackmann et al., 2001) (Table 7, Appendix A). 
Hegglin and co-workers showed that with intensive baiting over a long period (3.5 years) even in 
small areas (1 km2) the parasite was probably eliminated and recolonization took several years 
(Hegglin et al., 2003). Romig et al. (2007) highlighted the need to combine arial distribution of bait in 
rural areas with distribution by hand in more urban areas to get adequate coverage. 
Baiting frequencies have usually been every four or six weeks, in some studies baiting intensity has 
decreased over time (Table 7, Appendix A). Inoue et al. highlighted the importance of frequent baiting 
(monthly) at least during periods (summer, autumn) where transmission is considered high (Inoue et 
al., 2007). König et al (2008) and Hegglin et al (2008) also highlighted the need for frequent baiting 
(monthly). Romig and colleagues (2007) showed that baiting with six week intervals reduced the 
prevalence, when increasing the baiting interval to 3 months (after 21 months) the prevalence 
stabilised and increasing it to 6 months resulted in an increase in prevalence. 
Baiting intensity has usually been 50 baits/ km2, however in certain studies lower baiting density has 
been used, especially in those where baits are delivered by hand at fox dens (Table 7, Appendix A). It 
has been shown that it is possible to decrease prevalence in small, highly endemic areas if intensive 
baiting is done (Hegglin et al., 2003). The authors concluded that baiting densities in urban habitats 
should exceed 20 baits/ km2 and also that manual distribution of baits at selected sites will improve 
uptake of baits by foxes. König et al. (2008) concluded that a baiting intensity of at least 30 baits/ km2 
is needed and recommended at least 40/km2 to have a reserve. As the fox population has increased 
since rabies eradication, a higher intensity than during the rabies campaign (15/km2) is needed (König 
et al., 2008). Romig et al. concluded that one of the reasons for not being able to interrupt the life 
cycle in a baiting study was the low baiting intensity (20 baits/ km2) (Romig et al., 2007). 
The duration of baiting in the studies varied from seven months to four years. In one study it was 
concluded that baiting needs to be done for more than one year (Tsukada et al., 2002), which was 
supported by a study in Switzerland, where during the first year of baiting, the prevalence in foxes 
decreased significantly, but no difference was detected in the A. terrestris prevalence. However, the 
prevalence in A. terrestris in bait areas during the second year of baiting was significantly lower 
reflecting a lower infection pressure for intermediate hosts (Hegglin et al., 2003). König et al. (2008) 
showed that the prevalence in foxes could be reduced to close to zero in less than one year by 
intensive baiting (every four weeks initially and then every sixth week) and combining arial distribution 
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with distribution by hand at strategic places identified in previous studies. However, Hegglin et al. 
(2008) highlighted that, if local disappearance of the parasite is to be obtained, intensive baiting 
should be continued even after the prevalence has decreased drastically.  
Most studies used a dose of 50mg praziquantel which is considered sufficient, as a dose of 5mg/kg 
bodyweight has been shown to have a 100% deworming effect (Rommel et al., 1976). 
The importance of bait uptake was highlighted in a study by Antolova et al., (2006), where baiting 
failed to decrease the prevalence which was considered to be due to a high population density of wild 
boars interfering with bait uptake by foxes. The bait disappearance rate for the red fox has been 
shown to vary from 48% to nearly 100% (Marks and Bloomfield, 1999; Thoma, 2008; Hegglin et al., 
2004) cited by Janko and König (2011). Ecological parameters of the fox as well as bait competitors 
have great influence on bait disappearance (Janko and König, 2011). To ensure that baiting strategies 
are efficient and cost effective it is important to determine bait consumption of red foxes and 
competitor species (Janko and König, 2011). 
As baiting is quite expensive, there is also a need to identify how to distribute baits in a more cost 
efficient way (Schelling et al., 1997). König et al. (2008) highlighted the importance of involving 
hunters for bait distribution by hand in urban and suburban areas and also for evaluation of the 
results by collection of foxes. Kamiya et al. (2007) concluded that in all campaigns in Japan the 
involvement of local volunteers is important to obtaining a sustainable system to control the parasite. 
Hegglin et al. (2003) recommended that public health authorities should focus on urban areas 
intensively used for recreational activities where the parasite is highly endemic to decrease the 
potential risk of alveolar echinococcosis, a conclusion supported by Antalova et al. (2006) and König et 
al. (2008).  
Kamiya et al. summarised information on fox hunting and potential control of EM. In Eastern 
Hokkaido (Japan), hunting was increased in 1970 but despite that, the parasite is still present 
although at a low prevalence. A nation-wide hunting ban on foxes in the United Kingdom was 
reported not to have measurable impact on the fox population density in selected areas (Baker et al., 
2002 cited by Kamiya et al., 2007). Kamiya et al. (2007) concluded that fox hunting by culling or 
trapping does not have an effect on the number of foxes and therefore no effect on controlling EM. 
Hegglin et al. summarized that although under strict conditions the fox population can be reduced in 
extended areas (Heydon et al., 2000 cited by Hegglin et al., 2015), it is well accepted that regulating 
fox populations on a larger scale is difficult to achieve (Gentle et al., 2007 cited by Hegglin et al., 
2015). Culling can increase the proportion of sub-adult foxes which disperse over large distances and 
also may harbour higher worm burdens (Morishima et al., 1999 and Hofer et al., 2000). This is in 
accordance with a French fox hunting study where the proportion of sub-adult foxes and also the 
prevalence of EM increased to a higher level compared to the control area (Comte, 2014). 
Eradication of EM in the European wildlife could theoretically be achieved by means of baites in small 
areas where foxes are present, but the intervention needs to be perpetuated to maintain the status. 
In large areas, long term control - but not elimination - of the parasite may be possible by baiting. 
Increased fox hunting/trapping is not considered to be effective in controlling the parasite. Control by 
baiting requires more knowledge about how and where to control the parasite in a cost efficient way. 
Distribution of baits needs to cover both rural and urban areas, baiting frequency and bait density 
need to be high (approx. 50 baits/ km2), duration of baiting needs to be long (several years), areas 
where control is cost efficient need to be identified (urban/suburban), baiting uptake needs to be 
considered. More research, including modelling, is needed for long term sustainable control of the 
parasite: Can baiting frequency be reduced if the time/season of baiting is adapted to the life cycle of 
the foxes? Can baiting intensity be reduced by strategic placement of the baits? Can costs of baiting 
be reduced by involvement of local hunters/residents? 
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 Risk factors associated with human alveolar echinococcosis (linked 3.7.
to TOR3a)  
3.7.1. Cases of AE in EU  
Surveillance of human AE 
Alveolar echinococcosis is a parasitic zoonotic disease characterized by an asymptomatic incubation 
period in humans of around 5–15 years and the slow development of a primary tumour-like lesion 
which is usually located in the liver. Clinical signs usually include weight loss, abdominal pain, general 
malaise and signs of hepatic failure. Larval metastases may spread either to organs adjacent to the 
liver or distant locations following dissemination of the parasite via the blood and lymphatic system 
(http://www.who.int/mediacentre/factsheets/fs377/en) 
The true number of AE cases in Europe is unknown. This is primarily due to lack of notification 
requirement at the species level in several Member States (Table E1 in Appendix E). Moreover, case 
definitions of ‘Echinococcosis’ in Europe, according to Commission Decision 2012/506/EU, do not make 
distinction between alveolar and cystic echinococcosis and consequently between Echinococcus 
multilocularis and granulosus, respectively. In some MS notification requirement is at the genus level, 
however, as cases of CE usually far outnumber the cases of AE, the number of ‘Echinococcus’ cases in 
humans will primarily reflect the number of CE cases. This lack of notification requirement at the 
species level has been highlighted previously (EFSA opinion, 2006). In addition underreporting also 
occurs due to poor knowledge of clinical symptoms and incorrect clinical management (Romig et al., 
1999b; Jorgensen et al., 2008; Stojkovic et al., 2015).  
EurEchinoReg network was initiated in 1998 for the assessment of human alveolar echinococcosis 
across European borders. Five-hundred fifty-nine patients were voluntarily enrolled in the European 
Register (autochthonous cases diagnosed between 1982 and 2000). The majority of the cases 
originated from rural areas from Eastern France to Western Austria (Kern et al., 2003).  
According to Kern and colleagues, by December 2000, 73.0% of the patients were alive (n=408), 
21.3% had died (n=119), and 5.7% were lost to follow-up (N=32). Unfortunately such European 
register on AE was not available after 2000, while a European CE register was recently created in 
2015 (http://www.heracles-fp7.eu/erce.html; Tamarozzi et al., 2015). In France, a country previously 
known to register half of all European patients, a national register is still maintained in which AE was 
diagnosed in 509 patients from the period of 1982-2011 (Said-Ali et al., 2013). 
Some interesting features are coming from the endemic country of Germany where AE reporting 
became mandatory from 2001. In fact, Jorgersen and colleagues (2008) used a 3-source capture–
recapture analysis to generate an estimate of the true number of AE cases in Germany from 2003 
through 2005 and to assess the sensitivity of national surveillance. Results demonstrated that the 
national surveillance system failed to detect 67% of AE cases in Germany over 3 years (Jorgensen at 
al., 2008). Moreover, Nothdurft and colleagues (1995) conducted one of the few retrospective cross-
sectional studies in Europe to investigate the epidemiology of echinococcosis in Bavaria, Southern 
Germany. A standardized questionnaire was sent to all hospitals in Bavaria and in a second step, a 
team of reviewers was sent to all relevant hospitals for active case finding in hospital statistics and 
medical records. A total of 216 patients with echinococcosis were detected, of whom 58 had alveolar 
echinococcosis. According to these data, the prevalence in Bavaria was calculated to be 0.5 per 
100,000 inhabitants with peak values in the counties of Swabia (2.4) and Upper Bavaria (0.6). The 
annual mean incidence of newly diagnosed cases amounted to 0.03 per 100,000. The distribution of 
prevalence in man was closely correlated to the prevalence in foxes throughout Bavaria (p < 0.05). 
Moreover, EM was recently detected in animal hosts from Estonia (Moks et al., 2005), Latvia (Bagrade 
et al., 2008) and Lithuania (Mažeika et al., 2003; Bružinskaitė-Schmidhalter et al., 2012) (see Section 
3.2). Twenty-nine cases of AE were reported from Latvia during the period 1996-2010 (Tulin et al., 
2012) and 80 AE cases from 1997-2006 (Bružinskaitė et al., 2007), both from single hospitals.  
An increased incidence was also recently noted from countries recognized as historically highly 
endemic. For instance in Switzerland where Schweiger and colleagues (2007) retrospectively analysed 
AE cases from three centres with a total of 494 cases recorded during last 50 years. Annual incidence 
per 100,000 population increased from 0.12–0.15 during 1956–1992 and a mean of 0.10 during 
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1993–2000 to a mean of 0.26 during 2001–2005 (Schweiger et al., 2007). One possible explanation 
for increased human cases in Switzerland, is the increasing fox population after implementation of 
rabies control with 15 years shift due to the incubation period of the EM infections in man (Schweiger 
et al., 2007; Figure 7).  
 
Source: Schweiger et al. (2007) 
Figure 7:  Data points with moving 5-year average for annual incidence of human AE in Switzerland 
(A) and annual number of foxes hunted per year in Switzerland (B), used as a fox 
population density marker  
In line with the above trend, in Austria the annual incidence were reported as 2.4 and 2.8 
cases/100,000 population during 1991–2000 and 2001–2010, respectively. Hence, the registration of 
13 new AE patients in 2011 was unexpected for Schneider and colleagues (2013). The authors argued 
that the increasing fox populations and past AE underreporting might have caused such increase in 
reported cases. 
In addition, several factors were pointed out as reason of the increase of EM/AE in Europe, such as: 
the landscape change composition and use; urbanization of foxes; changing human attitudes and 
behaviour toward foxes; globalization; wildlife (re)introduction; effect of climate change on the 
environment and survival of eggs and DH/IH populations survival (synthesized in Davidson et al., 
2012; Atkinson et al., 2013; Gottstein et al., 2015). 
These recent findings/expanding of the parasite in several new areas such as the Baltic regions, 
Denmark, Netherlands, Poland, Romania, Slovakia, Slovenia and the unexpected increase of human 
AE incidence in endemic countries such as in Austria, France and Switzerland are suggesting the 
disease is spreading and increasing in Europe (see Table E2 in Appendix E on available scant data on 
AE). Improved awareness and better diagnostic tools may have also contributed to increase in records 
of this parasite in animals and humans. Nevertheless, over the past 20 years, intensive 
epidemiological research seems to confirm EM/AE expansion in European countries (Gottstein et al., 
2015).  
An appropriate surveillance/reporting scheme for AE at the EU level is not currently implemented and 
it should be considered necessary. Cases of both cystic and alveolar echinococcosis, caused by 
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E. granulosus and EM respectively, are reported jointly to ECDC as echinococcosis as the EU level case 
definition does not differentiate between the two clinical forms of the disease. They can be 
differentiated in the data reported to ECDC by the reported species, but this is not currently 
implemented. Also the notification of human echinococcosis is not mandatory in all MSs. Mandatory 
submission of echinococcosis data at species level should be considered, as necessary for 
understanding the epidemiology of different diseases as AE and CE. In fact, not only the true number 
of patients with AE is unknown in Europe, (because notification is not mandatory at EU level), but 
even when notification is provided at national level (for instance in Germany), the system failed to 
detect 67% of AE cases over 3 years (Jorgensen et al., 2008). An appropriate surveillance scheme, 
data models at the EU level and mandatory notification are necessary to overcome current quality 
problems of the data provided by Member States to EFSA and ECDC and reported in The EU summary 
report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks (EFSA and 
ECDC, 2013). As an example, 794 ‘echinococcosis’ cases in Europe have been reported in 2013. This 
does not correspond to 1,379 CE records per year reported by Hospital Discharge Records (HDRs) in 
Italy during the period of 2001–2013 (Brundu et al., 2014; Tamarozzi et al., 2015). Hence, a reporting 
scheme differenciating AE from CE and autochthonous from imported human cases would be 
important to trace back infections. 
Implementation of such mandatory surveillance and an improved reporting scheme at EU level is 
crucial to collect real epidemiological and clinical data for the management of this disease, overcoming 
currently problems on data quality and quantity. 
3.7.2. General risk factors  
The following risk factors of potential global relevance were identified in a Systematic Review (Casulli 
et al; 2015): dog ownership, playing with dogs, female gender, age above 20 years and occupation 
(livestock herding) (Table E4 in Appendix E). It must be emphasized that only risk factors that were 
identified in studies that were eligible according to the inclusion factors of the Systematic Review 
could be included. It is also important to note that some of the risk factors could be influenced by the 
socio-cultural situation in particular affected areas such as China, as several studies included in the 
analysis had been conducted there. The available data suggest that the dog can be relevant as a risk 
factor for human infection, although the dimension of the risk is influenced by the exposure of dogs to 
infected intermediate hosts, which have to be eaten by a dog to infect it, and socio-cultural conditions 
determining the exposure of humans to faeces of infected dogs and materials contaminated with such 
faeces.   
Five out of seven case-control studies included in the Systematic Review (Casulli et al; 2015) were 
conducted in the EU, one in China and one in North America. Dog ownership, cat ownership, having a 
kitchen garden, occupation (farming), haymaking in meadows not adjacent to water, going to forests 
for vocational reasons, chewing grass and handling foxes were identified as potential risk factors, 
whereas particular Human leukocyte antigen (HLA) types turned out to be protective against AE 
(Table E4 in Appendix E). When the analysis was restricted to case-control studies performed in 
Europe, dog ownership, cat ownership, living in a rural area, having a kitchen garden, occupation 
(farming), haymaking in meadows not adjacent to water, going to forests for vocational reasons, 
chewing grass and handling foxes were identified as potential risk factors, whereas particular HLA 
types turned out to be protective against AE (Table E4 in Appendix E). 
For some of the reported risk factors, a biological interpretation of the size and direction of the 
estimated impact on the risk of infection is lacking. It should be emphasized that some of these 
potential risk factors may represent confounders (e.g. age, gender and even dog ownership) or other 
types of biases. In principle, a pooled analysis of European data may be possible if the raw data from 
the respective studies were made available by the owners of the information. Such a joint analysis 
might attempt to separate true risk factors from potential confounders, e.g. by stratification or 
appropriate multivariate analysis. 
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3.7.3. Risk factors relevant in particular areas 
Risk factors in the EU 
In Europe, dog ownership, cat ownership, living in a rural area, having a kitchen garden, occupation 
(farming), haymaking in meadows not adjacent to water, going to forests for vocational reasons, 
chewing grass and handling foxes were identified as potential risk factors, whereas particular HLA 
types turned out to be protective against AE (Table E11 in Appendix E). 
Risk factors outside the EU 
Although the socio-cultural situation in affected areas outside Europe, in particular in China, may have 
a major impact on dog-related risk factors, it cannot be ruled out that dog ownership and playing with 
dogs might also be or become relevant as potential risk factors in Europe. 
3.7.4. Knowledge gaps 
The number of human AE cases in the MS is not known as there is no requirement for notification at 
species level at EU level. 
As mentioned before, for human AE, a substantial level of underreporting must be anticipated 
(Jorgensen et al., 2008; Schneider et al., 2013). The incidence of the disease may be three-fold 
higher as shown by German national surveillance data (Jorgensen et al., 2008). 
Although it is clear that humans get infected with EM by oral uptake of tapeworm eggs, the relative 
importance of some definitive hosts (fox, dog, raccoon dog) for human infection is not known. It can 
be assumed, however, that cats play a minor role because they often fail to develop patent infections 
or shed only a small number of eggs. 
The proportion of humans developing AE relative to the exposed population is unclear. It has been 
claimed that a substantial proportion of exposed people does not develop alveolar echinococcosis 
(Gottstein et al., 2014). 
The relative importance of the various risk factors for human infections is unknown. It is unclear, 
whether the importance of different risk factors varies among different areas. The unknown, 
presumably very long incubation period (several years) for human AE and the fact that oral uptake of 
tapeworm eggs is the predominant route of infection for humans makes it extremely difficult to study 
risk factors because neither the exposure to potentially contaminated food nor the presence in 
endemic areas can be established or excluded for such long periods of time. 
 Impact of E. multilocularis infection in animals on public health 3.8.
(linked to TOR3b)  
Burden of AE 
In untreated cohorts, the fatality exceeded 90% within 10 years (Ammann et al., 1996). The 
introduction of benzimidazoles such as albendazole during the seventies considerably improved the 
prognosis (Wilson et al., 1992). Long-term follow-up of 117 patients showed that the 5 year survival 
increased to 88% with this improved management (Bresson-Hadni et al., 2000). In a study from 
Switzerland, it was noted that for an average 54-year-old patient diagnosed with AE in 1970 the life 
expectancy was estimated to be reduced by 18.2 years for men and 21.3 years for women, 
respectively. By 2005, this was reduced to approximately 3.5 and 2.6 years, respectively (Torgerson et 
al., 2008). 
A global view on AE burden based on disability weights for hepatic carcinoma and estimated age and 
gender specific incidence, were used to calculate the AE disability-adjusted life years (DALYs) 
estimated in a median of 666,434 DALYs per annum (CIs 331,000–1.3 million) (Torgerson et al., 
2010). Approximately 18,235 (CIs 11,900–28,200) new cases of AE per annum are estimated globally 
with 16,629 (91%) occurring in China and 1,606 outside China. The annual incidence of confirmed 
cases was also estimate as 0.02–1.4 per 100,000 persons in Central Europe (WHO, 2001). A more 
recent estimation is reporting an average incidence of 0.03 to 0.30/100,000 inhabitants/year in 
endemic countries such as Austria, France, Germany and Switzerland, with some observed nested 
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clusters reaching an incidence from 4.7 to 8.1 cases/year/100,000 (Gottstein et al., 2015). The 
estimated median annual number of AE cases from the EU countries in 2010 was 130 (Torgerson et 
al., 2010), with the highest count for Germany (N=61), followed by France (N=21), and the Baltic 
states Estonia, Latvia and Lithuania with 9 cases each. The estimated annual number of cases from 
Switzerland was 20 (Torgerson et al., 2010). Increased incidence rates of human AE have been 
detected during the last 20 years (see Section 3.7.1). A more recent estimation is reporting around 
170-200 human AE cases per year in central and Eastern Europe (Conraths and Deplazes, 2015). 
The recent EM findings in several new areas such as Latvia, Lithuania, Estonia, Sweden and Denmark 
as well as the unexpected increase of human AE incidence in endemic countries such as Switzerland 
and Austria suggest a spread and increase of the parasite in Europe. 
Economic cost in humans: 
Benzimidazoles cost for a patient per year was estimated between US$5,500 to 17,800 (Reuter et al., 
1998). Total treatment cost per case per life was estimated at US$ 300,000 (Romig et al., 1999b). 
More recently, in Switzerland, the total median treatment cost for each case of AE was estimated at 
€103,312 (CIs €90,230–€118,146). In addition, each AE patient lost an average income of € 78,485 
(€45,454–€125,614). The median cost per case, when saved pension costs are deducted due to 
premature mortality, was estimated at €108,762 (€48,302–€178,568), with a total cost per year of 
€2.0 million (€0.9–€3.5 million). If saved pension costs are not deducted, then the cost per case rises 
to €182,594 (€144,818–€231,448), with total costs of €3.5 million (€2.5–€4.9 million) (Torgerson et 
al., 2008). 
In the UK, the estimated cost associated with AE potential introduction was composed by ‘loss of 
earnings + cost of hospitalizations + cost of long-term care + cost of fatalities’. Lowest case scenario 
(using the lowest incidence levels to assess the possible impact on the UK) was £2,177,965. Worst 
case scenario (using the highest incidence levels to assess the possible impact on the UK) was 
£33,310,056. 
All these economical estimations remain uncertain and extrapolation of costs at European level is 
difficult, mainly for two reasons: different health care costs among MS and different time to detection 
which deeply impact on disease stage and consequently on prognosis.  
As suggested by Gottstein and colleagues (2015), if early detection and clinical management do not 
make progress beyond current practices, European health systems could probably face costs in the 
range of one or more billion euro to care for the number of AE patients expected in the next two 
decades. 
Economic cost in animals: 
Since the life cycle of EM takes place largely in wild animals, deworming dogs with praziquantel is the 
only cost for animals. It should be considered as an indirect cost that can only be applied in those 
infected MS where the drug is not used for routine de-worming for other parasites. 
A model on cost/benefit analysis for deworming cats and dogs for EM was performed in Sweden 
accounting for veterinary fees. The cost of regular deworming of dogs and outdoor cats in risk areas 
during a year was estimated at 5.6 million euro for dogs and 4.2 for cats. The model assumed a 
regular deworming every 28 days with the recommended dose (5mg / kg body weight) of Droncit ® 
vet (packing tablets 2 x 50 mg) and assumed 7.5% of the dogs and 1.5%of cats in Sweden will be 
dewormed regularly in accordance with the recommendations. It was also estimated an average 
weight of 19 kg for dogs and 5 kg for cats.   
 Laboratory techniques for the detection of E. multilocularis (linked 3.9.
to TOR5)  
3.9.1. Overview of the laboratory techniques for detection of E. multilocularis  
The required properties of tests for EM diagnosis should be to measure the actual infection status with 
high sensitivity and specificity, able to perform intra vitam and post mortem examination of animals, 
suitable for mass-screening, enable DNA quantification, safe for laboratory personnel and cost 
effective. A comprehensive view on the descriptions and limitations of the intra vitam /post mortem 
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methods used for the detection of E. multilocularis in DH and IH is reported in Appendix G, namely 
sedimentation and counting technique (SCT), segmental sedimentation and counting technique 
(SSCT), intestinal scraping technique (IST), shaking in a vessel technique (SVT), copro-antigen ELISA, 
and DNA-based tests. 
Two main approaches are used for the diagnosis of EM in foxes:  
x The SCT is a post mortem approach at necropsy considered as the reference standard for the 
detection of EM. It focuses on the identification of EM worms in the intestines using classical 
parasitological methods. The lower limit of detection of the SCT is high (i.e. a high worm 
burden is needed for the test to give a positive response). Usually, and particularly in non 
endemic / free areas, the worm burden is low which reduces the probability of a positive 
diagnosis in an infected animal. This results in a diagnostic sensitivity of less than 100%, 
particularly if used in a period close to the introduction. Furthermore, the SCT is a time 
consuming approach 
x DNA-based methodologies for the detection of EM genetic material in faeces or intestinal 
contents. It is an intra vitam or post mortem approach providing indirect evidence on the 
presence of the parasite. Intrinsic limitations of DNA-based methodologies such as inhibitors, 
costs, small volume of sample to analyse, timing and sensitivity were recently overcome. It 
might be that newly developed DNA extraction methods such as DNA fishing (MC-PCR) and 
implemented real-time PCR methods are equally or more sensitive than SCT, particularly in 
samples with a low worm burden (Øines et al., 2014; Isaksson et al., 2014, Helene 
Wahlström, Personal communication, 2015). 
The diagnostic methods have increasing sensitivity with increasing worm burden (Karamon et al., 
2010), but are only applicable on dead animals. In addition, these tests are very labour intensive. The 
diagnosis of EM in faecal samples from living foxes and other definitive hosts in general is dependent 
on the stage of infection, i.e. pre-patent or patent infections, and may be hampered by intermittent 
shedding of eggs. Sieving/flotation can detect eggs, however using microscopy on faecal samples is 
difficult because the eggs cannot be differentiated from other taeniid eggs and sieving therefore has 
to be followed by PCR. The copro-antigen ELISA shows good sensitivity in high endemic areas, where 
infected animals are characterized by high worm burden, but it is not highly sensitive in animals with 
low worm burdens. Most PCR-tests have a lower sensitivity compared to the SCT. However, a recent 
study showed, by means of latent class analysis, that the sensitivity of the MC-PCR is comparable to 
SCT (Wahlström H, 2015). 
The predictive values of the different tests depend on the prevalence of EM in the particular study 
target population. SCT is considered the reference standard, but even this test has limitations in terms 
of sensitivity as indicated above.  
The available studies of the performance of the diagnostic tests for detection of EM in live or dead 
animals are very heterogenic, which complicates drawing any conclusions from them, also because 
the different tests aim at different targets (i.e. adult worms / eggs). A systematic review (Casulli et al, 
2015) demonstrated that there is a gap in evaluating diagnostic tests with scarce information on the 
diagnostic sensitivity, even for those tests considered as the most relevant to detect the parasite in 
definitive wildlife populations. In addition, a lack of standardization of the different diagnostic methods 
to detect EM may cause variation in diagnostic sensitivity and specificity between labs, which may 
adopt steps that are slightly deviating from the procedures described in the scientific literature. 
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Table 12:  Summary of the test diagnostic sensitivity values as reported by the MS in the framework 
of the surveillance implemented according to Commission Delegated Regulation (EU) No 
1152/2011 of 14 July 2011 compared to the values reported in Conraths et al., 2015 
MS 





Casulli et al. 
(2015) 
Conraths et al 
(2015) 
Finland MC-PCR (fishing Real time PCR 
targetting 12S rRNA gene  
(78% by internal validation)  
Isaksson et 
al., 2014 
88%–95.7% 88%  
(compared to Isaksson 
et al, 2014 on RT-PCR) 
Ireland Sedimentation and Counting 
Technique, tecnica parassitologica 
classica (Se 98%) 
Eckert, 2003 98% 83.8% 
(Eckert et al. 2001) 
Malta Sieving/flotation of faecal samples 
for copro-egg detection and 
Multiplex-PCR targetting 12S rRNA 
and nad1 genes (Se 94%) 
Mathis et al. 
1996 
88%–95.7% 50%  
(Trachsel et al., 2007) 
UK sieving/flotation of faecal samples 
for copro-egg detection and 
modified PCR Cest1-Cest2 targetting 
nad1 mithocondrial gene  
(proposed Se 85%) 
Mathis et al. 
1996; 
Dinkel et al., 
1998 
88%–95.7% 89%  
(compared with IST) 
Norway MC-PCR (fishing Real time PCR 
targetting co1mithocondrial gene) 
(Se 63%) 
Øines et al., 
2014 
88%–95.7% 88% 
(Isaksson et al., 2014) 
 
Table 12 summarises and describes the uncertainty around the diagnostic sensitivity of the different 
tests used by the laboratories involved in the surveillance programmes adopted by the MSs listed 
under the Commission Delegated Regulation (EU) No 1152/2011. It can be seen that there is a high 
degree of discrepancy between the values reported by the MSs and the ones reported in the reviews 
performed by Casulli and by Conraths (Casulli et al. 2015; Conraths et al., 2015). Morover, even when 
the reported method is similar (e.g. Finland and Norway) the proposed values are very different. 
Finland performed an internal validation of the test used, concluding differently from Isaksson 
(Isaksson et al., 2014) on the test sensitivity. This confirms the above statement on the important role 
of the internal protocol when estimating the diagnostic sensitivity and on the need for standardisation. 
In conclusion, studies on the diagnostic tests for detection of EM in animals are very heterogenic, 
which complicates drawing any conclusions from them. Conditions should be established to enable 
estimation of the test sensitivity of the individual laboratories participating in EM surveillance 
programmes, in order to achieve better estimates of the true confidence of absence of infection. This 
should preferable be done in line with the guidelines from OIE (OIE, 2013), which also require a case 
definition, and coordinated by the EURLP.  
3.9.2. Guidance to substantiate test sensitivity estimates  
Regulation (EU) No 1152/2011 provides that all Member States listed in Annex I thereof, i.e. the 
countries where no findings of the parasite have been recorded, shall implement a pathogen-specific 
surveillance programme. Test sensitivity is one of the parameters required to calculate the number of 
samples to be taken in a surveillance (EFSA, 2012b). The countries involved use different tests to 
detect EM (see Section 3.4.1) and their protocols often deviate from those used in publications 
reporting test sensitivity estimates. As there is no diagnostic method available with 100% sensitivity, it 
is difficult to evaluate the diagnostic sensitivity of the different tests. Furthermore, it is preferred that 
test characteristics are evaluated on the population on which the test shall be used. However, this 
raises another difficulty since there are no positive samples in countries where no findings of the 
parasite have been recorded. 
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Figure 8:  Sample size needed to detect the infection, should this be above the maximum allowed 
prevalence of 1%, with a 95% confidence, as a function of the test sensitivity 
A study should be undertaken to estimate the probability of each relevant test to detect infection, 
given that the animal is truly infected (according to the definition of test sensitivity), using an 
adequate sample of specimens from endemic areas where the entire range of different infection 
stages and intensities are represented. Such a study should follow the OIE Terrestrial Manual, Chapter 
1.1.5 (OIE, 2013), and could be coordinated by the EU Reference Laboratory (EURL) for Parasites. 
Until better documentation is available, the diagnostic sensitivity should be set conservatively to the 
lowest value from the ones listed in Table 12, excluding the lowest 20th percentile. In this case, the 
suggested value to be used for future surveys is 78%. The required sample size for each country will 
be equal to 383 (Figure 7), the latter allowing the detection of an infected animal with a 95% 
confidence, should the prevalence in the DH be above the maximum allowed prevalence of 1%. 
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4. Conclusions 
TOR 1: To describe E. multilocularis infection in animals in the EU and AC 
and in particular: 
a) the geographical distribution and prevalence of E. multilocularis infection in the main 
infected domestic and wildlife species involved in the E. multilocularis lifecycle: 
x Until the 1990s, only a ‘core’ area consisting of Eastern France, southern Germany and 
parts of Switzerland and Austria were known to be endemic. 
x Since the 1980s, EM-infections in animals were recorded in 17 countries in Central Eastern 
Europe where no cases were reported before. 
x The observed prevalence of EM-infected animals as well as the abundance of host species 
has increased in the Baltic regions, Denmark, the Netherlands, Poland, Romania, Slovakia, 
Slovenia during the 1990s and later. 
x The distribution of EM is not homogeneous, showing areas with high and low prevalence 
levels in foxes, ranging from values close to 0% (e.g. Denmark, northeast Germany, 
Sweden), to values close to 50% (e.g. part of France, southern Germany, part of 
Switzerland). 
x These differences in prevalence levels in foxes, among the countries where EM has been 
reported, have been linked most frequently to the use and structure of landscape, which 
influences the species range and abundance of rodents as intermediate hosts and to the 
microclimatic conditions necessary for the transmission and establishment of the parasite. 
x Accessible data indicate that, within the Russian Federation, EM and human AE are 
frequent in parts of Siberia and the Far East. 
b) the importance and role of the different host species in the life cycle of the parasite: 
Wild carnivores 
x Due to its high population densities, high susceptibility to EM infection, high worm burden 
in infected animals, and higher infection prevalence compared to other potential definitive 
hosts, the red fox is considered to be the principal definitive host in temperate parts of 
Europe, Asia and (probably) North America. 
x The prevalence of infected animals in raccoon dog populations in Eastern Europe and in 
Eastern Germany has been shown to reach levels similar to those observed in red foxes. 
x Raccoon dog, golden jackal and wolf can act as definitive host, but there is no evidence 
that they can maintain the lifecycle in the absence of red foxes. 
Domestic carnivores  
x There is no evidence that dogs and cats can maintain the life cycle of EM in the absence of 
red foxes. 
x The prevalence of EM in the general dog population is very low. 
x No systematic assessment has been done anywhere on the quantitative contribution of 
dogs to the infection of intermediate host populations. 
x Living and working with dogs might be or become relevant as potential risk factors for AE 
in Europe. 
x Cats show low susceptibility to experimental infection. 
x Natural infection of cats has been recorded in several countries. 
x Current knowledge suggests that the contribution of cats to the EM lifecycle is low. 
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Competent, epidemiologically relevant intermediate hosts  
x In Europe, various vole species of the genera Microtus, Arvicola, Myodes and Lemmus are 
confirmed as suitable intermediate hosts based on field studies and/or experimental 
infections. 
x The common vole, Microtus arvalis, is the most important intermediate host in areas such 
as Northeast France (Ardennes) and Switzerland, while the water voles Arvicola spp. may 
maintain transmission in Hungary and urban areas of Central Europe. 
x Muskrats (Ondatra zibethicus), nutria/coypu (Myocastor coypus) and beaver (Castor fiber) 
are suitable intermediate hosts, but are likely to be infrequent prey for foxes due to their 
large size and habitat specificity. 
x The relative importance of different rodents and other small mammal species for 
maintenance of the lifecycle differs according to geographical areas, the type of 
environment, prevalence of infection and other parameters. This extreme variability does 
not make any of those potential IH particularly suitable for surveillance purposes. 
c) the risk factors for and the probability of introduction and establishment of E. 
multilocularis in areas where it is has never been recorded, through the movement of 
infected domestic and wildlife species involved in the E. multilocularis lifecycle; 
Introduction 
x Movement of definitive hosts with a pre-patent or patent infection (i.e. infected domestic 
and wildlife species involved in the E. multilocularis lifecycle) is an important introduction 
pathway. 
x In principle, EM can also be introduced by infected intermediate hosts that carry fertile 
larval stages (metacestodes) or infectious parasitic stages, or by other items, e.g. plants, 
contaminated with eggs into free areas. 
x It is difficult to distinguish introduction of EM from its first detection (i.e. established, but 
not detected) if no adequate surveillance had been in place in areas deemed to be free. 
x Based on the introduction model used in this opinion, in order to reach a probability of 
introduction of at least 75%: 
– The presence of the border compliance checks increases the number of dogs 
that need to pass the border by 1.75 to 4 times. 
– If no border compliance check is in place for a country adjacent to an endemic area 
(prevalence in foxes equal to 16%) introduction would require 75 to 1200 times 
more dogs than foxes crossing the border. If border compliance checks are in place, 
150 to 2550 times more dogs than foxes crossing the border. 
– For a free country adjacent to an area with a very low prevalence in foxes 
(0.001%) the crossborder movement of dogs has a prominent role (1.16 to 2.31 
fewer dogs coming from an endemic area relative to migrating foxes). 
– The degree of non-compliance to treatment among dogs that are not 
checked at the border (because no border checks are in place or because the 
border checks have been evaded) plays a less important role on the probability of 
introduction of EM, compared to other parameters. 
– Despite the implementation of appropriate mitigation measures, it is inevitable that 
infected dogs enter free countries. However, other factors in addition to introduction 
are important in establishing EM in free countries. 
x In this opinion, the model results do not represent any particular MS.  
Establishment 
x For the transmission and establishment of the life cycle, appropriate definitive and 
intermediate hosts must be present. 
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x Environmental factors influence the persistence of the lifecycle; therefore the probability of 
EM becoming established will vary from one area to another. However, the knowledge on 
the geographical distribution of the environmental factors for the persistence of the life 
cycle is scarce. 
x In areas where no suitable autochthonous wild canid hosts and no highly suitable 
intermediate hosts exist, e.g. Malta, establishment of the EM cycle is considered close to 
impossible. 
TOR2: To assess the current situation in the EU and AC regarding: 
a) the monitoring and surveillance programmes of E. multilocularis infection in definitive 
and intermediate hosts, and the probability of detection if E. multilocularis is 
introduced into areas where it is has never been recorded; 
x Only the countries that are listed under Commission Delegated Regulation (EU) No 
1152/2011 are obliged to implement surveillance activities.  
x The diagnostic sensitivity of the tests used in these EM surveillance programmes is not 
supported by robust scientific evidence and the tests are not validated according to OIE 
standards. 
x Obtaining a representative sample from host populations is hampered by the impossibility 
of implementing a representative random sample in wildlife and the scarcity of knowledge 
on the distribution of red fox populations at regional level. 
x Political borders do not necessarily match with the epidemiologically relevant units as they 
do not provide a barrier for wildlife EM hosts.  
x In order to allow early detection of EM infection, a very low design prevalence of e.g. 0.1% 
is required, as it may take many years for EM to reach a prevalence of 1% in the 
population. However, such a low design prevalence may make surveys for early detection 
impracticable due to the large sample size required. 
x Provided that the risk factors are properly documented, the implementation of a risk based 
approach may allow a reduction of the sample size. 
x For the purpose of demonstrating absence of infection, the inclusion of the concept of the 
Bayesian Probability of Freedom in the regulation, may allow a reduction of the sample 
size. 
x The notification of the detection of the parasite is mandatory only in a few MS and there is 
no requirement for monitoring or surveillance of EM in EU countries where findings of the 
parasite have been recorded. 
x The detection of the parasite is currently not notifiable in non-free MS. Occurrence may be 
reported at genus or species level. However, E. multilocularis and E. granulosus, although 
they belong to the same genus, have different lifecycles and cause completely different 
pathologies in humans. Echinococcus notifications should always be done at species level 
to enable an understanding of the actual trend and geographical distribution of these 
infections. 
x Considering the spatial and temporal heterogeneity in the EM distribution within a country, 
the results of local or regional surveys cannot be extrapolated to a whole country. 
b) the programmes for the eradication of E. multilocularis in wildlife host species; 
x Eradication of EM in the European wildlife could theoretically be achieved by means of baits 
in small areas where foxes are present, but the intervention needs to be perpetuated to 
maintain the status. 
x In large areas, long term control - but not elimination - of the parasite may be possible by 
baiting. 
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x Control by baiting requires more knowledge about how and where to control the parasite in 
a cost efficient way. 
x Increased fox hunting/trapping is not considered to be effective in controlling the parasite. 
TOR3: To describe the current situation in the EU and AC regarding: 
a) the risk factors associated with human AE; 
x The following potential risk factors have been identified in Europe: Dog ownership, cat 
downership, living in a rural area, having a kitchen garden, occupation (farming), and 
haymaking in meadows not adjacent to water, going to forests for vocational reasons, 
chewing grass and handling foxes.  
x Particular Human leukocyte antigen types have been found out to be protective against AE. 
x The presumably very long incubation period of the human AE makes the study of risk 
factors extremely difficult; hence uncertainty on the risk factors is high. 
b) the impact of E. multilocularis infection in animals on public health; 
x The true number of cases of AE is not known in Europe mainly because of under-reporting. 
x There has been an increase in the number of reported AE cases in new areas, such as 
Lithuania and Latvia, and an increase of the human AE incidence in endemic countries, 
such as Austria, France, Poland and Switzerland, which suggests a geographic spread and 
an increase of this disease/infection in Europe. 
x If early detection and clinical management do not make progress beyond current practices, 
European health systems could probably face costs in the range of one or more billion of 
euros to care for the number of AE patients expected in the next two decades. 
TOR4: To describe the efficacy of available E. multilocularis drugs and the 
effectiveness of the current species-specific treatment protocols to 
protect domestic species against the parasite; 
x Due to its favorable pharmacokinetic properties and activity against both immature and 
mature stages, praziquantel is the substance of choice for the treatment of EM in definitive 
hosts, including travelling or imported dogs. 
x In addition to treatment efficacy, the treatment timing is crucial. A general rule is to treat 
as close as possible to entry into a free country. 
x Results of model simulations indicate that: 
– The risk of introduction/transmission/establishment, expressed as a function of the 
number of eggs deposited in a free area, can be reduced by treating moving dogs 
before or after entering the free area. 
– Treating dogs earlier than 24 hours before entering a free area allows the risk of 
reinfection before moving. Therefore, the risk introduction / transmission / 
establishment is the lowest when treating one day prior to crossing the border and 
increases when the treatment is administered more than 24 hours before crossing the 
borders. 
– The shorter the visit of a dog living in an endemic area to a free area, the more 
effective it is to treat the dog before it enters the free area compared to treating the 
dog after it enter the free area. 
– The shorter the visit of a dog living in a free area to an endemic area, the greater is 
the advantage of delaying treatment until the dog has returned to the free area. 
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TOR5: To assess the laboratory techniques for the detection of E. 
multilocularis in live and dead animals, in terms of sensitivity, 
specificity, predictive values and practicability (i.e. rapidity, large 
scale use, ease of use). 
x The SCT is a post mortem approach at necropsy considered as the reference standard for the 
detection of EM. The lower limit of detection of the SCT is high. Usually the worm burden is 
low and this results in a diagnostic sensitivity of less than 100%, particularly if used in a 
period close to the introduction. Furthermore, the SCT is a time consuming approach 
x DNA-based methodologies for the detection of EM genetic material in faeces or intestinal 
contents may be equally or more sensitive than SCT. Intrinsic limitations of DNA-based 
methodologies such as inhibitors, costs, small volume of sample to analyse, timing and 
sensitivity were recently overcome. 
x Lack of standardization of diagnostic methods detecting EM probably causes variation in 
sensitivity and specificity between labs. 
x Studies on the diagnostic tests for detection of EM in animals are very heterogenic, which 
complicates drawing any conclusions from them. Conditions should be established to enable 
estimation of the test sensitivity of the individual laboratories participating in EM surveillance 
programmes, in order to achieve better estimates of the true confidence of absence of 
infection. 
5. Recommendations 
x The public health risk associated with human cases of AE is the reason behind the EU 
regulation to control and monitor EM in animal species. It is therefore essential that 
notification of human AE (and CE) cases be made mandatory in all Member States to enable 
effective and coherent monitoring of trends of AE (and EC) occurrence in humans. A 
reconsideration of ‘echinococcosis’ case definition in the current Commission Decision 
2012/506/EU, differentiating alveolar from cystic echinococcosis, will be crucial to collect 
specific epidemiological and clinical data to manage and trace back these infections. 
x Routine surveillance to substantiate the absence of EM in domestic dogs is not scientifically 
justified in countries where no definitive wildlife hosts are present. Such countries, e.g. Malta, 
do not need to carry out surveillance on domestic dogs to substantiate EM-freedom. The 
option of making the treatment non compulsory anymore for dogs entering such country is a 
public health issue and relates to the risk of humans getting infected by the parasite by 
means of contaminated dog faeces. 
x Surveillance to enable early detection of newly introduced EM in an assumed free country 
requires a considerable increase in the number of samples and tests compared to what is 
needed for substantiating absence of infection from EM at a design prevalence of 1%. 
x Reconsideration of some aspects of the current legislation to optimise the surveillance 
activities might be relevant. In detail: (i) the identification of epidemiologically relevant units 
should be independent from the political borders; (ii) for the purpose of demonstrating 
absence of infection, the inclusion of the concept of the Bayesian Probability of Freedom in 
the regulation, may allow a reduction of the sample size. 
x Studies to improve the knowledge on epidemiological risk factors, including geographical risk 
factors, should be encouraged to enable well-founded risk-based sampling in geographical 
subpopulations of hosts to improve the detection. 
x Studies to improve the knowledge on the probability of transmission and establishment of 
new EM introduction in free countries should be encouraged.  
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x Reconsideration of the definition of the optimal treatment window (presently up to 120 hours 
before entry) when moving dogs from infected to non-infected countries might be worthwhile 
to reduce the risk of reinfection. A general rule is to treat as close as possible to entry into a 
free country. 
x A study should be undertaken to estimate the probability of each relevant test to detect 
infection, given that the animal is truly infected (according to the definition of test sensitivity), 
using an adequate sample of specimens from endemic areas where the entire range of 
different infection stages and intensities are represented. Such a study should follow the OIE 
Terrestrial Manual, Chapter 1.1.5 (OIE, 2013), and could be coordinated by the EURL for 
Parasites. 
x Until better documentation is available, the diagnostic sensitivity should be set conservatively 
to the lowest value, excluding the lowest 20th percentile, from the ones reported in the 
scientific literature and related to the diagnostic tests implemented by the countries listed 
under Commission Delegated Regulation (EU) No 1152/2011. In this case, the suggested 
value to be used for future surveys is 78%. 
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Adjacent country Country sharing a land border with a Member State of the European Union 
Border check Checks made by appointed staff at the entry points into the UK for travelling pets. The 
transport companies (airlines, ferry operators and Eurotunnel staff) are responsible for 
ensuring the paperwork for travelling pets is correct. In turn, the transport companies are 
licensed and audited by APHA to make sure they are doing a good job. 
Patency the condition of showing detectable parasite infection 
Prepatent period The interval between infection of an individual and the first ability to detect from that host 
a diagnostic stage of EM. 
Proglottid One of the segments of a tapeworm, containing the reproductive organs. 
Probability of 
introduction  
Probability that at least one infected definitive host, or that at least one infected and 




Given that introduction has occurred, it is the probability that the parasite infects an 
intermediate or definitive host which in turn infects a definitive or intermediate host. 
Probability of 
establishment 
Probability that an infected DH is introduced into a free area and is able to transmit the 
parasite to an IH and the next DH; such that it leads to completing the life cycle and into 
the future.  A function of both the introduction and transmission probabilities, but also 

















AC adjacent country 
AE alveloar echinococcosis 
BC border compliance checks 
CE cystic echinoccosis 
cELISA copro-antigen enzyme-linked immunosorbent assay 
CI confidence Interval 
CL confidence Level 
DALY disability-adjusted life years 
DH definitive host 
EM Echinococcus multilocularis 
EUSR European Surveillance Report 
HLA human leukocyte antigen 
IH intermediate host 
IST intestinal scraping technique 
MC-PCR magnetic capture – polymerase chain reaction 
MS Member State of the European Union 
NBC no border compliance checks 
OIE Office International des Épizooties 
SCT sedimentation and counting technique  
SSCT segmental sedimentation and counting technique 
SVT shaking in a vessel technique 
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Appendix A – Overview tables for host species, geographic distribution 
and prevalence 
Table A1: Evidence regarding definitive host species for E. multilocularis in Europe 
Host species Type of evidence References (selected) 
Red fox (Vulpes vulpes) Natural and experimental 
infection 
See refs. Table A4; Kapel et al., 2006 
Arctic fox (Vulpes lagopus) Natural infection Peklo, 2014; Stien et al., 2010 
Raccoon dog (Nyctereutes 
procyonoides) 
Natural and experimental 
infection 
Machnicka et al., 2003; Schwarz et al., 
2011; Kapel et al., 2006 
Wolf (Canis lupus) Natural infection Bagrade et al., 2009; Schurer et al., 2014 
Golden jackal (Canis aureus) Natural infection Szell et al., 2013 
Domestic dog Natural and experimental 
infection 
Gottstein et al., 2001; Dyachenko et al., 
2008; Kapel et al., 2006 
Wild cat (Felis s. silvestris) Natural infection Umhang et al., 2015 
Domestic cat Natural and experimental 
infection 
Meyer & Svilenov, 1985; Petavy et al., 
2000; Dyachenko et al., 2008; 
Kapel et al., 2006; Umhang et 
al., 2015 
 
Table A2: Evidence regarding intermediate host species for E. multilocularis 
Host species Type of 
evidence 
Host competence 
in hosting / 
transmitting EM 
References (selected) 
Common vole (Microtus arvalis) natural and 
experimental 
infection 
competent Loos-Frank, 1987; Delattre et al., 
1988; Woolsey et al., 2015a 
Field vole (Microtus agrestis) natural and 
experimental 
infection 
competent Delattre et al., 1988; Woolsey et 
al., 2015b 
Common pine vole (Microtus 
subterraneus) 
natural infection competent Delattre et al., 1988 
Sibling vole (Microtus levis) natural infection competent Stien et al., 2010 
Bank voles (Myodes spp.) natural infection competent Delattre et al., 1988; Reperant et 
al., 2009 
Water voles (Arvicola spp.) natural infection competent Hofer et al., 2000; Petavy et al., 
2003 
Snow vole (Chionomys nivalis) natural infection competent Genov et al., 1980; Siko Barabasi 
et al., 1995 
Lemming (Lemmus lemmus)  natural and 
experimental 
infection 
competent Peklo, 2014; Ohbayashi et al., 
1971 
Muskrat (Ondatra zibethicus) Natural and 
experimental 
infection 
competent Romig et al., 1999a; Hanosset et 
al., 2008; Ohbayashi et al., 1971 
Beaver (Castor spp.) natural infection competent Janovsky et al., 2002; Cirovic et 
al., 2012 
Nutria (Myocastor coypu) natural infection competent Hartel et al., 2004, Umhang et al., 
2013 
Alpine marmot  
(Marmota marmota) 
natural infection competent Callait, 2003 
Muridae (Apodemus spp., Mus 




partly competent Delattre et al., 1988; Petavy et al., 
1991; Ohbayashi et al., 1971 
Brown hare (Lepus europaeus) natural infection competent Chaignat et al., 2015 
Shrew (Sorex sp.) natural infection competent Ohbayashi et al., 1971 
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Host species Type of 
evidence 
Host competence 
in hosting / 
transmitting EM 
References (selected) 









Sydler et al., 1998; Pfister & 
Frank, 1988; Pfister et al., 1998 









Lukashenko 1971; Ohbayashi et 
al., 1971; Miyauchi et al., 1984 







Deplazes & Eckert, 2001; 
Rehmann et al., 2005; Ohbayashi 
et al., 1971 
Domestic dogs Natural infection Invasive, but largely 
sterile growth 
Deplazes & Eckert, 2001 
 
Table A3: Current E.multilocularis status of EU MS and adjacent countries (present as map). 
Presence in humans is only reported for Turkey (strong, but almost exclusive evidence of presence) 
and for countries of doubtful endemicity status (defined as such due to uncertainty on the origin of 
infection). DH: definitve hosts, IH: intermediate hosts 
A: Endemic 
countries 
Evidence for presence (recorded host 
species with number of references) 
References (only one reference per 
species) 
Austria DH: red fox (6) See Table A4 
Belarus DH: fox (2) 
IH: voles (1), muskrat (1), coypu (1), other 
rodents (1), shrews (1) 
See Table A4; Marcinkute et al., 2015 
Belgium DH: red fox (8) 
IH: voles (1), muskrat (2) 
See Table A4; Hanosset et al., 2008 
Bulgaria IH: voles (2) Genov et al., 1980, Genov et al., 1981 
Czech Republic DH: red fox (3), dog (1), cat (1) 
IH: voles (1) 
See Table A4; Martinek et al., 1998; Martinek et 
al., 2001a; Cada et al., 1999 
Denmark DH: red fox (3), cat (1) See Table A4; Dyachenko et al., 2008 
Estonia DH: red fox (1), raccoon dog (1) See Table A4; Marcinkute et al., 2015 
France DH: red fox (17), dog (1), cat (2) 
IH: voles (13), muskrat (2), coypu (1), 
other rodents (2) 
See Table A4; Petavy et al., 1991; Petavy et al., 
2000; Delattre et al., 1988; Umhang et al., 
2013; Umhang et al., 2015 
Germany DH: red fox (52), raccoon dog (3), dog (2), 
cat (5) 
IH: voles (3), muskrat (9), coypu (2) 
See Table A4; Schwarz et al., 2011; Dyachenko 
et al., 2008; Loos-Frank, 1987; Romig et al., 
1999a; Hartel et al., 2004 
Hungary DH: red fox (4), golden jackal (1) See Table A4; Szell et al., 2013  
Italy DH: red fox (5) See Table A4 
Latvia DH: red fox (1), raccoon dog (1), wolf (1) See Table A4; Bagrade et al., 2008; Bagrade et 
al., 2009 
Liechtenstein DH: red fox (1) See Table A4 
Lithuania DH: red fox (2), raccoon dog (1), dog (1) 
IH: muskrat (1), pig (1) 
See Table A4; Bruzinskaite et al., 2007; 
Bruzinskaite et al., 2009; Bruzinskaite-
Schmidhalter et al., 2012; Mazeika et al., 2009 
Luxembourg DH: red fox (1) 
IH: muskrat (1) 
See Table A4; Nicodemus, 2012 
Netherlands DH: red fox (6), cat (1) 
IH: muskrat (1) 
See Table A4; Dyachenko et al., 2008; 
Borgsteede et al., 2003 
Norway 
(Svalbard only) 
DH: arctic fox (1) 
IH: voles (1) 
Stien et al., 2010 
Poland DH: red fox (14), raccoon dog (1) See Table A4; Machnicka et al., 2003; EFSA, 








Evidence for presence (recorded host 
species with number of references) 
References (only one reference per 
species) 
IH: pig (2), wild boar (1) 2015a 
Romania DH: red fox (1) 
IH: voles (1) 
See Table A4; Siko Barabasi et al., 1995 
Russia  DH: red fox (1), arctic fox (1) 
IH: lemming (1) 
Peklo, 2014 
Slovakia DH: red fox (11), raccoon dog (1), wolf 
(1), dog (2) 
See Table A4; Hurnikova et al., 2009; Martinek 
et al., 2001b; Antolova et al., 2009 
Slovenia DH: red fox (1) 
IH: Apodemus (1) 
See Table A4; Brglez & Krystufek, 1984 
Sweden DH: red fox (2) See Table A4 
Switzerland DH: red fox (14), dog (2), cat (1) 
IH: voles (10), pig (2) 
See Table A4; Gottstein et al., 2001; Stieger et 
al., 2002; Sydler et al., 1998 
Turkey  Numerous human cases, mainly from 
eastern Anatolia; old unverifiable record 
from one fox and (probably misdiagnosed) 
cases in cattle 
Altintas, 1998; Altintas, 2003; Miman & Yazar, 
2012 
Ukraine DH: red fox (2) See Table A4 
B: Free 
countries 
Evidence for absence (number of 
references, examined host species) 
References 
Finland 5 (red fox, raccoon dog, voles) Wahlström et al., 2011; EFSA, 2007; EFSA, 
2013a; EFSA, 2014 
Ireland 4 (red fox) Murphy et al., 2012; EFSA 2011-2014 
Malta 2 (dog) EFSA, 2013b; EFSA, 2014 
Norway 
(mainland only) 
8 (red fox) Davidson et al., 2009; Eckert et al., 1991; 
Wahlström et al., 2011 ; EFSA, 2013a; EFSA, 
2015a ; EFSA, 2015b 
United Kingdom 5 (red fox, dog, cat) Smith et al., 2003; Learmount et al., 2012; 







Reason for uncertainty References 
Albania No data  
Bosnia-
Herzegovina 
Old, unverifiable records from cattle 
(probably misdiagnosed) 
Kolarova, 1999 
Croatia Border to endemic country (one negative 
survey of 85 foxes) 
Rajkovic-Janje et al., 2002 
Cyprus Insufficient data (28 dogs tested negative) EFSA, 2015a 
Greece Few unverified human cases Theodoropoulos et al., 1978 
Iceland No data  
Macedonia 
(FYR) 
One human case reported to European 
Registry (under country ‘Greece’) 
Kern et al., 2003; Kern, pers. comm. 
Moldavia Border to endemic countries; old record 
from Mus musculus 
Andreiko, 1961 (cited in Abuladze, 1964) 
Montenegro No data  
Portugal No data  
Serbia Border to endemic countries; one negative 
survey of 1000 foxes); one case of infected 
beaver, probably introduced 
Cirovic et al., 2012 
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Table A4: E. multilocularis prevalence (%) in red fox in EU MS and adjacent countries. Data are from necropsy of fox carcasses unless stated otherwise. 
Prevalence is expressed as the median of study results. Data are divided in two periods, before and after 1995. Fox population increases (and, where 
evidence exists, E. multilocularis prevalence increases) have started around 1990 in most countries, a development that lasted until approximately 2000. 
Therefore, the data are (approximately) divided into periods of low and high fox densities. When data were obviously published more than once, only the 
publication with the most comprehensive information (e.g. regional distribution within a country) was considered (this also applies to EUSR data). 







Number studies (references) 
Austria 
  West (Vorarlberg,, 
Tyrol) 
20.5 (-) 1 (EurEchinoReg, 1999) No data  
  Other regions 2.7 (-) 1 (EurEchinoReg, 1999) 6.4 (0.2-7.4) 3 (Duscher et al., 2005a; Duscher et al., 2005b; EurEchinoReg, 
1999) 
Belarus No data  7.4 (-) 1 (Shimalov & Shimalov 2003) 
Belgium     
  North and Brussels 2.0 (-) 1 (Vervaeke et al., 2006) 0.7 (0.0-1.8) 4 (Brochier et al., 2007; Vervaeke et al., 2003; Vervaeke et al., 
2005; Van Gucht et al., 2010) 
  South 33.1 (15.3-51.0) 2 (Losson et al., 1997; 
Brochier et al., 1992) 
20.2 (19.4-25.1) 3 (Vervaeke et al., 2006; Losson et al., 2003; Hanosset et al., 2008) 
Czech Republic No data  11.5 (7.4-33.7) 4 (EurEchinoReg, 1999; EFSA, 2006; EFSA, 2007; EFSA, 2013a) 
Denmark No data  0.6 (0.03-1.2) 2 (Saeed et al., 2006; Wahlström et al., 2015) 
Estonia No data  29.4 (-) 1 (Moks et al., 2005) 
France 
  ‘old’ endemic area 21.5 (4.2-33.7) 7 (Coudert et al., 1970; 
Petavy et al., 1990; Bert et 
al., 1987; Baudouin & 
Aubert, 1993; Pesson & 
Carbiener, 1989; Petavy et 




4 (Guislain et al., 2008; Raoul et al., 2001; Combes et al., 2012; 
EFSA, 2013a) 
 
29.9 (-) (urban) 1 (Robardet et al., 2008) 
  ‘new’ endemic area No data  9.6 (-) 1 (Combes et al., 2012) 
Germany 
  Bavaria 27.8 (15.1-28.0)  3 (Zeyhle et al., 1990; Vos 
& Schneider, 1994; 
Nothdurft et al., 1996) 
41.4 (40.4-55.5) 
 
3 (König et al., 2005; Janko et al., 2011; König & Romig, 2010) 
20.2 (-) (urban) 1 (König & Romig, 2010) 




www.efsa.europa.eu/efsajournal 79 EFSA Journal 2015;13(15):4373 
 







Number studies (references) 
  Baden-Württemb. 22.9 (12.0-57.9) 9 (Ewald, 1990; Zeyhle et 
al., 1990; Schott & Müller, 
1990; Wessbecher et al., 
1994; Janka & Stoye, 
1998; Fesseler, 1990; 
Bilger et al., 1995) 
37.0 (-) 
17.3 (-) (urban) 
1 (EurEchinoReg, 1999) 
1 (Deplazes et al., 2004) 
  Berlin 0.0 (-) 1 (Schoeffel et al., 1991) No data  
  Brandenburg 8.3 (-)  1 (Tackmann et al., 1998) 2.4 (-)  1 (Staubach et al., 2001) 
  Bremen No data  No data  
  Hamburg 0.0 (-) 1 (Zeyhle et al., 1990) No data  
  Hesse 29.0 (3.0-38.0) 3 (Zeyhle et al., 1990; 
Eskens, 1997; Ballek, 
1991) 
38.2 (35.9-40.5)  2 (Immelt et al., 2009; Eskens, 1997) 
  Lower Saxony 9.8 (5.8-13.8) 2 (Zeyhle et al., 1990; 
Berke et al., 2008) 
14.4 (-) 1 (Berke et al., 2008) 
  Mecklenburg-Vorp. 0.6 (-) 1 (Kiupel, 1996) No data  
  North Rhine-West. 7.5 (6.8-11.1) 3 (Zeyhle et al., 1990; 
Ballek, 1991; Takla, 1996) 
23.6 (16.1-36.8) 3 (Hartel et al., 2004; Takla, 1996, EurEchinoReg, 1999) 
  Rhineland-Palatin. 6.5 (4.1-9.0)  2 (Jonas & Hahn, 1984; 
Jonas & Dräger, 1998) 
33.8 (-) 1 (Jonas & Dräger, 1998) 
  Saarland 25.6 (19.9-31.3) 2 (Ahlmann, 1996, Meine & 
Müller, 1996) 
No data  
  Saxony-Anhalt 0.8 (-) 21/2573 1 (EurEchinoReg, 1999) 10.2 (1.4-19.0) 2 (EurEchinoReg, 1999, Denzin et al., 2014) 
  Saxony 0.0 (-) 1 (Enge, 1996) No data  
  Schleswig-Holstein 0.2 (0.0-0.4) 3 (Lucius et al., 1988; 
Nebel, 1996) 
0.0 (-) 1 (Manke & Stoye, 1998) 
  Thuringia 16.2 (-) 1 (Staubach et al., 2011) 30.9 (-)  1 (Staubach et al., 2011) 
Hungary No data  9.4 (5.0-12.7) 3 (Tolnai et al., 2013; Sreter et al., 2003; Sreter et al., 2004) 
Italy 
  Trento-Alto Adige No data  0.8 (0.6-1.0) 2 (Di Cerbo et al., 2008; Manfredi et al., 2002) 
10.0 (-) (c-PCR) 1 (Manfredi et al., 2006 
  other regions 0.0 (0.0-0.0) 6 (Soldati et al., 1976; 
Rossi et al., 1983 ; 
Poglayen et al., 1985 ; 
Leoni et al., 1986; Iori et 
al., 1990 ; Guberti & 
Poglayen, 1991) 
0.0 (0.0-0.0) 3 (Di Cerbo et al., 2008; Calderini et al., 2009; Magi et al., 2009) 
0.0 (-) (c-PCR) 1 (Manfredi et al., 2006) 
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Number studies (references) 
Latvia No data  35.6 (-) 1 (Bagrade et al., 2008) 
Liechtenstein 34.9 (-) 1 (Ewald & Eckert, 1993) No data  
Lithuania No data  58.7 (-) 1 (Bruzinskaite-Schmidhalter et al., 2012) 
Luxembourg GD No data  21.0 (0.0-37.9) 8 (Ahlmann, 1996; EFSA, 2006; EFSA, 2007; EFSA, 2013a; EFSA, 
2015a) 
Netherlands 0.0 (-) 1 (Borgsteede, 1984) 9.4 (0.7-59.5)  3 (Takumi et al., 2008; Van der Giessen et al., 2004; Van der 
Giessen et al., 1998; Franssen et al., 2014; Maas et al., 2014) 
Poland 2.6 (-) 1 (Malczewski et al., 1999) 
(data until 1998) 
15.1 (1.0-20.1) 8 (Borecka et al., 2008; Karamon et al., 2008; Karamon et al., 
2011; Borecka et al., 2007; Malczewski et al., 2008; Borecka et al., 
2009; Pacon et al., 2006; Karamon et al., 2014) 
Romania 0.0 (-) 1 (Siko Barabasi et al., 
1995) 
4.8 (-) 1 (Barabasi et al., 2010) 
Russia 16.6 (-) 1 (Peklo, 2014) No data  
Slovakia No data  19.0 (16.7-30.3) 3 (Miterpakova & Dubinsky, 2011; EFSA 2013a, 2015a) 
Slovenia No data  2.6 (-)  1 (Vergles Rataj et al., 2010) 
Sweden No data  0.1 (0.0-0.1) 3 (Wahlström et al., 2011; Wahlström et al., 2012;, SVA 2015) 
Switzerland 
  North / Northeast 48.7 (34.2-63.2)  2 (Ewald & Eckert, 1993; 
Alther, 1996) 
48.5 (44.3-52.7)  2 (Hofer et al., 2000; Hegglin et al., 2003) 
  Central (Alps) 7.8 (3.9-11.7)  2 (Ewald & Eckert, 1993, 
Alther, 1996) 
No data  
  Berne / Northwest 37.8 (-) 1 (EurEchinoReg, 1999) No data  
  West 37.2 (25.5-49.0) 2 (Gottstein et al., 1996, 
EurEchinoReg, 1999) 
45.9 (45.7-46.1)  2 (Reperant et al., 2007; Fischer et al., 2005) 
  South / Southeast 4.8 (2.2-7.1)  3 (Ewald & Eckert, 1993, 
Alther, 1996, 
EurEchinoReg, 1999) 
4.7 (3.1-6.4) 1 (Tanner et al., 2006; Guerra et al., 2014) 
Ukraine No data  2.3 (1.6-3.0) 2 (Kharchenko et al., 2008; Kornyushin et al., 2011) 
 
Austria (n = 3928): Older data show a clear division with high prevalence in the West (Voralberg, Tyrol) and low prevalence in the remaining country. 
Temporal changes are unclear, because surveys in different parts of Austria were done in different time periods. From 2004/2005, 8/105 fox without regional 
allocation were reported (EFSA, 2006) 
Belarus (n = 94): Only southern part of Belarus studied. Cumulative data 1981-2001. Small sample size. 
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Belgium (n = 3755): Sample size from the previous period is far smaller than from the latter period (430 vs. 3325); no temporal decrease of prevalence can 
be construed from these data. There is a clear gradient with high prevalences in the south and low prevalence in the north of Belgium. 
Czech Republic (n = 5413): No clear geographical pattern recognizable, a focus with high prevalence in Klatovy district (28 of 44 foxes). Possibly 
increasing: most recent survey (2011, n=1484) gave 33.7% prevalence. 
Denmark (n = 2209): In two country-wide surveys, a total of seven positive foxes clustered in two distinct areas (on Zealand near Copenhagen and on the 
mainland near the German border). 
Estonia (n = 17): Extremely small sample size. 
France (n = 6032): Only eastern and parts of northern and central France have ever been surveyed, with a recent overall prevalence of 17.0% (n = 3307). 
In most the historical endemic areas (eastern France from the Ardennes to Doubs/Jura and Massif Central), prevalence increases compared to pre-1995 
surveys are reported. No data are available for western and southern France. 
Germany (n = 97,872: Bavaria 5660; Baden-Württ. 18200; Berlin 100; Brandenburg 7895; Hamburg 2; Hesse 2308; Lower Saxony 8488; Mecklenburg-
Vorpommern 3576; North Rhine-Westphalia 2058; Rhineland-Palatinate 9824; Saarland 385; Saxony 2155; Saxony-Anhalt 9731; Schleswig-Holstein 1270; 
Thuringia 26220). Prevalence differences are apparent both countrywide (lower prevalences in the Northeast, higher prevalences in central and southern 
Germany), but also within federal states (Bavaria, Baden-Württemberg, Thuringia and Lower Saxony). Generally, mountainous, sparsely populated areas 
show higher prevalence levels than low lying, densely populated regions. Temporal increase pronounced in most parts, although quality of evidence is 
variable (best documented in Lower Saxony, Baden-Württemberg and Thuringia) 
Hungary (n = 1862): Country-wide survey shown gradient from northwestern to southeastern Hungary. 
Italy (n = 2717): Positive records only from provinces Trento and Bolzano. Pre-1990 negative surveys (n = 778) from Piemont, Lazio, Emilia-Romagna and 
Sardinia, more recent negative surveys (n = 858) from Aosta, Lombardy, Veneto, Liguria, Tuscany and Lazio.  
Latvia (n = 45): Extremely small sample size. According to a recent review (Marcinkute et al., accepted), a sample of 430 foxes gave a much lower 
prevalence (‘almost halved’). 
Liechtenstein (n = 129): Only old data available. 
Lithuania (n = 269): The high prevalence appears to be evenly spread across the country, even in suburban areas (Kaunas). 
Luxembourg (Grand Duchy) (n = 860): In some reviews the country was confused with the Belgian province of the same name. Fox prevalence similar to 
adjacent parts of Belgium and Germany. Recently AE was found to be common in muskrats. 
Netherlands (n = 967): Three of the five studies focus on the only known endemic areas (Groningen and Limburg). The two wider survey (n = 589) gave 
0.7% and 1.1% prevalence, which is likely to be more representative for the country. 
Poland (n = 7414): Highest regional prevalences in the South (Tatra region) and the Northeast (Warmia and Mazuria), lowest in the Northwest. A trend 
towards increasing prevalence levels is reported for most parts of the country. 
Romania (n = 1096): Surveys restricted to the central and northwestern parts of the country. 
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Russia: According to Bessonov (2002) and Martynenko et al. (1988), alveolar echinococcosis is endemic in at least 33 regions of the Russian Federation, 
mainly in the Asian parts. Maps provided in these publication place transmission foci in the Far East and in southern Siberia, while all regions bordering 
neighbouring countries in Europe (Finland, Baltic states, Belarus and Ukraine) are considered low endemic with morbidity of human AE of <1 / 100 000. 
According to Peklo (2014), records of E. multilocularis from animals in the northwestern part of European Russia are restricted to the tundra area of Nenetsia. 
The prevalence given in the table refers to red fox infection in Nenetsia Autonomous Okrug. 
Slovakia (n = 5580): Prevalence range within the country between 11.5% (Bratislava) and 49.6% (Tatra region, north-central). 
Slovenia (n = 428): Country-wide presence, prevalence appears to increase towards the Southeast. 
Sweden (n = 8723): No positive samples from a national monitoring 2000-2009, six positive samples from four different areas of south-central Sweden from 
national monitoring after 2010. 
Switzerland (n = 8646): Pronounced regional differences with high prevalence in the North and West, and low prevalence in the Alps and south of the Alps. 
Most data before 1995, no information on temporal change due to lack of recent data (except in the southern cantons, where prevalence seems to persist at 
a low level) 
Ukraine (n = 418): Prevalence not representative for the country: recent positive records only from foxes in in western Ukraine, there possibly high 
prevalence (4 of 14 foxes). Old records from foxes also in Crimea region (Abuladze, 1964). 
 
Table A5: Effectiveness of available EM deworming drugs 












placebo isotonic saline solution once NA 28 dpi 9 9 100% 
5 mg praziquantel / kg body weight once 21 dpi 28 dpi 9 0 
Schroeder et 
al., 2009 
1 mg emodepside and 5 mg praziquantel/kg body weight once 11 dpi 25, 26 dpi 8 1 99.9996% 
1 mg emodepside and 5 mg praziquantel/kg body weight once 21 dpi 25, 26 dpi 8 0 
Placebo tablets once NA 25, 26 dpi 8 8 
Eckert, 2001 5,2-5,8 (5,4) mg/ kg body weight once 20 dpi 24 dpi 4 2 99.60% 
NA NA 24 dpi 4 4 
4,9 - 5,3 (5,1) mg/ kg body weight once 20 dpi 24 dpi 4 2 
NA   4 4 
Andersen, 
1985 
praziquantel 1mg/kg of body weight + febantel 10 mg/kg of body 
weight 3 times (21, 22, 23 dpi) 
21,22, 23 dpi 28 dpi 6 0  
NA NA 28 dpi 6 6 
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NA NA 30 dpi 6 6 100% 
5,0 mg/kg body weight once 27 dpi 30 dpi 5 0 
NA NA 30 dpi 5 5 
5,0 mg/kg body weight once 14 dpi 30 dpi 4 0 
10,0 mg/kg body weight once 14 dpi 30 dpi 4 0 
NA NA 30 dpi 4 4 
Sakashita et 
al., 1995 
NA 17 dpi 21 dpi 2 2  
5 mg/kg body weight 17 dpi 21 dpi 1 0 
Thomas et 
al., 1978 
10 mg/kg body weight 24-27d 2-3 days 
after 
treatment 
1 0 100% 
5 mg/kg body weight 24-27d  3 0 
control NA  4 4 
control NA  1 1 
control NA  2 2 
control NA  2 2 
control NA  1 1 
control NA  1 1 
control NA  2 2 
10 mg/kg body weight 14d  4 0 
5 mg/kg body weight 14d  2 0 
control NA  2 2 
control NA  2 2 
Sakamoto et 
al., 1977 
none 25 dpi 27 dpi 5 5 99.996% 
5 mg/kg body weight once 25 dpi 27 dpi 5 1 
10 mg/kg body weight once 25 dpi 27 dpi 5 0 
       
Kazacos et 
al 1994 
5-7 mg /kg Praziquantel 1, 7, 14 dpi 7, 14, 21, 
24, 26 , 30 
dpi 
6 0 100% 
Kazacos et 
al 1993 
5-7 mg /kg Praziquantel 21 dpi 28 dpi 18 0 100% 
The publications taken into account consist of the selected ones by the SLR excluding those without data on worms. Two additional relevant abstracts were included (not retrieved by the SLR as 
without full text). This final collection of papers was also used by EMA to define the recommended treatment dose. 
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Appendix B – Probability of E. multilocularis introduction and 
establishment: a modelling exercise 
Probability of introduction  
In this appendix, the probability of introduction of the infection into a naïve population is explored 
through a quantitative model and a few theoretical scenario. The aim is primarily to describe the 
respective routes and barriers affecting the probability of introduction by the two most relevant 
routes, i.e. by wild canids (mainly foxes) and by domestic dogs. The difference between those two 
categories of DH is considerable and can be summarised in a few main points as reported in Table B1. 
Table B1: Comparison between wild canids and domestic dogs as DH for EM and the respective 
characteristics related to the probability of introduction 
Characteristic Wild canids Domestic dogs 
Treatment NO Possible, and required when entering a MS 
listed under Commission Delegated Regulation 
(EU) No 1152/2011  
Border compliance 
checks 
NO Possible in some MS where no findings of the 
parasite have been recorded (airports and 
harbours) 
Environment / Habitat Mainly rural - Suitable for EM Mainly Urban –less suitable for EM compared to 
a mainly rural environment 
Data on movements Dispersal distance and population 
density vary according to 
geographical and ecological 
parameters and regions. Some 
data in scientific literature 
Move by owners 
(Official import data from the UK and Ireland) 
Prevalence data for 
country of origin 
Available data in scientific 
literature  
Available data in scientific literature 
 
Because of the differences listed in Table B1, different approaches to estimate the probabilities of 
introduction by foxes and by domestic dogs have to be used. The two estimates may subsequently be 
combined in order to estimate an overall probability of introduction into a free area. 
In the following sections, the first parameter that is calculated is the probability of introduction 𝑃௜௡௧௥௢, 
defined as the probability that at least one infected DH, that is or will be excreting eggs, is introduced 
into a free MS during a one year period. Note that the IH’s are not included in this modelling exercise 
as a route of introduction (the short range movements and the absence of monitoring and control 
measures make IH less relevant for introduction compared to canids). The important role of the IH’s is 
however included in the probability of transmission (𝑃௧௥௔௡௦). 
Probability of introduction: foxes  
The quantitative model described in this appendix aims at estimating the probability that at least one 
infected fox will migrate from an endemic area into a free area. In the calculations, a case (s) is 
defined as any fox harbouring at least one live parasite, irrespective of its stage of development; the 
population of interest (𝐍𝑾𝑰𝑳𝑫) is defined as the total number of foxes crossing the borders from an 
endemic area to a free area in a given time period, the latter being 1 year considering the framework 
given by the legislation in force. 
From the Binomial probability mass formula, it is possible to derive the probability that, out of the 
total number of foxes moving from an endemic area to a free area (Nௐூ௅஽) in a given period, at least 
one is infected (x > 0), given a certain true prevalence (ρௐூ௅஽) of infected foxes in the country of 
origin. This probability is the probability of introduction (𝑃௜௡௧௥௢ௐூ௅஽). Equation C1 gives the formula of 
the probability of introduction. 
P(x > 0) = P(x ≥ 1) = 1 − P(x = 0) = 1 − [൫1 −ρௐூ௅஽௜൯
୒ೈ಺ಽವ೔] = 𝑃௜௡௧௥௢ௐூ௅஽೔  
B1 




www.efsa.europa.eu/efsajournal 85 EFSA Journal 2015;13(15):4373 
 
Where Nௐூ௅஽௜ is the number of foxes moving from the 𝑖
௧௛ endemic area to a free area, x is the 
number of infected animals, ρௐூ௅஽௜ is the prevalence of infected foxes in the 𝑖
௧௛ area of origin and 
𝑃௜௡௧௥௢ௐூ௅஽೔ is the probability of introduction in a free area from that 𝑖
௧௛area of origin. 
Data input 
It can be seen that the two parameters needed to model the 𝑃௜௡௧௥௢ௐூ௅஽೔ are: i) the number of foxes 
moving from an endemic area to a free area (Nௐூ௅஽௜) and; ii) the prevalence (ρௐூ௅஽௜) of infected 
foxes in the area of origin.  
Those two parameters are characterised by a large variability. The prevalence, as explained in Section 
3.2, is not homogeneous across Europe and there can been large differences even between areas that 
are close to each other. The number of foxes crossing the borders depends mainly on three 
parameters: the border length, the fox population density and the distance covered during the 
migration phase. Several other factors actually influence the movements of foxes: natural factors (e.g. 
availability of food, reproductive period, competitions among adults and males, competition with other 
predators, presence of natural barriers) and human factors (hunting pressure, artificial barriers, etc.). 
However, this level of detail was considered not relevant for the scope of the modelling exercise. 
For this reason, different scenarios were investigated: Figure B1 shows the behaviour of the 
probability of introduction as a function of the number of animals crossing the border (Nௐூ௅஽) and of 
the hypothetical prevalence (different colours) in an adjacent endemic area where the animals come 
from. 
The range of prevalence values in Figure B1 reflect realistic prevalence rates of EM infections in foxes 
observed across the EU member states where findings of the parasite have been recorded, the lowest 
one (0.1%) representing infected Swedish regions and the highest one (40%) representing high-risk 
areas e.g. in Germany and inthe Baltic MS (see Table A4 in Appendix A). 
  








Figure B1: probability of introduction (𝑷𝒊𝒏𝒕𝒓𝒐𝑾𝑰𝑳𝑫) as a function of the number of wild canids (foxes 
in this modelling exercise) moving from an endemic area to a free area(𝑵𝑾𝑰𝑳𝑫) and of 
the hypothetical true prevalence of infected foxes in the adjacent endemic area where 
the animals come from (different colours) 
It can be seen that, the higher the prevalence in the (endemic) area of origin and the more the foxes 
that cross the border, the higher the chance that at least one infected animal is introduced in the free 
country. 
This is of course the simplest scenario, where the area of origin can be considered as a single 
epidemiological area, characterised by a unique prevalence value. Considering that many authors 
(Section 3.2 and Appendix A, Table 6) agree on the fact that the geographical distribution of EM is not 
homogeneous over an area, it is plausible to subdivide the area of origin in sub-areas, each of them 
characterised by a different true prevalence (of infected foxes) and a different number of foxes 
moving from an endemic area to a free area. 
Figure B2 shows the graphical representation of a model which estimates the probability of 
introduction from an endemic area of origin subdivided into sub-areas (𝑆𝑢𝑏 − 𝑎𝑟𝑒𝑎௜), each 
characterised by a different true prevalence (ρWILDi) and a different number of migrating animals 
(NWILDi). 
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Figure B2:  Graphical representation of the model used to estimate the probability of introduction 
from an endemic area of origin subdivided into sub-areas. NWILDi is the number of 
foxes moving from the ith sub-area to a free area and ρWILDi is the true prevalence in 
the ith sub-area. 
Following the same reasoning as described above, it is possible to estimate the probability that, out of 
the total number of animals moving into a free area (𝑁 = ∑ 𝑁௜௡௜ୀଵ ), from at least one of the sub-areas 
(𝑆𝑢𝑏 − 𝑎𝑟𝑒𝑎௜), at least one animal is infected. 
This probability is given by Equation C2  







where 𝑃௡௢ି௜௡௧௥௢ௐூ௅஽೔ is the probability that no infected animal will move into the free area, 𝑛 is the 
total number of sub-areas identified in the area of origin and P௜௡௧௥௢ௐூ௅஽೔ is the probability of 
introduction calculated at sub-area level using equation C1. Of course 𝑃௡௢ି௜௡௧௥௢ௐூ௅஽೔ and P௜௡௧௥௢ௐூ௅஽೔ are 
complementary probabilities. 
It has to be noted that this probability does not express the probability of establishment in the free 
area. The conditions for turning an introduction into an establishment are discussed in this Appendix. 
Probability of introduction: domestic dogs  
Estimating the possibility of an introduction by means of an infected domestic dog is completely 
different. The main differences between the two routes of introduction are presented in Table C1. In 
practice, many events may occur before an infected dog is introduced into a free area and is able to 
disseminate eggs in the environment. 
These events are captured in the model developed for domestic dogs by the following probabilities: 
x Probability that a domestic dog (potentially infected) goes through all the barriers in place 
(𝑃௧௛௥௢௨௚௛). The barriers considered in the modelling are listed and described in Table C2. 
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x Probability that a domestic dog, coming from an endemic area j (with a prevalence of infected 
dogs equal to 𝑃𝑟𝑒𝑣஽ைீ೔), and which went through all the barriers in place is infected 
(𝑃௜௡௧௥௢஽ைீೕ೔ = 𝑃௧௛௥௢௨௚௛ ∙ 𝑃𝑟𝑒𝑣஽ைீ೔ ) 
x Probability that, out of the total number of domestic dogs showing up at the borders of the 
free country, at least 1 of them goes through the barriers and is infected (𝑃௜௡௧௥௢஽ைீ) 
 
 
Figure B3:  Scenario tree developed to estimate the probability that a domestic dog (potentially 
infected) goes through all the barriers in place (P୲୦୰୭୳୥୦) in a free area where border 
compliance checks are in place. The dashed arrows indicate the successful paths for a 
potential introduction. The black squares indicate the paths that are not successful. 
Border compliance checks in place  
Figure B3 shows the most complete model, developed assuming a free area with border compliance 
checks (BC) in place, in order to estimate the probability that a domestic dog (potentially infected) 
goes through all the barriers in place (𝑃௧௛௥௢௨௚௛஻஼). 
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Table B2: Barriers, preventing or reducing the probability of introduction by a potentially infected 
domestic dog going to an area with border compliance checks n place 




Checks made by appointed staff at the entry 
points into the UK for travelling pets. The 
transport companies (airlines, ferry operators 
and Eurotunnel staff) are responsible for 
ensuring the paperwork for travelling pets is 
correct. In turn, the transport companies are 
licensed and audited by APHA to make sure they 



















A dog is in compliance with Regulation EC 
1152/2011 if the deworming treatment has been 

















values need to 
be considered: 






and one for 
the ones that 
do not evade 
(𝑃௞௡௘). 
In fact, it is 
likely that the 
probability of 
not being in 
compliance is 






The deworming treatment can be not fully 
effective. Usually, every treatment kills the 
majority of the worms but it might happen that 
the clearance is not complete. For the purpose 
of this modelling and according to the case 














The deworming treatment is considered fully 
effective if it is administered not more than 24 
hours before entering a free area. 
Probability 





that a dog has 
been 
dewormed not 







If a dog has been treated between 24 and 120 
hours before it enters a free area (‘old 
treatment’), the possibility of reinfection in the 
(potentially) endemic area in which it lives 









more than 24 
hours before 
their entrance) 
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It is now possible to follow the branches of the scenario tree to identify the paths that lead to a 
potential risk (see Table B3). 
It can be seen that the probability that a domestic dog (potentially infected) goes through all the 
barriers in place in a free area where border compliance checks are in place (𝑃௧௛௥௢௨௚௛஻஼) is therefore: 
𝑃௧௛௥௢௨௚௛஻஼ = ൣ(1 − 𝑃௘௩) ∙ 𝑃௞௡௘ ∙ 𝑃௙௔௜௟൧ + ൣ(1 − 𝑃௘௩) ∙ 𝑃௞௡௘ ∙ (1 − 𝑃௙௔௜௟) ∙ (1 − 𝑃ௗ௔௬ଵ) ∙ 𝑃௥௘௜௡௙൧
+ ൣ𝑃௘௩ ∙ 𝑃௞௘ ∙ (1 − 𝑃௙௔௜௟) ∙ (1 − 𝑃ௗ௔௬ଵ) ∙ 𝑃௥௘௜௡௙൧ + ൣ𝑃௘௩ ∙ 𝑃௞௘ ∙ 𝑃௙௔௜௟൧
+ [𝑃௘௩  ∙ (1 − 𝑃௞௘) ∙] 
B3 
Equation B3 estimate the probability that a single dog introduces the infection, should this dog be 
infected. Indeed, up to this point, the probability of a dog being infected as not been taken into 
account yet. 
Table B3:  Probability matrix for a domestic dog (potentially infected) going through all the barriers 
in place in a free area where border compliance checks are in place (P୲୦୰୭୳୥୦୆େ). 
 
Border compliance checks NOT in place  
If the free country has no border compliance checks in place, the scenario tree and the related 
probabilities are different. Figure B4 shows a scenario tree for these countries and Table B4 
summarises the probability values linked to the barriers (yes please include the values used. 
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Figure B4:  Scenario tree on the probability that a domestic dog (potentially infected) goes through 
all the barriers in place (P୲୦୰୭୳୥୦୒୆େ) in a free area where no border compliance checks 
are in place. The dashed arrows indicate successful paths. The black squares indicate 
no risk. 
Table B4: Barriers, preventing or reducing the probability of introduction by a potentially infected 
domestic dog going to an area where border compliance checks are NOT in place 
Event Description Probability Notation Definition 
TREATMENT 
COMPLIANCE 
A dog is in compliance with 
Regulation EC 1152/2011 if the 
deworming treatment has been 
administered not more than 120 





a domestic dog 
has been treated 
not more than 
120 hours before 
entering the free 
country) 
𝑃௞ே஻஼ Two different values 
need to be considered: 
one for the animals that 
evade the border 
compliance checks (𝑃௞௘) 
and one for the ones 
that do not evade 
(𝑃௞௡௘). 
In fact, it is likely that 
the probability of not 
being in compliance is 
higher in the escaped 
one (usually hidden) 
TREATMENT 
FAILURE 
The deworming treatment can be 
not fully effective. Usually, every 
treatment kills the majority of the 
worms but it might happen that 
the clearance is not complete. For 
the purpose of this modelling and 
according to the case definition, 
these dogs still represent a risk. 
Probability of 
failure 
𝑃௙௔௜௟ Probability that a 
deworming treatment 
does not operate a full 




The deworming treatment is 
considered fully effective if it is 
administered not more than 24 
hours before entering a free area. 
Probability that a 
(in compliance) 
treatment is old. 
𝑃ௗ௔௬ଵ Probability that a dog 
has been dewormed not 
more than 24 hours 
before its entrance. 
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Event Description Probability Notation Definition 
PROBABILITY OF 
REINFECTION 
If a dog has been treated between 
24 and 120 hours before it enters 
a free area (‘old treatment’), the 
possibility of reinfection in the 
(potentially) endemic area in 




𝑃௥௘௜௡௙ Probability that a 
treated dog gets re-
infected. 
(Relevant for dogs 
treated more than 24 
hours before their 
entrance) 
Similarly to the previous situation, it is now possible to follow the branches of the scenario tree to 
identify the paths that lead to a potential risk (see Table B5). 
TableB5:  Probability matrix for a domestic dog (potentially infected) going through all the barriers 
in a free area where no border compliance checks are in place (P୲୦୰୭୳୥୦୒୆େ). 
 
The overall probability that a domestic dog (potentially infected) goes through all the barriers 
(𝑃௧௛௥௢௨௚௛ே஻஼) in a free area where no border compliance checks are in place is therefore: 
𝑃௧௛௥௢௨௚௛ே஻஼ = [1 − 𝑃௞ே஻஼ ] + ൣ𝑃௞ே஻஼ ∙ 𝑃௙௔௜௟൧ + ൣ𝑃௞ே஻஼ ∙ (1 − 𝑃௙௔௜௟) ∙ (1 − 𝑃ௗ௔௬ଵ) ∙ 𝑃௥௘௜௡௙൧ B4 
Equation B4 estimates the probability that a single dog introduces the infection, should this dog be 
infected. Indeed, up to this point, the probability of a dog being infected as not been taken into 
account yet. 
Individual probability of introduction 
As a second step, it is now necessary to include the probability that a domestic dog, which showed up 
at the border and went through all the barriers in place, is actually infected or not. This probability is 
available once the prevalence of infected dogs in the area of origin is estimated (𝜌஽ைீ). However, it 
has to be considered that if a dog has spent only a little time in an endemic country (e.g. 2 weeks, as 
an average holiday period), the probability of being infected will be lower than the prevalence in that 
country. In this specific example of a dog living in a free country, spending 14 days in an endemic 
country and then coming back home, the probability of getting infected will be 14/90 (see also Section 
3.5). Therefore, the probability of introduction by means of a domestic dog is given by Equation B5 
𝑃௜௡௧௥௢஽ைீೕ = 𝑃௧௛௥௢௨௚௛(஻஼ ௢௥ ே஻஼) ∙ 𝐹௜௡௙ ∙ 𝜌஽ைீ  B5 
Where 𝐹௜௡௙  is the reduction factor of the probability of being infected (𝜌ௗ௢௚ ) as a function of the time 
spent in an endemic area (this will be 1 for dogs living in endemic areas and then entering a free 
country and 14/90 for dogs living in a free country, spending 14 days in an endemic country and then 
coming back home) and 𝑃௜௡௧௥௢஽ைீೕ is the probability that a single dog (the j
th dog) introduces the 
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disease into a free area with or without border compliance checks in place, i.e. it is infected and went 
through all the barriers.  
In case more than one area of origin needs to be included in the calculation, Equation B5 can be 
modified as in Equation B6 
𝑃௜௡௧௥௢஽ைீೕ೔ = 𝑃௧௛௥௢௨௚௛(஻஼ ௢௥ ே஻஼) ∙ 𝑃௜௡௙ ∙ 𝜌஽ைீ೔  B6 
where 𝑃௜௡௧௥௢஽ைீೕ೔ is the probability that a dog from area 𝑖 will introduce the infection into a free area. 
Overall probability of introduction 
It is now possible, following the same principle used for the wildlife, to estimate the probability that at 
least one infected dog, out of the total number of dogs showing up at the border, will introduce the 
infection into a free area (𝑃௜௡௧௥௢஽ைீ೔; see Equation B7) 
𝑃௜௡௧௥௢஽ைீ೔ = 1 − ൤ቀ1 − 𝑃௜௡௧௥௢஽ைீೕ೔ቁ
ேವೀಸ೔൨ B7 
where 𝑁஽ைீ೔ is the total number of dogs showing up at the border originating from area 𝑖. 
When more than one area of origin has to be taken into account, the 𝑃௜௡௧௥௢஽ைீ  needs to be calculated 
for each area by means of with Equation B7. The overall probability will then be estimated by 
Equation B8 and will represent the probability that, out of the total number of dogs showing up at the 
border from a given number of endemic areas, at least one of these dogs from at least one of the 
endemic areas will introduce the infection. 




where 𝑛 is the total number of areas of origin. 
Probability of transmission  
In the previous section, the probability of introduction has been extensively defined for wildlife and 
foxes. 
In order to estimate the probability of establishment, however, another step needs to be considered. 
In fact, once an infected-infectious definitive host (DH) has entered a free area, it will transmit the 
infection, with a given probability, to a suitable intermediate host (IH), which in turns will infect, with 
a given probability, a naïve suitable DH in the free area. Only if these events take place, the infection 
will remain in the new (previously free) area.  
Many factors are involved in the definition of these probabilities which can be actually only estimated 
and explored, at this time, by means of ‘what if scenarios’. This is because of the lack of specific 
quantitative data. As a consequence, the function itself that links the two transmission probabilities to 
the overall probability of transmission is not known. 
Some examples of the data that would be needed are: the probability that a DH disseminates eggs in 
a habitat which is suitable for the IH and therefore for the parasite; the probability that a DH, 
depending on its behaviour and feeding conditions, eats an infected IH. It has to be considered that 
these probabilities may differ consistently between domestic dogs and wild red foxes, making the 
latter more effective in initiating and maintaining an EM life cycle although no or little evidences are 
available. 
Probability of establishment 
In the case of EM, the incursion and establishment are two separate events which involve three 
populations of animals: imported dogs (incursion); resident rodents (arvicolid rodents most 
commonly; establishment) and a wildlife carnivore, the red fox or raccoon dog either as a resident 
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(establishment) or trans-boundary from neighbouring area where findings of the parasite have been 
recorded (incursion).  
Given the probability of transmission (P୲୰ୟ୬ୱ୛୍୐ୈ and P୲୰ୟ୬ୱୈ୓ୋ) and the number of infected animals 
entering the free area (N୧୬୲୰୭୛୍୐ୈ and N୧୬୲୰୭ୈ୓ୋ), it is then possible to estimate the probability of 
establishment, which is: 
𝑃௘௦௧ௐூ௅஽ = 1 − (1 − 𝑃௧௥௔௡௦ௐூ௅஽)ே೔೙೟ೝ೚ೈ಺ಽವ  
𝑃௘௦௧஽ைீ = 1 − (1 − 𝑃௧௥௔௡௦஽ைீ)ே೔೙೟ೝ೚ವೀಸ 
B9 
When both foxes and domestic dogs need to be accounted for in the calculation, the overall 
probability of introduction will be estimated by Equation B10. 
𝑃௘௦௧ = 1 − {[(1 − 𝑃௧௥௔௡௦ௐூ௅஽)ே೔೙೟ೝ೚ೈ಺ಽವ] ∙ [(1 − 𝑃௧௥௔௡௦஽ைீ)ே೔೙೟ೝ೚ವೀಸ]} B10 
It is now possible to consider different theoretical scenarios for the probability of introduction at 
member state level accounting for both the introduction by means of foxes moving from one or more 
endemic areas and by means of domestic dogs.  
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Data needs 
The data needed in order to solve the equations presented in the previous sections are summarised in 
the following tables (see Table B6 and Table B7). 
Table B5: Definitions of the probabilities needed to estimate the probability of establishment. All 
parameters refer to 1 year period. 
𝑷𝒕𝒉𝒓𝒐𝒖𝒈𝒉(𝑩𝑪 𝒐𝒓 𝑵𝑩𝑪) Probability that a domestic dog showing up at the border, goes through all the barriers 
𝑷𝒊𝒏𝒕𝒓𝒐𝑾𝑰𝑳𝑫 Probability that, out of the total number of foxes entering a free country from at least 1 of 
the adjacent endemic countries and/or endemic sub-areas, at least 1 animal is 
infected. 
𝑷𝒊𝒏𝒕𝒓𝒐𝑫𝑶𝑮(𝑩𝑪 𝒐𝒓 𝑵𝑩𝑪) Probability that, out of the total number of domestic dogs that show up at the border from 
at least 1 of the endemic countries and/or endemic sub-areas, at least 1 dog is 
infected. 
𝑷𝒕𝒓𝒂𝒏𝒔(𝑾𝑰𝑳𝑫 𝒐𝒓 𝑫𝑶𝑮) Probability of transmission of the parasite from DH to a naïve IH and from the latter to a 
naïve DH. 
𝑷𝒆𝒔𝒕 Probability that the parasite, given its introduction, finds the optimal conditions to start a 
biological cycle in the naïve area where it has been introduced. 
Table B6: Data and estimates needed (left column) to calculate the probabilities of interest (top 
row). The crosses indicate that the quantity is always needed, ‘BC’ are the estimates 
needed in case of the free area having border compliance checks in place and ‘NBC’ in 
























































𝝆𝑾𝑰𝑳𝑫𝒊 Prevalence of infected foxes in the ith country of origin X    X 
𝝆𝑫𝑶𝑮𝒊 Prevalence of infected domestic dogs in the i
th country 
of origin 
   X X 
𝑵𝑾𝑰𝑳𝑫𝒊 Number of foxes crossing the borders in 1 year from 
the ith country of origin 
X    X 
𝑵𝑫𝑶𝑮𝒊 Number of domestic dogs showing up at the borders in 
1 year 
   X X 
𝒏 Total number of adjacent countries and/or sub-areas 
with endemicity 
X   X X 
𝑷𝒆𝒗 Probability that a dog showing up at the borders evades 
the border compliance checks in place 
 X  BC BC 
𝑷𝒌𝑬𝑽 Probability that a dog is in compliance, given that it 
evaded 
 X  BC BC 
𝑷𝒌𝑵𝑬𝑽 Probability that a domestic dog is in compliance, given 
that it did not evade 
 X  BC BC 
𝑷𝒌𝑵𝑩𝑪 Probability that a domestic dog showing up at the 
borders where no check is in place is in compliance 
  X NBC NBC 
𝑷𝒐𝒍𝒅𝑻 Probability that a in compliance domestic dog 
underwent a treatment between 2 and 5 days 
 X X X X 
𝑷𝒏𝒆𝒇𝒇 Probability that the treatment was NOT effective, given 
that it is was administered between 2 and 5 days 
 X X X X 
Estimation of the probability of introduction and establishment by means of 
theoretical scenarios 
As discussed in the previous sections, the data needed to estimate the probability of introduction, 
transmission and of establishment are rather specific. It is unlikely that all the relevant countries have 
valid evidences to support the estimates for the parameters listed above. 
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Nevertheless, even if the aim of estimating the exact probability of introduction for a given free 
Member State is not realistically achievable, it is still possible to better understand the relationship 
between input (the model parameters) and output (probability of introduction and/or establishment). 
This is commonly known as ‘sensitivity analysis’ (Saltelli et al., 2008) 
Two main aspects were investigated in this modelling exercise: i) the impact of the border compliance 
checks (in place / not in place) on the overall probability of introduction; ii) the impact of the red fox 
on the overall probability of introduction. 
Parameterisation of the model 
Parameters related to dogs 
Number of dogs showing up at the borders in 1 year (𝑵𝑫𝑶𝑮𝒊): 
Official data were provided by UK (DEFRA – APHA, Helen Roberts, personal communication).  
Table B7: Data on number of dogs showing up at the borders in UK from 2010 to 2014 
 2010 2011 2012 2013 2014 
Number of dogs 82,512 85,786 139,644 152,075 155,445 
Rate of variation  0.003 0.627 0.089 0.022 
Number of dogs moving to the free area (𝑵𝒅𝒐𝒈𝒔): 
This is an independent variable. The range explored in the modelling exercise was limited to 0 – 
30,000 as sufficient to reach a 100% probability of introduction. 
Probability of evading the border compliance checks (𝑷𝒆𝒗): 
The number of dogs evading the border compliance checks has been estimated by the UK 
representatives to be around 10% (worst case scenario) of the dogs entering the country (Helen 
Roberts, personal communication). The last observed data point is 155,445 (Table B8, year 2014). 
Therefore, the number of dogs that evaded the border compliance checks in 2014 are estimated to be 
15,545. 
The total number of dogs that leave their countries to go to UK is therefore given by the sum of the 
number of dogs showing up at the border (155,445) and the number of dogs that evade the border 
compliance checks (15,545). The total is estimated to be around 170,990. 
It is therefore possible to estimate the probability of evading, which is given by the ratio between the 
number of dogs evading the border compliance checks (15,545) and the total number of dogs that 
leave their countries to go to UK (170,990). The best guess for the probability of evading is 0.09. 
The estimated values were used as parameters of a Beta probabilistic distribution, with uniform prior, 
in order to include a degree of uncertainty around the best guess (Figure B6). 
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Figure B5: Probabilistic density distribution of the probability of evading.  
Probability that a dog NOT evading the border compliance checks is in compliance with 
the deworming treatment (𝑷𝒌𝒏𝒆): 
Official data from UK (DEFRA – APHA, Helen Roberts, personal communication) report a number of 
deworming treatment failure of 2,145 in 2014 (Table B9). These represent the number of domestic 
dogs which are checked and found to not be in compliance with the deworming treatment. They will 
be withheld and treated before being allowed to travel. As border checkpoints are not continuously 
manned (for example at night), there will be a number of pets which are not checked and a 
proportion of these are likely to be non- in compliance as well. 
Table B8: Data on number of dogs showing up at the borders in UK from 2010 to 2014 
 2010 2011 2012 2013 2014 
EM deworming treatment failures 1,571 1,455 1,762 1,887 2,145 
EM deworming compliances 80,941 84,331 137,882 150,188 153,300 
 
It is therefore possible to estimate the probability that a dog that does not evade the border 
compliance checks is in compliance, which is given by the ratio between the number of EM deworming 
compliances (153,300) and the total number of dogs that do not evade the border compliance checks 
(155,445). The best guess for the probability of being in compliance in not evading dogs is 0.99. 
The estimated values were used as parameters of a Beta probabilistic distribution, with uniform prior, 
in order to include a degree of uncertainty around the best guess (Figure B7). 
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Figure B6:  Probabilistic density distribution of the probability of compliance with the deworming 
treatments in dogs not evading the border compliance checks.  
Probability that a dog evading the border compliance checks is in compliance with the 
deworming treatment (𝑷𝒌𝒆): 
Non official data from UK (Helen Roberts, personal communication) allowed to estimate the probability 
of a dog evading the border compliance-checks to be around 80%. Although this value is much above 
the known level of compliance (at ~97%), it was considered the most appropriate conservative value. 
The same percentage was used as the worst level in the quantitative risk model for rabies introduction 
(Defra, 2011). No uncertainty was considered around this estimate. 
Probability that a deworming treatment does not operate a full clearance (𝑷𝒇𝒂𝒊𝒍): 
The scientific literature reports some cases of failure of the deworming treatment (Table A4). More 
specifically, in some cases not all worms were killed by the treatment. For the purpose of this 
modelling exercise, those dogs which still host some worm do represent a risk. The value used for this 
probability comes from the scientific literature and it is the ratio between the number of not-complete 
clearance out of the total number of dogs treated (0.08). No uncertainty was considered around this 
estimate. 
Probability that a deworming treatment has been administered within 24 hours before 
entering the free area (𝑷𝒅𝒂𝒚𝟏): 
The available options for a deworming treatment being in compliance are 5 (i.e. 1, 2, 3, 4 or 5 days 
before entrance). The same probability of occurrence has been assumed for each option (0.2 
probability each). Therefore, the probability of a treatment being administered within 24 hours before 
the entrance is 0.2. No uncertainty was considered around this estimate. 
Probability that a dog treated between 24 and 120 hours before entering a free country 
(i.e. between 2 and 5 days before) gets re-infected after a fully effective deworming 
treatment (𝑷𝒓𝒆𝒊𝒏𝒇): 
The data derive from the deterministic model described in Section 3.5. The probability of re-infection 
is summarised in Table B10. Considering that an adult worm does not live more than 90 days in its 
host, a dog can be at maximum getting infected 90 days before its entrance to represent a risk. This 
means that a dog living or travelling in an endemic country will have 1/90 probability each day of 
getting re-infected.  
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Table B9: Probability of re-infection for each treatment day. 
Treatment day (before entrance) Probability of re-infection 
-2 (within 48 hrs) 1/90 
-3 (within 72 hrs) 2/90 
-4 (within 96 hrs) 3/90 
-5 (within 120 hrs) 4/90 
 
Therefore, if a treatment is administered 2 days before the entrance into a free country and 
considering that the dog cannot be re-infected within 24 hours from the treatment, it will have only 1 
day to get re-infected (1/90). The overall probability of a dog getting re-infected, given that the 
treatment has been administered between 24 and 120 hours, is therefore the average of the four 
probabilities listed in Table B9 (0.03). No uncertainty was considered around this estimate. 
Probability that a dog entering a free country where no border compliance checks are in 
place is in compliance with the deworming treatment (𝑷𝒌𝑵𝑩𝑪): 
This probability was considered analogous to the probability that a dog evading the border compliance 
checks is in compliance with the deworming treatment (𝑷𝒌𝒆). However, it was considered plausible 
that a dog’s owners could be less incentivised in treating their pets before entering a free country if 
they know that no border compliance checks are in place. On the other hand, it could not be excluded 
that dog’s owners actually treat their animals independently from a potential control measure. In a 
study conducted in Sweden (Helene Wahlström, personal communication based on Hirvonen, 20107) 
where no border compliance checks are in place, it was estimated that about 40% of owners were in 
compliance with the regulation. In a report from the Norwegian Committee on Food safety (VKM, 
2012) it was estimated that about 80% of dogs entering Norway by road was in compliance. The 
present modelling exercise explores both scenarios using 40% and 80% probability of compliance. No 
uncertainty was considered around these estimates. 
Prevalence of infected dogs in the country from which the entering dog comes (𝝆𝑫𝑶𝑮𝒊): 
The data were retrieved from the most recent paper published on the matter (Dyachenko, 2008). A 
number of 43 dogs were found positive out of 21,588 examined and tested from Germany and other 
European countries, giving a raw prevalence of 0.002. The study used faecal samples sent to a 
veterinary laboratory for routine coprological examination. This implies a likely bias towards well-kept 
dogs which are dewormed frequently and do not roam unsupervised. The prevalence found is 
therefore likely to be an underestimate compared to the general dog population. However, this 
fraction of the dog population is also likely to travel as pets with their owners, so we consider it 
justified to use this figure. The reported values were used as parameters of a Beta probabilistic 
distribution, with uniform prior, in order to include a degree of uncertainty around the best guess 
(Figure B7). 
Another scenario with a higher prevalence value (0.01) was considered. No uncertainty was 
considered around these estimates. 
                                                          
7  Dogs on the move – a study of the travel habits of Swedish dogs and their owners’ awareness of infectious diseases, 
Examensarbete  inom veterinärprogrammet. Fakulteten för Veterinärmedicin och husdjursvetenskap Institutionen för Kliniska 
Vetenskaper, Sveriges Lantbruksuniversitet, Uppsala, 2010. http://stud.epsilon.slu.se/2118/1/Hirvonen_K_110110.pdf 
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Figure B7: Probabilistic density distribution of the prevalence in domestic dogs 
Parameters related to foxes 
Number of foxes moving to the free area (𝑵𝒇𝒐𝒙𝒆𝒔): 
This is an independent variable. The range explored in the modelling exercise was limited to 0 – 50 as 
sufficient to reach a 100% probability of introduction. 
Prevalence of infected foxes in the country from which the entering fox comes (𝝆𝑾𝑰𝑳𝑫𝒊): 
The data were retrieved from the most recent paper published on the matter (Karamon J, 2014). A 
number of 256 foxes were found positive out of 1,546 examined and tested in Poland, giving a raw 
prevalence of 0.166.  
However, this study was conducted in a highly endemic area and cannot represent the European 
situation. As an example, the prevalence of infected foxes in the Southern borders of Sweden was 
estimated to be 0.01, i.e. 10 times higher than the national prevalence (Helene Wahlström, personal 
communication based on Wahlström et al., 2012 and SVA, 20158) and a similar prevalence (0.008) 
has been estimated from a survey implemented in a restricted area, known to be infected, in Middle 
Sweden in 2011 (Wahlström et al., 2015). 
In order to cover a range of plausible prevalence values, two scenarios were explored: a first scenario 
where the number of infected foxes is extremely low, as in Sweden and a second one where the 
proportion of infected foxes is considerably higher. The two values assigned to these two scenarios 
are 0.001 and 0.16. For the latter, the reported values in Karamon’s paper were used as parameters 
of a Beta probabilistic distribution, with uniform prior, in order to include a degree of uncertainty 
around the best guess (Figure B8), while no uncertainty was considered around the estimated 
prevalence of the low-prevalence scenario. 
                                                          
8 http://www.sva.se/globalassets/redesign2011/pdf/djurhalsa/zoonoser/em-rav-slutredovisning-per-lan.pdf 
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Figure B8: Probabilistic density distribution of the prevalence in foxes 
 
Table B10 summarises the values used in the modelling exercise. 
Table B10: Summary of the values used in the modelling exercise. 
Notation Short description Values Source 
𝝆𝑾𝑰𝑳𝑫𝒊 Prevalence of infected foxes in the i
th country of 
origin 
0.0001 Romig T and Wahlström H., 
personal communication 
0.16 (stocastic) Karamon J, 2014 
𝝆𝑫𝑶𝑮𝒊  Prevalence of infected domestic dogs in the ith 
country of origin 
0.002 (stocastic) Dyachenko, 2008 
0.01 (Worst case scenario) 
Romig T, personal 
communication 
𝑷𝒆𝒗 Probability that a dog showing up at the borders 
evades the border compliance checks in place 
0.09 (stocastic) Roberts H, personal 
communication 
𝑷𝒌𝒆 Probability that a dog is in compliance, given that 
it evaded 
0.8 Roberts H, personal 
communication 
𝑷𝒌𝒏𝒆 Probability that a domestic dog is in compliance, 
given that it did not evade 
0.99 (stocastic) Roberts H, personal 
communication 
𝑷𝒌𝑵𝑩𝑪 Probability that a domestic dog showing up at the 




Wahlström H, personal 
communication 
𝑷𝒇𝒂𝒊𝒍 Probability that a deworming treatment does not 
operate a full clearance of the parasite in the 
treated dog 
0.08 (stocastic) Table A4 
𝑷𝒅𝒂𝒚𝟏 Probability that the treatment has been 
administered within 24 hours before the dog 
enters a free country 
0.2 Roberts H, personal 
communication 
𝑷𝒓𝒆𝒊𝒏𝒇 Probability that a dog gets re-infected following a 
fully effective deworming treatment administered 
between 24 and 120 hours 
0.03 Bødker R, personal 
communication 
(Section 3.5) 
𝑷𝒊𝒏𝒇 Probability that a dog which is not in compliance 
(and it evades or no border compliance checks are 
in place) or on which the treatment did not 
operate a full clearance gets reinfected 
0.16  
(2 weeks in an 
endemic area) 




(living in an 
endemic area) 
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The Probability that a fox has to initiate the EM lifecycle (P୲୰ୟ୬ୱ୛୍୐ୈ) and the Probability that a dog has 
to initiate the EM lifecycle (P୲୰ୟ୬ୱୈ୓ୋ) were not parameterised in this modelling exercise as no data 
were available (see Section 3.3.3) 
Results 
The results of the modelling exercise are shown in Figure B10. In order to improve the readability of 
the outcomes, letters were assigned to the columns and numbers to the rows of the trellis plot, as 
shown in Figure B13. 
 
Figure B9: Identification of the plots in the trellis graph shown in Figure B14 
 
Columns A and B refer to dogs living in a free country, travelling in an endemic country for two weeks 
and then coming back home. 
Columns C and D refer to dogs living in an endemic country and then entering a free country. 
Columns A and C consider a low-prevalence fox scenario. 
Columns B and D consider a high-prevalence fox scenario (worst case). 
Rows 1 and 2 refer to a probability of compliance in countries where no border compliance checks are 
in place equal to 40%. 
Rows 3 and 4 refer to a probability of compliance in countries where no border compliance checks are 
in place equal to 80%. 
Rows 1 and 3 consider a low-prevalence dog scenario. 
Rows 2 and 4 consider a high-prevalence dog scenario (worst case). 
The red and the blue lines refer to dogs (border compliance checks in place / no border compliance 
checks in place, respectively), while the green lines refer to foxes. 
The black x-axis in each small plot indicates the number of dogs. Relevant for blue and red lines. 
The green x-axis at the bottom of the figure refers to foxes. Relevant for the green line. 
 
It can be seen that in all scenarios, independently from the prevalence of infected dogs in the country 
of origin and from the probability of compliance when no border compliance checks are in place, the 
presence of border compliance checks always reduce the probability of introduction (the red line 
increases always less rapidly than the blue line). 
It can also be observed that in case the prevalence of foxes reaches a value of 16% (columns B and 
D), the relative impact of the dogs on the probability of introduction is considerably small.  
In order to make the comparison easier and less qualitative, Table B11 reports the number of dogs 
and foxes needed to reach a probability of at least 75% (value arbitrary chosen). 
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Table B11: Number of dogs and foxes for a probability of introduction of at least 75% in the 
different scenarios 
    𝑃௥௘௜௡௙ = 0.16 𝑃௥௘௜௡௙ = 1 
    𝜌௙௢௫ = 0.001 𝜌௙௢௫ = 0.16 𝜌௙௢௫ = 0.001 𝜌௙௢௫ = 0.16 
    A B C D 
𝑃௞ே஻஼ = 𝑃௞ா௏
= 0.4 
𝜌ௗ௢௚ = 0.002 1 Dogs BC 17400 17400 4800 4800 
Dogs NBC 6000 6000 1200 1200 
Foxes 1386 8 1386 8 
𝜌ௗ௢௚ = 0.01 2 Dogs BC 3600 3200 1200 1200 
Dogs NBC 1200 1200 <600 <600 
Foxes 1386 8 1386 8 
𝑃௞ே஻஼ = 𝑃௞ா௏
= 0.8 
𝜌ௗ௢௚ = 0.002 3 Dogs BC 20400 20400 6600 6600 
Dogs NBC 9600 9600 1800 1800 
Foxes 1386 8 1386 8 
𝜌ௗ௢௚ = 0.01 4 Dogs BC 4200 4200 1200 1200 
Dogs NBC 2400 2400 <600 <600 
Foxes 1386 8 1386 8 
BC: Border compliance-checks in place 
NBC: No Border compliance-checks in place 
 
It can be seen that the presence of the border compliance checks implies that the number of dogs 
that need to show up at the borders of the free country in order to reach at least 75% probability of 
introduction is 1.75 to 4 times higher, compared to a situation where no border compliance checks are 
in place. 
The figures confirm what is shown in the trellis plot about the impact of the foxes. In case a free 
country is adjacent to an endemic area (prevalence of foxes equal to 16%, scnearios B and D) the 
number of dogs that need to show up at the borders to reach at least the same probability of 
introduction of 75% is 75 to 1200 times higher that the number of foxes. 
In case a free country is adjacent to a country where findings of the parasite have been recorded with 
a very low prevalence in foxes (0.01%), the situation is not so dissimilar. In case the considered dogs 
are all coming back to their free country, where no border compliance checks are in place, after a 2 
weeks period in an endemic area (scenario A), where the prevalence in dogs is 0.2% or 1%, still the 
number of dogs that need to show up at the borders (coming back home) to reach at least the same 
probability of introduction of 75% is 1.7 to 6.9 times higher than the number of foxes. Only in one 
case the number of dogs and foxes is almost comparable, i.e. when the probability of compliance is 
only 40% (scenario A1). In all other cases, where the border compliance checks are in place, the 
foxes still represent the main route of introduction (scenarios from A2 to A4). 
The situation slightly changes if the free country is adjacent to a country where findings of the 
parasite have been recorded with a very low prevalence in foxes (0.01%), and if the considered dogs 
all live in an endemic country and enter the free country, where no border compliance checks are in 
place, for a given period (scenario C). In this case the situation is the opposite, although the 
proportions are not even comparable. In order to reach at least the same probability of introduction of 
75%, the number of foxes that need to cross the borders is at max 2.3 times higher than the number 
of dogs that need to shouw up at the border. It has to be noted that, in the same conditions, if we 
consider a country where border compliance checks are in place, foxes play again a prominent role in 
the introduction: only if the dogs all live and come from an endemic area with a high prevalence (1%) 
can have a relatively higher impact on the probability of introduction, i.e. the number of dogs needs to 
be 1.16 times higher than the number of foxes. 
Finally, it has to be highlighted that, considering the number of dogs entering a free country every 
year (Appendix B, Table B8) the probability that at least one of them will introduce a worm or its 
eggs is 100%. 
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Figure B10: Trellis plot with 16 different scenarios. X-axis=number of dogs/foxes. Y-axis=probability of introduction. Red line: dogs & border checks in place. Blue line: dogs 
& no border chacks in place. Green line: foxes. The black x-axis in each small plot indicates the number of dogs (blue and red lines). The green x-axis at the 
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Appendix C – E. multilocularis surveillance and monitoring programmes 
in EU Member States 
Surveillance and Monitoring in EU Member States where no findings of the parasite have 
been recorded 
Malta is a small island of just 246 km2area. There is a population of 60,000 dogs, of which an 
estimated 2,000 are stray dogs. The dog is considered the epidemiological unit for surveillance 
purposes. There are no wild definitive hosts and the risk of introduction is limited totravelling pets, but 
the risk of establishment is negligible due to the absence of wild canids.  
Ireland forms part of an island (shared with Northern Ireland, a devolved administration of the UK). 
The risk of introduction is from the movement of travelling pets as any fox movement across the land 
border is from another area where no findings of the parasite have been recorded. The surveillance is 
designed to detect establishment of disease/infection. The Regulation is currently worded to allow 
Ireland to retain disease/infection freedom even if Northern Ireland would detect a positive fox. This 
in effect would mean the risk to Ireland will have changed, as it should now consider the movement 
of infected wild definitive hosts into the area where no findings of the parasite have been recorded, 
not only the movement of travelling pets. Ireland carries out 100% checks of (identified) travelling 
pets arriving from countries where findings of the parasite have been recorded; pets arriving from the 
UK are not checked. 
UK consists of two epidemiologically distinct areas, GB and NI. Although pets may travel between the 
two areas without the requirement for tapeworm treatment, there is no movement of foxes. The 
Regulation is worded at present that the detection of an infected fox in GB would mean that NI would 
also lose infection free status, or that an infected fox in NI would mean GB would lose free status. 
This should be addressed so that infection absence should be associated with the distinct area, as is 
allowed in EU legislation. The entry points for pet movement into mainland GB are numerous, 
however at the entry points there are 100% checks in place for compliance, carried out by the ferry 
operators and Eurostar. The movement of pets into Northern Ireland will generally be from GB by 
ferry (limited checks) or across the border (no checks) from republic of Ireland).  
Finland is the largest of the four Member States where no findings of the parasite have been 
recorded, has two populations of wild definitive hosts and has land borders withan EU MS with low 
prevalence (Sweden), and EU MS with medium to high prevalence (Estonia) and a third country with 
unknown prevalence (presumed also medium to high; Russian Federation).  
In 2011, all four Member States provided evidence for ten years of infection absence from EM. 
Sweden was not able to apply given their finding of EM in a wild fox in 2011. Different health 
prevention regimes were in place in these countries prior to the harmonisation under the Pet Travel 
Scheme. In Finland, a treatment window of 30 days prior to entry was permitted; in Sweden 10 days 
prior to entry (similar to Norway) and in Malta, UK and Ireland a window of just 48 to 24 hours was 
permitted. Under the new harmonised controls (date), a treatment window of 5 days to 24 hours prior 
to entry into the Member State, based on was put in place for all countries listed in Annex I Part A.  
Table C1:  Change in tapeworm treatment regimes and changes in risk of introduction of the parasite 
after harmonisation of control, for the countries considered EM free prior to 2011 
harmonisation. 
 Finland Ireland Malta UK Sweden(a) Norway(b) 
Pre 2011 30 days 24–48 hr 24–48 hr 24–48 hr 10 days Before arrival and 
7 days after 
Post 2011 1–5 days 1–5 days 1–5 days 1–5 days N/A Same 
Change in risk Decrease Increase Increase Increase Increase Status quo 
(a): Although Sweden lost official freedom in 2011 after detection of a positive fox, the authorities were part of the initial 
negotiation with the EU on harmonisation and retention of tapeworm requirements.  
(b): Norway, although not an EU member state, also provided information on their history of disease freedom as part of the 
negotiations. 
 
Surveillance programmes for the four Member States followed recommendations made in the 
Regulation (EU) No 1152/2011, but there were differences, appropriate to the situation in the Member 
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State. Finland reports for two definitive host populations, the red fox (Vulpes vulpes) and the Raccoon 
Dog (Nyctereutes procyonoides) as both have been shown to be suitable hosts for EM infection. 
Raccoon dogs are more populous than red foxes particularly in areas bordering Estonia and the 
Russian Federation which represent a risk for disease/infection introduction through movement of 
wildlife. Ireland, like the UK, reports on surveillance in red foxes, as there are no other wild definitive 
hosts for EM present; Malta reports on surveillance in domestic dogs as the red fox or other wild 
definitive hosts are absent from the island, but the analysis takes account of different risk factors for 
different sub groups of dog. The UK is separated into devolved administrations and Northern Ireland 
forms a separate epidemiological unit therefore reporting is done for the two areas, both for red 
foxes, but using different tests.  
Malta implements a risk-based surveillance system, testing only dogs as no wild definitive hosts are 
assumed to be present on Malta. Two risk indicators are used: exposed to intermediate hosts or not 
(which depended on the dog being a hunting or rural dog) and: imported dogs (imported and stray 
dogs (as stray dogs could originate from illegally imported dogs). The relative risk for the groups was 
given as 1.2 for both risk categories. However, evidence forthe assigned relative risk ratios is required 
(EFSA, 2014).  
Norway has also recently provided details of their surveillance programme to show evidence of 
disease infection absence. Since 2002, 3,405 fox carcases have tested negative (none positive) of an 
estimated population of between 70,000 – 120,000 red foxes. Of these, 1600 were tested prior to 
2009. Surveillance is carried out on the mainland, covers all counties but does not include the islands 
of Svalbard. Pet treatment is required (and non-in compliance pets are placed in quarantine until in 
compliance) but border compliance checks are not complete and there is a long land border with 
Sweden, where positive fox carcases have been detected just 80 km from the border (Wahlström et 
al. in press).  
Surveillance and Monitoring in non-‘free’ EU Member States 
Sweden: following the first report of EM in a fox carcase in 2011, intensive surveillance was carried 
out to determining the geographical extent of the infection. Fox carcases (2985 animals) were 
collected from all over Sweden and tested. Positive results were found in three areas, with a very low 
national prevalence (0.1%) suggesting very low endemicity (Wahlström et al. 2011). A second survey, 
using probabilistic sampling was conducted to obtain a more accurate prevalence estimate, a baseline 
to be used for comparison in the future to evaluate if prevalence changes over time. Furthermore, for 
cost-efficiency reasons, fox faecal samples instead of fox carcasses was collected and analysed with a 
new magnetic probe PCR method (Isaksson et al 2014). Three infected areas were identified two 
previously known and one new. Import controls in Sweden between 1994 and 2011 required pet dogs 
to enter with a veterinary certificate of deworming treatment having taken place in the ten days prior 
to entering Sweden. There are currently import recommendations for pet owners travelling from 
highly endemic areas to deworm their dogs. Guidance is also given for all pet owners in Sweden to 
regularly deworm their pets every month if they are concerned. 
Denmark first detected EM in fox carcases in 2000 in Copenhagen, when 3 of 340 animals tested 
positive, but no further studies in Denmark were carried out until 2011. Between 2011 and 2014 
1,500 carnivores were tested: 1,169 foxes, 265 raccoon dogs and 66 other wild carnivores. The first 
positive result was found in November 2011 near the border with Germany, but further surveillance in 
this area of 28 foxes showed high local prevalence as 9 tested positive (32%) as well as two raccoon 
dogs. Current national prevalence is estimated at 1.2% for foxes and 0.75% for raccoon dogs (95% 
confidence) (Wahlström et al. in press). Import controls for dogs entering Denmark have relied on the 
voluntary deworming of dogs from highly endemic areas following the recommendations of the Danish 
Veterinary and Food Administration in 2013.  
Norway (Islands of Svalbard) first reported EM in Arctic foxes (Vulpes lagopus) in 2000 (Henntonen et 
al. 2001 & Fuglei et al. 2008). As a result of surveillance of the sibling vole (Microtus levis) which has 
a very limited geographical distribution, bounded by the availability of suitable food plants. 
Surveillance of fox faeces in areas of high vole distribution showed these areas are the highest 
prevalence of EM. It is thought that while the arctic foxes roam freely across pack ice and may have 
already acquired the parasite in Russia, it only became established in Svalbard following the 
anthropogenic introduction of the sibiling vole at the end of the twentieth Century.  
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Appendix D – Survey design for demonstrating absence of infection 
Introduction 
The basic principle when dealing with absence of infection involves estimation of the so called 
sensitivity of the surveillance system (SSe), i.e. the probability that qualifies a statement on the 
presence/absence of a given infection (Cameron and Baldock, 1998). Since 1982, when Cannon and 
Roe published their manual on disease surveys techniques, many authors contributed to the 
development of methodologies to increase the performance of a survey. In a recent publication 
Cameron (2012) outlined this evolution, starting from early tools to calculate the sample size for 
representative surveys (Cannon and Roe, 1982) up to recent sophisticated methodologies. These 
latter imply the use of risk based sampling techniques. More insight is required to implement such 
sampling techniques compared to a simple random sampling, and some of this insight may not be 
properly documented and has to be assumed for the population in question. However, the advantages 
in terms of effectiveness/efficiency of such methods are substantial and should be considered when 
dealing with Disease Detection or Demonstration of Freedom from Disease.  
The full methodology is described in detail in the EFSA Technical Report published in 20129 related to 
the implementation of a absence of infection framework specifically on Echinococcus multilocularis. 
Design prevalence in the ‘freedom from disease’ framework 
It has to be noted that, analytically speaking, it is not possible to demonstrate ‘freedom’ from a given 
disease/ infection. If equation D1 is solved setting DP equal to 0, the sample size required (𝑛) would 
be equal to −∞.  
𝑛 =  
𝑙𝑜𝑔(1 − 𝑅𝑆𝑒)
𝑙𝑜𝑔(1 − 𝐷𝑃 ∙ 𝑇𝑆𝑒)
 D1 
 
To estimate the probability that the actual prevalence is below a given threshold (DP), this value must 
be greater than zero. There are no right or wrong values, but some considerations are useful to define 
a proper threshold. 
The closer to ‘zero’, the more similar to ‘absence’. As an example, it can be decided to define the 
design prevalence as the reciprocal of the target population (1/N), i.e. the worst case scenario of only 
1 infected individual in the population. The drawback here is that the lower the DP-value, the greater 
the sample size. So, for large populations, as for foxes, the required sample size would be 
impracticable (see also Figure D1). 
A more applicable threshold can be set using a value which can be considered and accepted as 
synonymous with absence. E.g. if a disease is characterised by a very high R0, the threshold can 
justifiably be set above 1%, because shortly after the infection has been introduced in a free area, the 
prevalence would increase to over 1%. In such case, saying that the prevalence is below 1% or 
saying that the infection is absent is approximately the same thing. Unfortunately, in most situations, 
E.m. is a slow-moving infection, i.e. it has a low R0, and therefore, ideally, a relatively low design 
prevalence value should be set. However, the EU-regulation defines the DP to be 1% when evaluating 
possible absence of EM. 
 
                                                          
9 EFSA (European Food Safety Authority), 2012. A framework to substantiate absence of disease: the risk based estimate of 
system sensitivity tool (RiBESS) using data collated according to the EFSA Standard Sample Description – An example on 
Echinococcus multilocularis. Supporting Publications 2012:EN-366. 44 pp. Available online: www.efsa.europa.eu/publications 
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Figure D1: Sample size as a function of the design prevalence; dp: design prevalence. SSe: 
required surveillance system sensitivity (confidence); TSe: sensitivity of the test; N: 
target population size.  
System Sensitivity (SSe) and Probability of Freedom (Pfree) in the ‘freedom from 
disease’ framework 
The concept of the system sensitivity (SSe) as outlined above, foreseen in Regulation (EU) No 
1152/2011, allows an increased efficiency and flexibility when compared to the input-based type of 
survey. However, it does not address how to take into account, among others aspects, the outcome of 
previous surveillance activities. Briefly, the confidence that MS ‘A’ is free from a given infection (i.e. 
DP < 1%) would be higher if previous surveillance activities had been carried out without finding 
infected animals when compared to MS ‘B’, which is implementing a survey for the first time. To 
address this issue, another parameter was introduced in the framework of demonstrating absence of 
infection: the Probability of Freedom (Pfree). 
In probabilistic language, the System Sensitivity (equation D2) is the probability of getting at least one 
positive test given that the infection is present at or above, say, 1% prevalence in the target 
population: 
𝑆𝑆𝑒 = 𝑃(𝑆 + |𝐷+) D2 
 
In contrast, the Probability of Freedom is the probability of the infection being absent (i.e. DP < 1%) 
given that all samples tested negative: 
𝑃௙௥௘௘ = 𝑃(𝐷 − |𝑆−) D3 
 
which is also known as the Negative Predictive Value of the Surveillance System. 
Pfree can then be calculated incorporating historical evidence of infection absence from previous 
surveillance activities using Bayes’ theorem as follows: 
𝑃௙௥௘௘ =
𝑃𝑟𝑖𝑜𝑟𝑃௙௥௘௘
𝑃𝑟𝑖𝑜𝑟𝑃௙௥௘௘ + [(1 − 𝑃𝑟𝑖𝑜𝑟𝑃௙௥௘௘) ∙ (1 − 𝑆𝑆𝑒)]
 
D4 
where 𝑃𝑟𝑖𝑜𝑟𝑃௙௥௘௘ is the prior probability of infection absence and 𝑆𝑆𝑒 is the System Sensitivity.  


















www.efsa.europa.eu/efsajournal 109 EFSA Journal 2015;13(15):4373 
 
A stepwise analysis of historical data provides a progressively updated estimate of the probability of 
infection absence. However, in order to take into account the decreased value of historical data, each 
prior estimate of the probability of infection absence must be adjusted to take into account the risk of 
introduction of infection since the surveillance was undertaken. This latter adjusted probability of 
infection absence will be the 𝑃𝑟𝑖𝑜𝑟𝑃௙௥௘௘ for the next year (see Figure D2). When no information is 
available from previous surveillance activities, the first 𝑃𝑟𝑖𝑜𝑟𝑃௙௥௘௘ can be set at 0.5 (50%). 
 
Figure D2:  Continuous update of the probability of infection absence taking into account the 
probability of introduction and the additional evidences gathered from both the recent 
and the past surveillance activity 
In order to harmonise the process of demonstrating absence of infection and to ensure equivalence 
between different Surveillance Systems, Regulation (EU) No 1152/2011 refers to the the ‘confidence’, 
which according to the available scientific literature is equal to the 𝑆𝑆𝑒. Therefore the concerned MS 
will have to implement each year a survey with an overall 𝑆𝑆𝑒 of at least 95%. In this situation, and 
assuming a probability of introduction equal to 48% (i.e. relatively high) the 𝑃௙௥௘௘, if calculated, would 
reach the value of 100% in 3 years (Figure D3). 
Including the 𝑃௙௥௘௘, (i.e.the Negative Predictive Value of the surveillance system) in the regulation, 
rather than the 𝑆𝑆𝑒, would potentially lead to a reduction of the required annual sample size. 
 
Figure D3: Trend over time of the System Sensitivity and of the probability of infection absence 
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Appendix E – Human alveolar echinococcosis 
Questionnaire circulated to … 
REQUEST FOR INFORMATION REGARDING ECHINOCOCCUS MULTILOCULARIS in addition 
to what is already published or submitted for EUSR 
Prevalence data in the period 2012-2014:  
x Number of samples tested per year? Intra vitam 
x Number of positive samples detected per year?  
x Locations where samples were taken (NUTS2 or NUTS3 if possible).  
x Which diagnostic procedure was  used and provide a reference, if possible.  
x Which matrix was sampled (individual intestinal content, faeces taken from an animal or 
from the environment) and from which species: individual  
x What was the reason for sampling (e.g. prevalence estimation, evaluation of control 
measures taken, …)? 
x If sampling was not homogeneous throughout your country, please specify regional 
differences.  
Host populations 
x Is there a homogeneous distribution of definitive hosts (foxes, wild canids and domestic 
dogs) in your country? If not, could you explain the regional differences?  
x Has E. multilocularis been detected in an intermediate host in your country? If yes, please 
provide details (species, date, location, diagnostic method, sampling design, ...)  
x Any other species found to be positive for E. multilocularis? (e.g. imported beavers (which 
the UK has had) or zoo species)  
Notification of E. multilocularis:  
x Is E. multilocularis in animals notifiable in your country? (If yes, since when? and isthere a 
discrimination between E. multilocularis and E. granulosus in the reporting?)  
x Is E. multilocularis in humans notifiable in your country? (if yes, since when? and is there 
a discrimination between E. multilocularis and E. granulosus in the reporting?)  
Alveolar echinococcosis (AE) cases in humans: 
x Is the number of AE cases known in your country?  
x If yes, what has been the number of annual AE cases in your country since 2000? Is the 
origin of these cases known (domestic, foreign or not known)? Please provide details.  
Surveillance 
x How did you first detect that E. multilocularis was present in your country? (to give info 
on what type of  activity detected the parasite).  
x How did you detect the first case in a definitive host?  
x How did you detect the first case in an intermediate host?  
x How did you detect the first human case?  
Dog movements  
x Do you have data on dog movements across your external borders?  
x If yes, how many dogs are entering (transit or stay) and leaving the country every year? 
How are the numbers collected//estimated?  
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Table E1: Notification of AE human cases in EU and AC 
COUNTRY NOTIFICATION of HUMAN AE 
CASES 
DIFFERENTIATION BETWEEN CE and 
AE CASES 
Albania   
Austria Yes  
Belgium Yes No 
Belarus Yes  
Bosnia Herzegovina   
Bulgaria Yes  
Croatia Yes  
Cyprus No  
Czech Republic Yes  
Denmark Yes No 
Estonia Yes No 
Finland   
France No No 
FYR Macedonia   
Germany Yes  
Greece   
Hungary Yes Yes 
Iceland Yes  
Ireland Yes  
Italy No  
Latvia   
Lithuania   
Liechtenstein   
Luxembourg   
Malta Yes No 
Kosovo   
Moldova   
Montenegro   
Netherlands No No  
Norway Yes No  
Poland Yes  
Portugal Yes  No 
Romania   
Serbia   
Slovakia Yes Yes 
Slovenia Yes  
Spain Yes No 
Sweden   
Switzerland No  
Turkey   
Ukraine   
United Kingdom Yes  
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Table E2: Estimation of annual number of AE human cases in the EU and AC 
COUNTRY ESTIMATED ANNUAL 
NUMBERS of CASES 
REFERENCES 
Albania   
Austria 7 Kern et al., 2003; Auer and Aspock, 2001; Torgerson et 
al., 2010 
Belgium 1 Torgerson et al., 2010 
Belarus 6 Torgerson et al., 2010 
Bosnia Herzegovina   
Bulgaria 1 Torgerson et al., 2010 
Croatia   
Cyprus   
Czech Republic 1 Torgerson et al., 2010 
Denmark   
Estonia 9 Torgerson et al., 2010 
Finland   
France 21 Abdullaev et al., 2006; Torgerson et al., 2010 
FYR Macedonia 1 Torgerson et al., 2010 
Germany 61 Torgerson et al., 2010 
Greece 1 Torgerson et al., 2010 
Hungary 1 Torgerson et al., 2010 
Iceland   
Ireland   
Italy   
Latvia 9 Torgerson et al., 2010 
Lithuania 9 Torgerson et al., 2010 
Liechtenstein   
Luxembourg   
Malta   
Kosovo   
Moldova 1 Torgerson et al., 2010 
Montenegro   
Netherlands   
Norway   
Poland 3 Torgerson et al., 2010 
Portugal   
Romania   
Russia 1.180 Torgerson et al., 2010 
Serbia   
Slovakia 4 Torgerson et al., 2010 
Slovenia 2 Torgerson et al., 2010 
Spain   
Sweden   
Switzerland 20 Torgerson et al., 2010 
Turkey >100 Torgerson et al., 2010 
Ukraine 10 Bessanov et al., 2003;  Torgerson et al., 2010 
United Kingdom   
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Table E3: Case series reporting AE human cases in the EU and AC 
COUNTRY CASE SERIES (PERIOD) REFERENCES 
Albania   
Austria 2.4 cases/100,000  (1991–
2000) and 2,8/100,000 (2001–
2010); 13 cases (2013) 
Schneider et al., 2013 
Belgium 1 case reported (2002); 3 
cases reported in 2004 
Landen et al., 2013 ; Detry et al., 2005 
1 case per year Questionnaire from MS 
Belarus   
Bosnia Herzegovina   
Bulgaria   
Croatia   
Cyprus   
Czech Republic 20 cases (1998–2014) Kolářová, et al., 2015 
Denmark 2 cases Samuelsson and Kapel, 2004 
15 cases (2010–2013) Questionnaire from MS 
Estonia   
Finland   
France 509 diagnosed cases (1982–
2011) 
Said-Ali et al., 2013 
FYR Macedonia 1 case  Druschky et al., 1995 
Germany 114 cases (2003–2013) Jorgersen et al., 2008 
Greece 1 case (1980–2000) Vuitton et al., 2003 
Hungary 1 case (2004); 
1 autochthonous case (2015) 
Horvat et al., 2008; 
personal communication: Balázs Dezsényi, 15/09/15, 
St. Ladislau Hospital, Budapest (Hungary) and 
Thomas F.E. Barth, 14/09/15, Institute of Pathology, 
University of Ulm, (Germany) 
Iceland   
Ireland   
Italy   
Latvia 29 cases from Pauls Stradins 
University Hospital (1996–
2010)/ 
14 cases from Infectivology 
Centre of Latvia (1999–2010) 
Tulin et al., 2012 
Lithuania 80 cases at the State Hospital 
for Tuberculosis and Infectious 
Diseases in cooperation with 
the Santariškių Clinic (Vilnius 
University) (1997–2006) 
Bružinskaitė et al., 2007 
Liechtenstein   
Luxembourg   
Malta   
Kosovo   
Moldova   
Montenegro   
Netherlands Approx. 1 case per year 
(2008–2014) (most likely 
autochthonous cases) 
Questionnaire from MS 
Norway   
Poland 121 cases (1990–2011) Nahorski et al., 2013 
Portugal   
Romania 2 cases Siko’ et al., 2011 
Russia   
Serbia   
Slovakia 26 cases (2000–2013) Antolova et al., 2014 
Slovenia 0.45 per 100,000 inhabitants  
(2001–2005) 
Logar et al., 2007 
Spain   
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COUNTRY CASE SERIES (PERIOD) REFERENCES 
Sweden 2 cases (imported) Wahlström et al., 2015 
Switzerland incidence: 0.12– 0.15 (1956–
1992)/ 0.10 (1993–2000) / 
0.26  (2001–2005) 
Schweiger et al., 2007 
Turkey 162 cases Miman et al., 2012 
Ukraine   
United Kingdom 1 case (unknown origin) Cook et al., 1991 
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Table E4: Overview of risk factors for AE 
Risk factor Study area Cross-sectional studies Case-control studies 













Dog ownership Europe China    4/1011 2.30  
[1.56, 3.40] 
Casulli et al, 2015 
  5/13883 2.88 [2.30, 3.62]  
Casulli et al, 2015 
5/1068 2.50  
[1.73, 3.62] 




Europe    – – – 
Global  3/5348 6.94 [4.99, 9.66] – – – 
Gender: female Europe    – – – 
Global  10/42812 1.50 [1.35, 1.67] – – – 
Age>20 Europe    – – – 
Global  8/24988 2.96 [2.39, 3.68] – – – 
Ethnic group: 
Tibetan  
Europe    – – – 
China  4/25952 2.03 [1.56, 2.63 – – – 
Low Income Europe    – – – 
China  2/4124 3.92 [2.42, 6.36] – – – 
Source of drinking 
water other than 
well or tap 
Europe    – – – 
Global  5/23714 1.81 [1.52, 2.17] – – – 
Occupation: 
farming 
Europe    – – – 
Global  5/17878 1.29 [0.97, 1.72] 4/1011 4.50  
[2.74, 7.39] 
Casulli et al, 2015 
Occupation: 
herding 
Europe    – – – 
Global  5/21045 2.22 [1.76, 2.81] – – – 
Drinking not boiled 
water 
Europe    – – – 
China  2/7096 0.63 [0.48, 0.84] – – – 
Hunting /handling 
foxes 
Europe    – – – 
Global  3/9442 1.29 [0.97, 1.71] 4/959 2.27  
[1.35, 3.81] 
– 
Low education Europe    – – – 
China  2/5297 4.81 [2.73, 8.48] – – – 
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Risk factor Study area Cross-sectional studies Case-control studies 













Allowed dog into 
the house 
Europe     2/216 1.80 [0.90, 3.62]  
Casulli et al, 2015 Global     2/216 1.80 [0.90, 3.62] 
Playing with dogs Europe     1/159 2.07 [0.97, 4.42] 
Global     2/216 1.42 [0.75, 2.66] 
Cat ownership Europe     2/265 2.63 [1.42, 4.85] 
Global     2/265 2.63 [1.42, 4.85] 
Living in rural area Europe     2/746 3.12 [1.95, 5.01] 
Global     3/803 3.44 [2.19, 5.41] 
Having a kitchen 
garden 
Europe     2/746 5.21 [2.65, 10.22] 
Global     2/746 5.21 [2.65, 10.22] 
Did haymaking in 
meadows not 
adjacent to water 
Europe     2/238 3.50 [1.63, 7.55] 
Global     2/238 3.50 [1.63, 7.55] 
Went to forests for 
vocational reasons 
Europe     2/266 2.61 [1.13, 6.05] 
Global     2/266 2.61 [1.13, 6.05] 
Ate unwashed 
strawberries 
Europe     4/1006 1.39 [0.87, 2.23] 
Global     4/1006 1.39 [0.87, 2.23] 
Chewed grass Europe     2/252 3.20 [1.65, 6.20] 
Global     2/252 3.20 [1.65, 6.20] 
Hunting Europe     4/1007 1.25 [0.73, 2.15] 
Global     5/1064 1.13 [0.69, 1.83] 
Handling foxes Europe     3/902 2.84 [1.57, 5.15] 
Global     4/959 2.27 [1.35, 3.81] 
Eating mushrooms Europe     2/255 0.72 [0.38, 1.39] 
Global     2/255 0.72 [0.38, 1.39] 
Consumption of 
wild vegetables and 
fruit 
Europe     4/990 1.50 [0.98, 2.31] 
Global     5/1046 1.38 [0.90, 2.10] 
Protective HLA Europe     1/604 0.55 [0.34, 0.88] 
Global     2/743 0.50 [0.32, 0.80] 
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Appendix F – Modelling E. multilocularis treatment protocols 
A mathematical model was developed at the National Veterinary Institute DTU by René Bødker. The 
model was used to quantitatively compare the effects of different treatment protocols. The model 
allows for treatment of dogs up to 90 days before moving to a free area, and also up to 90 days after 
entering the free area as the latter will also reduce the number of excreted eggs in the free area. The 
model has been used to quantify the relative treatment effect of dogs from, endemic areas imported 
or visiting free areas (section 3.5.4), and of dogs from free areas visiting endemic areas and then 
returning to their free areas (section 3.5.5). Finally the model was used estimate the level of 
compliance (with the deworming requirements) that was needed in order not to increase the risk 
when treating earlier than day -1 (default) and instead treating day -2 and up to day -6 (section 
3.5.6).  
The magniture of the probability of transmission is unknown, however in the model, it is assumed that 
the probability of establishing the parasite in a free area is linearly proportional to the number of eggs 
excreted in this area, given the area has an environment that is suitable for transmission. Therefore, a 
deterministic mathematical model (built in an Excel spread sheet) was used to calculate the average 
number of eggs excreted in a free country by an infected dog entering a free country. The probability 
that a dog is infected depends on the prevalence level and the duration of exposure in the endemic 
area and also on dog behavior i.e. probability of eating rodents. In the model, calculations do not 
quantify the actual infection risk in the endemic areas but merely measure the relative effect of 
different treatment protocols regardless of the absolute exposure level. The model does however 
calculate the effect of the duration of exposure in the endemic area and also of the duration of stay in 
the free country as the relationship between the risk and these two measures is not linear and in 
some cases complex. 
In a previous EFSA risk assessment (2007), risk was defined as the probability of introduction of an 
infected dog. In this section of the present scientific opinion, risk is defined as being proportional to 
the number of eggs deposited in a free country. Therefore, the focus is no longer on the number of 
dogs crossing the border but on the number of worms crossing the border and specifically on how 
many eggs these worms will be able to produce in a free area before the dog leaves the area or 
before the worms dies of either natural causes or from treatment. Hence, a dog with only immature 
worms entering and leaving before worms mature, is not considered a risk albeit the infection is 
technically temporarily introduced to the free country. This is because these immature worms will not 
excrete any eggs in the free country. Also a dog with many worms is considered a relatively higher 
risk than a dog with few worms. In addition, a dog with a young worm is considered a relatively 
higher risk than a dog with an old worm, since young worms will live longer and produce more eggs in 
the free area. Also the duration of the visit in a free country is important since a long visit will result in 
more eggs being deposited. The timing of the treatment is important because the drug is excreted in 
just 24 hours after which the dog may be reinfected. Treating five days before crossing the border will 
therefore leave 4 days where the dog can be reinfected. Since the worms only live for 90 days the 
maximum exposure period is effectively just 90 days after which the maximum worm load is reached. 
Thus a four days re-exposure period is equivalent to 4.4% of the maximum risk (4/90) and therefore 
relatively important compared to e.g. treatment failure. 
An important effect of defining risk as the number of deposited eggs is that preventive treatment can 
be applied after entering a free area since delayed treatment will still reduce the number of excreted 
eggs. Somewhat surprisingly, delaying treatment until after crossing the border may in some cases 
reduce the risk compared to the traditional protocol of applying treatment in the endemic area shortly 
before entering a free country (Figure F2).  
The lifespan of a worm is assumed to be 90 days, meaning that a maximum worm load will be 
reached after 90 days exposure (although the absolute worm load is specific for the prevalence level 
in the area). The egg production per mature worm is assumed constant over time regardless of the 
age of the worm, and it also assumes the eggs produced are excreted by the worm within 24 hours. 
Essentially the model calculates the daily rate of infection as 1/90 of that maximum. The model 
assumes each infecting worm goes through a 30 days pre-patent stage followed by a 60 days egg 
excreting stage. The model therefore keeps track of the age of each daily infecting worm cohort. The 
model either assumes a full 90 days exposure followed by visits to free areas of various durations 
(dogs living in endemic areas visiting or being imported to free countries) or a full 90 days stay in a 
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free country that follows exposure periods of various durations in endemic areas (dogs living in free 
countries and visiting endemic areas before returning to the free area). Prevalence levels and duration 
of exposure is not taking into account in EU legislation. For practical reasons, present legislation 
simply distinguishes between dogs moving from free areas to not-free areas. But in the present model 
duration of exposure as well as duration of the period spend in the free country are important drivers 
of risk. 
Model structure  
The model describes an average dog and the unit of time is one day. The rows in the spread sheet 
are days relative to the crossing the border (at day 0) ranging from 100 days before until 100 days 
after. The columns in the spread sheet represent different development stages of worms and also 
count the eggs produced in each time step. One column counts the number of prepatent worms 
infecting an average dog each day (as 1/90 of the maximum worm burden for a specific exposure 
area). Another column counts the number of immature worms maturing to adult worms each day (the 
number of infecting worms 30 days previously). A third column calculates the number of patent 
worms dying (the number of infecting worms 90 days earlier). A fourth column calculates the daily 
number of adult worms as the number of patent worms the day before plus the daily number of 
worms maturing minus the number of worms dying. Another column then calculates the daily number 
of excreted eggs based on the number of adult worms that day. This assumes the egg production per 
worm is always the same regardless of the age of the patent worm and also assumes that all eggs 
produced by a worm is excreted within 24 hours both assumptions are simplifications. A final column 
calculates the cumulative number of eggs produced by a dog, but only while the dog stays in a free 
area. This total number of eggs produced in the free area is the ‘risk’. 
In the model it is then possible to treat the dog at any day before or after crossing the border (equal 
to day 0 in the model). Treatment will affect both the prepatent and patent worms equally. Treatment 
is assumed to kill a proportion of the worms while leaving the remaining worms unharmed and able to 
produce eggs. While this and other assumptions are an important simplification of the biological effect 
of deworming it is likely to capture the key average effect. In the model, non-compliance is simply 
treated as another form of treatment failure.   
Model results 
The model distinguish between dogs being exposed for a full 90 day period and then visiting a free 
country for shorter periods and dogs being exposed for various periods less than 90 days and then 
staying a full 90 days period in a free area. Combinations of short exposure periods combined with 
short periods in a free area were not explored here. Figure F1 shows dogs with a 90 days exposure 
that then visits a free area for ninety, sixty, twenty, ten or five days. As the maximum lifespan of a 
worm is 90 days, a 90 day visit is equal to permanent import. When the treatment effectiveness is 
very high, the risk stems almost only from re-infection of the dog between treatment and entering the 
free country. The best time is to treat is day -1 as this prevents re-infection of the dog and ensures all 
eggs are excreted before crossing the border and therefore prevent excretion of eggs in the free 
country.  
When the dogs are exposed for 90 days and then stay 90 days in the free area, the risk after 
treatment is symmetrical over treatment days, in the sense that the risk is the same whether the dog 
is treated e.g. ten days prior to crossing the border or ten days after. The risk is symmetrical because 
treating dogs before entry will result in a few re-infecting worms that will live a long time in the free 
area, while treating the dog after entry will result in many worms that only live the short period until 
the treatment day. Thus, the number of eggs produced in the free area is the same whether the dog 
carries a few worms that live long or many worms that live short (figure F1-A). 
However, if a dog from an endemic area is going to a free country for a short visit and is treated 
earlier than day -1 this may not always affect risk. This is because potentially re-infecting worms will 
not be able to mature in the free area before the dog returns to the endemic country, as long as the 
dog returns within 30 after beting treated. If the dog is treated prior to crossing the border, the risk is 
therefore always smaller the shorter the visit is (left side of Figure F1-B to E). However if the dog is 
treated after crossing the border, the duration of stay has little importance as only the period until 
treatment allows for egg excretion. Only when the treatment effectiveness is low, the duration of stay 
after treatment will add to the risk. Hence at visits shorter than 90 days the risk is no longer 
symmetrical around day-1 (figure F1-B to E). 
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Figure F1.  Proportion of number of eggs deposited in a free area by dogs living in endemic areas 
and visiting free countries for five different duration scenarios. Different treatment days 
are considered. Treatment day -1 results in the lowest risk while treatment earlier than 
day -90 or later than day +90 has no effect at all. If the visit in the free area is more 
than 90 days then the risk is symmetric around day -1, so whether treatment is done n 
days before entry on n days after does not affect the number of eggs excreted in the 
free area. If a dog from an endemic area visits a free area for 60 days the risk is no 
longer symmetric. It is possible to treat the dog at any day before the visit to the free 
area or during any of the sixty days in the free area. However treating n days before 
crossing the border results in fewer eggs deposited in the free area than treating n days 
after crossing the border. If a dog from an endemic area visits a free area for 20 days 
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much fewer eggs being deposited in the free area compared to treating n days after 
crossing the border. If a dog from an endemic area visits a free area for 10 days the 
risk is very asymmetric. Treating such a dog day -5 results in minimal risk since any 
reinfecting worms in the dog will not be able to mature before the dog returns from the 
free area. If a dog from an endemic area visits a free area for just 5 days the risk is 
highly asymmetric. Treating such a dog later than day -25 results in minimal risk since 
any reinfecting worms in the dog will not be able to mature before the dog returns from 
the free area up to 30 days later. 
 
The risk is very different in the reverse situation where dogs from a free county are exposed for 
various short periods before returning home (Figure F2-A to D). If treated prior to returning the re-
infection risk is almost the same regardless of the duration of the visit. However, if treated after 
returning to the free area, the risk may be much lower at short visits because many of the worms or 
even all worms aquirred during the short stay in an endemic area will still be in the prepatent stage 
(right side of Figure F2 A to D). 
 
 
Figure F2: If a dog from a free area visits an endemic area for 60 days before returning to the free 
area the risk is also asymmetric. But now it is slightly better to treat n days after 
crossing the border than treating n days before crossing to the free area. If a dog from 
a free area visits an endemic area for 20 days before returning to the free area the 
asymmetric relationship increases. And it is now markedly better to treat n days after 
crossing the border than treating n days before. If a dog from a free area visits an 
endemic area for just 10 days before returning to the free area the asymmetric 
relationship increases. Treating such a dog five days after entry results in minimal risk 
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in the free area. If a dog from a free area visits an endemic area for just 5 days before 
returning to the free area the risk is highly asymmetric. Treating such a dog up to 25 
days after entry results in minimal risk since any acquired worms in the dog will be 
unable to mature before the dog is treated in the free area. 
 
Increasing the treatment window may increase the number of eggs deposited in the free area (figure 
F1 and F2). An increased treatment window from 1 to 5 days may also increase treatment compliance 
because it makes it considerably easier for the owners to plan the treatment during their travel and 
thus more likely to comply with legislation as it may be difficult to find a veterinarian in e.g. 
weekends. Increased compliance during this time period may thus counteract the increased risk of re-
infection. A mathematical equation has not been generated for the relationship between the size of 
the treatment window and the breakeven compliance level. The relationship will also be affected by 
the treatment efficacy of the drug as well the type of movement (permanent import or short exposure 
in endemic areas or short visits to free countries). Instead, the risk for six selected scenarios has been 
estimated (Tables 1-6 in Section 3.5.5.): 
x a scenario where long term exposed (more than 90 days) dogs were permanently imported 
into a free country (Figure F3 A),  
x three scenarios where long-term exposed dogs stayed 60, 20 and 5 days in the free country 
(Figur F3 B, C and D)  
x and two scenarios where dogs were exposed for 20 or 5 days before returning to the free 
area and staying there permanently (Figur F3 E and F).  
For each scenario, the risk was first calculated as a function of treatment day for three compliance 
levels ranging from 50% to 99% and then the results were interpolated for each compliance level 
(Figures F3). Only treatment prior to entering the free area was examined as present legislation does 
not allow for treatment after entering a free country. 
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Figure F3. Treating dogs early will increase risk of reinfection after treatment but may also 
increase compliance. The six graphs show the interpolated relationship between day of 
treatment and risk (number of egg deposited in a free country). The relationship is 
calculated for three levels of compliance ranging from 50% to 95%. If treatment is 
given earlier (towards the left of the chart) then the more eggs will be deposited 
(increased risk) and compliance therefore needs to increase to counteract this increase 
in risk. A) The dog is long term exposed and then move permanently to a free area. 
E.g. if the initial compliance at day -1 is only 80% then the risk is about 20%. If a wider 
treatment window is desired for the convenience of owners and the risk at the same 
time has to be kept at 20%, then treatment can be allowed as early as day -10 if 
compliance at the same time increases to about 95% since the risk is also 20% for 
treatment day -10 at a 95% compliance level. B) The dog is long term exposed in an 
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compliance needs to increase to prevent the risk from increasing, but not as much as 
for permanent import. E.g. if the initial compliance at day -1 is only 80% and risk is 
about 18% then treatment can be allowed as early as day -15 without increasing risk as 
long as compliance increases to about 95%. C) The dog is long term exposed and visits 
a free country for 20 days if the initial compliance at day -1 is only 80% and risk is 
about 7% then treatment can be allowed as early as day -31 without increasing risk as 
long as compliance increases to about 95%. D) The dog is long term exposed and visits 
a free country for just 5 days. E.g. if the initial compliance at day -1 is only 80%  and 
risk is about 1.8% then treatment can be allowed as early as day -40 without increasing 
risk as long as compliance increases to about 95%. E) The the dog is not long term 
exposed but only exposed in an endemic area for 20 days before returning to stay in a 
free area for more than 90 days. If treatment is given earlier then compliance need to 
increase relatively much to prevent the risk from increasing. E.g. if the initial 
compliance at day -1 is only 80% and risk is about 6.5% then treatment cannot be 
allowed earlier than about day -4 without increasing risk even if compliance increases to 
about 95%. F) The dog is only exposed in an endemic area for 5 days before returning 
to stay in a free area for more than 90 days. If treatment is given earlier then 
compliance need to increase dramatically to prevent the risk from increasing. E.g. if the 
initial compliance at day -1 is only 80% and risk is about 1.8% then treatment cannot 
be allowed earlier than about day -2 without increasing risk even if compliance 
increases to about 95%. 
 
The actual compliance levels for dogs entering the free Member States has been estimated to be 
between 40% and 80% in countries without border control (NO and FIN) and higher in contries with 
border controls (UK, Ireland). Therefore, three different suboptimal compliance levels of 95%, 80% 
and 50% were explored at the optimal treatment time (day -1). These compliance levels capture the 
problems and advantages of increasing the treatment window given that a wider window will result in 
better compliance. 
The increase in compliance required to keep the risk at the same level as treatment day -1 was 
calculated given treatment instead was applied at day -2, day -3, day -4, day -5 or day -6. Because 
the re-infection risk increases as treatment is given earlier, it is calculated how much compliance 
would be required to increase to at least hold the risk stable. This break-even point is presented in 
Tables 1-6 (Section 3.5.5).  
There are two conclusions regarding size of treatment windows, compliance and risk. One conclusion 
applies to dogs living in endemic areas and visiting free areas and another conclusion applies to dogs 
living in free countries and visiting endemic areas before returning to remain in their free countries: 
x The shorter the period a dog from an endemic area visits a free country, the more likely the 
risk is to break even if a wider treatment window will lead to an increase in compliance above 
the compliance level at the optimal treatment time (which is one day before entry). If the visit 
is so short that the dog from an endemic area will return within 30 days after being treated, 
then re-infection does not increase risk and therefore any improvement in compliance will 
actually reduce the overall risk of eggs being deposited in the free area. Increasing the 
treatment window may therefore be beneficial if this makes dog owners more likely to comply 
better with treatment regulations. And especially where the initial compliance is low as may 
be the case in countries without border control. 
x However, this only applies to dogs from endemic areas visiting free areas. Dogs living in free 
countries and visiting endemic areas for shorter periods before returning to their free 
countries constitutes a risk of egg excretion in their home countries that will require large 
increases in compliance to counteract the the reinfection risk resulting form an increase in 
treatment window. Increasing the treatment window from e.g. day -1 (-24 hours) to day -5 (-
120 hours) is therefore likely to increase the risk of establishment of the infection unless the 
initial compliance at day-1 is very low and the increase in compliance with a larger window at 
the same time is very high. 
The over all effect of increasing the treatment window for a specific country therefore depends on the 
compliance level before increasing the treatment window (which may depend on presence or absence 
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of border control), the resulting increase in compliance resulting from the increases treatment 
window, the proportion of dogs crossing the border that are either foreign or domestic and finally on 
the duration of exposure in the endemic area and the duration of stay in the free country. Thus if 
initial compliance is high (as it may be in countries with border controls) and travelling dogs are 
mostly domestic and only visit endemic areas for short periods then increasing the treatment window 
will increase the risk of introduction (but allowing treatment of domestic dogs after returning to the 
free country could keep the risk low even with a wider treatment window). But if the initial compliance 
is low with a narrow treatment window and compliance will increase with a bigger treatment window 
and the visiting dogs are mostly foreing and only visiting the free country for short periods then 
increasing the treatment window may be safe and may even reduce the overall risk while at the same 
time making travelling between EU countries easier for dog owners.   
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Appendix G – Diagnostic tests in animals 
SEDIMENTATION AND COUNTING TECHNIQUE (SCT) – Post mortem test 
Target: intestine of dead animals. 
Description: at necropsy, the intestine is removed, opened and incubated in physiological saline. The 
intestinal mucosa is scraped between two fingers, after sedimentation the worms can be counted from 
the sediment with a binocular microscope. The SCT is considered as the gold standard and it is based 
on identification of morphologic features of EM. Despite that the sensitivity is dependent on the worm 
burden as shown by Karamon and colleagues, (2010). They estimated the limit of detection of the 
SCT by testing samples of small intestines, experimentally enriched with known numbers of EM 
tapeworms. Forty samples containing 2, 5, 10 and 30 tapeworms were examined and EM was 
detected in 30% using two spiked adult worms, increasing to 40% (five worms), 60% (ten worms) 
and 100% (30 worms). These results show that the sensitivity of the SCT depends on the worm 
burden. The worms that were used for spiking the samples, however, had been stored in 70% 
ethanol, potentially influencing the SCT test. However using spiked samples is expected to over-
estimate the sensitivity as the quality of spiked samples is expected to be better compared to natural 
samples, also worms are more easily accessible in spiked samples where the worms are free in the 
lumen, compared to natural samples where worms can be located in the intestinal villi, finally it is 
easier to identify a small number of worms in a section of an intestine (spiked samples) compared to 
natural samples where the whole small intestine has to be examined. The detection limit of the SCT 
needs to be further investigated to confirm the reported results by Karamon et al., 2010. 
In high endemic areas, the worm distribution is skewed with a small proportion of foxes with a high 
worm burden (Hofer et al., 2000; Tackmann et al., 2001). The sensitivity of SCT might be lower in low 
endemic areas compared to high endemic areas.  
Moreover, bias of the investigators by overlooking worms cannot be excluded. Therefore, Eckert 
(2003) suggested a sensitivity for SCT of about 98%.  
Limitations: SCT is a time-consuming technique. The use of SCT is restricted to the examination of 
necropsy material with related costs to manage the carcasses. 
Approximate working intensity per person per day (according to Conraths and Deplazes, 2015): 50-
100 animals depending on worm burdens and quantification (necropsy included). 
Safety for laboratory personnel: precautions must be strictly followed when using this diagnostic test. 
Carcasses of definitive hosts from which samples are collected have to be frozen at −80°C for 7 days 
in order to achieve thorough deep-freezing and inactivate the eggs. 
SEGMENTAL SEDIMENTATION AND COUNTING TECHNIQUE (SSCT) – Post mortem test 
Target: intestine of dead animals. 
Description: Similar to SCT, but intestine is divided in 5 segments and 3 are selected for analysis. In 
SSCT the examination of S1 (or S2) and S4 segments have a sensitivity of 98.3% compared to SCT 
(Umhang et al., 2011). This method is able to detect pre-patent period. SSCT is suitable for routine 
examination of fox intestines for large epidemiological studies. 
Limitations: SSCT is an optimization of SCT because only selected segments (with higher probability to 
find EM) from the intestine are analysed, instead of analyzing the whole intestine. Reported sensitivity 
compared to SCT was 98.3% (Umhang et al., 2011) but sensitivity as lower worm burdens has not 
been reported. It remains a time-consuming technique, it is however less time consuming than SCT. 
The detection limit of the SSCT needs to be further investigated to confirm the reported results. 
Managing the carcasses remains costly. 
Approximate working intensity per person per day (according to Conraths and Deplazes, 2015): 
around 100 animals depending on worm burdens and quantification (necropsy included). 
Safety for laboratory personnel: precautions must be strictly followed when using this diagnostic test. 
Carcasses of definitive hosts from which samples are collected have to be frozen at −80°C for 7 days 
in order to achieve thorough deep-freezing and inactivate the eggs. 
INTESTINAL SCRAPING TECHNIQUE (IST) – Post mortem test  
Target: intestine of dead animals. 
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Description: fifteen deep mucosal scrapings are made from the intestines after necropsy. These 
scrapings can be performed with microscope slides. With (light and stereo) microscopy, the adult 
worms can be counted. The specificity of the IST is very high like the SCT because the diagnosis is 
based on the morphologic features of EM. In contrast to SCT, only small parts of the mucosa are 
investigated and therefore parasites present in low numbers may be overlooked. This method is not 
able to detect pre-patent period. In comparison with the SCT, the sensitivity of the IST was 78% 
(WHO OIE manual on Echinococcosis). This method is less time consuming compared to SCT and 
SSCT. 
Limitations: it is a time-consuming and expensive technique (but not as labour intensive as SCT). The 
use of IST is restricted to the examination of necropsy material. 
Approximate working intensity per person per day (according to Conraths and Deplazes, 2015): 100-
150 animals depending on worm burdens (necropsy included). 
Safety for laboratory personnel: precautions must be strictly followed when using this diagnostic test. 
Carcasses of definitive hosts from which samples are collected have to be frozen at −80°C for 7 days 
in order to achieve thorough deep-freezing and inactivate the eggs. 
 
SHAKING IN A VESSEL TECHNIQUE (SVT) – Post mortem test 
Target: intestine of dead animals. 
Description: SVT is a modified sedimentation technique to examine intestines for smaller helminthes 
such as EM (Duscher et al., 2005). The opened small intestines with all its contents have to be placed 
into the vessel. After filling with water, the vessel is closed with a lid, covered by a steel mesh. By 
shaking the vessel, the water was decanted out. After filling the vessel again, the process must be 
repeated until the decanted water was clear. After stripping the intestines between two fingers, the 
vessel with intestines was refilled and shaken again. The remaining sediment can be microscopically 
scanned for worms. No sedimentation is necessary which saves time, and the method reduces the risk 
to lose worms by the decantation process. The sensitivity was better than the IST to which it was 
compared in the study, and the specificity of the SVT is very high, like the SCT, because the diagnosis 
is based on the morphologic features of EM. When SVT was applied after IST, sensitivity resulted 
in 96.2%. This method is not able to detect pre-patent period. The detection limit of the SVT needs 
to be further investigated to confirm the reported results. 
 
Limitations: Very small worms can be washed through the sieve, worms can also be overlooked. 
Approximate working intensity per person per day (according to Conraths and Deplazes, 2015): 100 
animals depending on worm burdens (necropsy included). 
Safety for laboratory personnel: precautions must be strictly followed when using this diagnostic test. 
Carcasses of definitive hosts from which samples are collected have to be frozen at −80°C for 7 days 
in order to achieve thorough deep-freezing and inactivate the eggs. 
 
COPRO-ANTIGEN ENZYME-LINKED IMMUNOSORBENT ASSAY (cELISA) – Ante/Post mortem test 
Target: faeces. 
Description: fecal samples can be examined by ELISA to detect pathogen-specific antigens in the feces 
(copro-antigens, further referred to as cELISA). The excretion of copro-antigens is closely correlated 
to the presence of the intestinal worms. The detection rate rises with increasing worm burden. 
Deplazes and colleagues (1999) defined the overall diagnostic sensitivity of the cELISA in foxes with a 
known worm burden, as determined by using the SCT. The sensitivity of the cELISA ranged from 
40% to 100% in fecal samples of animals with worm burdens ranging from 4-20 to 520-60.000 
(REF)Deplazes et al., 1999) The overall sensitivity was 84%, with a higher sensitivity of the cELISA in 
fecal samples with a moderate to high worm burden (REF)Deplazes et al., 1999)  
The specificity against Echinococcus antigens is often reported to be high, but in the field, cross 
reactivity can easily occur with antigens from Taenia species or other helminthes. It is important to 
note that the cELISA can detect the antigens already during the prepatent period. Commercial test 
kits are available. In fact, comparing this method with conventional PCR on DNA (isolated directly 
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from the faecal samples and from the eggs obtained by the flotation/sieving procedure), cELISA was 
the most sensitive to detect pre-patent infections (63%; Al-Sabi et al., 2007). Samples from the low 
patent infections were positive in 77% by microscopy and in 80% by egg-DNA PCR, being significantly 
more sensitive than cELISA and copro-DNA PCR (Al-Sabi et al., 2007). The detection limit of the 
cELISA needs to be further investigated to confirm the reported results. 
Limitations: it can be performed in living and dead animals and is useful for population studies, but 
testing animals in areas with a low or unknown endemicity, the ELISA is less useful. In fact, this test 
has been shown to have high sensitivity when worm burdens are moderate to high, but the 
occurrence of false negatives when worm burdens are lower such as 50 or less worms (Allan and 
Craig, 2006). Cross reactions are affecting the specificity of the test.  
Approximate working intensity per person per day (according to Conraths and Deplazes, 2015): 500-
800 samples (for procedures see Sakai et al., 1998; Deplazes et al., 1999; Allan et al., 1992; Craig et 
al., 1995).  
Safety for laboratory personnel: precautions must be strictly followed when using this diagnostic test. 
Carcasses of definitive hosts or feces from which samples are collected have to be frozen at −80°C for 
7 days in order to achieve thorough deep-freezing and inactivate the eggs. 
 
DNA-BASED TESTS – Ante/Post mortem test 
Target: feces, eggs, worms. 
Description: Polymerase Chain Reaction (PCR) tests are used to detect EM DNA in fecal samples. At 
least three steps are included in the diagnostic procedure: DNA extraction, specific amplification of E. 
multilocularis DNA and subsequently visualization or measurement of the PCR products. Various 
methods exist for the different steps.  
Extraction of taenid DNA is the first step and it can be achieved in three different ways: 
1) Concentration of taenid eggs by a combination of sequential sieving and flotation (Mathis et al., 
1996). This method only retrieves particles of a size close to the size of taenid eggs. This means that 
detached parts of worms such as proglottids will not be detected. On the other hand the method can 
handle large sample sizes (3-20 g). After concentration, the eggs are digested by alkaline lysis and 
DNA is extracted. Often the extraction is done by using a Boom-silica spin column kit. 
2) Extraction directly from feces (Dinkel et al., 1998; Knapp et al., 2014) by the use of a general DNA 
extraction method, often Boom-silica (Boom et al., 1990) in the form of a spin column extraction kit. 
This method generally cannot handle more than a maximum of 0.5 g, but will extract all taenid DNA 
and also DNA from other organisms from the sample. 
3) DNA fishing method/magnetic capture: selective extraction of taeniid DNA by the means of a more 
or less specific hybridization probe connected to magnetic beads, Magnetic Capture (MC) (Isaksson et 
al., 2014; Øines et al., 2014). This method will also be able to retrieve taeniid DNA from other sources 
than just eggs, e.g. disintegrated worms. The probe will hybridize to the taeniid DNA target 
selectively, thus excluding the vast amounts of bacterial DNA present in feces. This method can 
handle 3 g of sample material, but could be automized and optimized to up to 10 g of sample 
material. 
In approach 1 and 3, more sample material can be used in the extraction with less risk of inhibition of 
the following PCR, thus potentially increasing the sensitivity of the test. The reason is that these 
methods in different ways selectively enrich the target, allowing more material to be used in the 
assay. The floatation method achieves the enrichment by concentrating taeniid eggs, and the 
Magnetic Capture method by concentrating the target gene itself from both eggs and disintegrated 
worms. The advantage of enrichment (besides potentially ‘catching’ more of the target from the larger 
sample size) is that a large part of the PCR inhibitory substances are effectively removed. Inhibition 
considered to be a problem when trying to do direct nucleic acid extraction from more than a few 
hundred mg of feces. A comprehensive comparison between approach 1 and approach 3 is presented 
in Øines et al., 2014. Since this comparison, the MC-PCR has been improved somewhat by exchanging 
one of the primers and by automation of the washing of the magnetic beads. 
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For as concern the methodologies to use for the DNA extraction, they mainly consist of classical 
phenol-chloroform DNA extraction from faeces (e.g. Bretagne et al., 1993; Monnier et al., 2005), 
commercial DNA isolation kits (Al Sabi et al., 2007; Jiang et al., 2012) or the DNA fishing 
method/magnetic capture (Isaksson et al., 2014; Øines et al., 2014). The second step is amplification 
of the target sequence by PCR-based methods. Mitochondrial DNA molecules are most important PCR 
target because of their amount present in several copies per mitochondrion, and total up to several 
tens of thousands of copies per cell. Examples of mitochondrial DNA targets are: 12S, 12S,nad1 and 
cox1 genes. An example of a repeated target sequence present in the genomic DNA is ITS1 which is 
present in hundreds of copies per cell. PCR-amplification performed on DNA extracted directly from 
worms should not pose any problems whatsoever regardless of the chosen assay. 
Furthermore, DNA amplification can be done in a single target conventional-PCR, a multiplex-PCR 
(Trachsel et al., 2007), a nested-PCR (Dinkel et al., 1998) or in a real time-PCR (Dinkel et al., 2011; 
Knapp et al., 2014). New techniques like the DNA fishing method/magnetic capture followed by real 
time-PCR show high sensitivity and high specificity, especially with worm burdens > 100 worms. It 
can be done partially automated, making it well-suited for nationwide EM surveillance programmes 
(Isaksson et al., 2014; Øines et al., 2014). The detection limit of the SSCT needs to be further 
investigated to confirm the reported results. 
An obvious advantage of using PCR is the possibility to use feces as sample. The saving of not having 
to shoot, transport and perform necropsies on foxes in order to be able to do SCT/SSCT is probably 
quite large, although no one has published data on this. On the contrary, the disadvantages of using 
faeces is the incorrect identification of the host species and oversampling same individuals. 
 
Limitations: due to the large variability in both the DNA extraction and the DNA amplification methods, 
it is difficult to compare studies with exactly the same PCR-methods. For this reason there are very 
sparse data about the sensitivity of the diagnostic tests. In general, when targeting a specific 
gene fragment of Echinococcus multilocularis, PCR can be highly specific. Some information are 
coming from Isaksson and colleagues (2014) that were evaluating the sensitivity of MC-PCR using the 
SCT as the golden standard. In this study sensitivity was evaluated as 88% compared to SCT 
positive panel, and 95.7% considering samples with more than 100 worms (Isaksson et al., 
2014).  
 
To increase the sensitivity, larger volumes of feces are required, but this is often hampered by the 
DNA extraction method. Inhibition of the PCR may result in false negative results, lowering the 
sensitivity of the PCR. A solution for this problem is extracting DNA of purified taeniid eggs or using an 
internal control (Mathis et al., 1996). PCR gives no information about the worm burden, though a Q-
PCR gives information on the (relative) amount of DNA in the sample. Even though there is a strong 
negative correlation between worm burden and Cq-value when using real time-PCR assays, molecular 
assays can hardly be called quantitative. This is most likely due to that immature worms do not shed 
eggs and that shedding of eggs is not continuous even for mature worms. 
It is important to note that PCR approaches usually haven’t a so high sensitivity because cannot 
detect pre-patent period with the exception of the above mentioned PCRs using DNA fishing. PCR is 
also a laborious and expensive technique (as far as SCT) but the automation of processes and the 
decreasing of the costs will enormously simplify the approach to this methodology in surveillance 
programmes on E. multilocularis. 
 
Approximate working intensity per person per day (according to Conraths and Deplazes, 2015):  
x Conventional-PCR or Multiplex-PCR withsieving procedure for egg isolation from faeces: 
40-80 samples depending on taeniid prevalence (for procedures see Mathis et al., 1996; 
Trachsel et al., 2007);  
x Nested-PCR for total DNA isolation from faeces: around 70 samples (for procedures see 
Monnier et al., 1996; Dinkel et al., 1998; Van der Giessen et al., 1999); 
x Real Time-PCR for total DNA isolation from faeces: 70 samples (for procedures see Dinkel 
et al., 2011; Knapp et al., 2013); 
x MC-PCR with manual DNA fishing from faeces: 70 samples (for procedures see Isaksson et 
al., 2014);  
x MC-PCR with automated DNA fishing from faeces: 240 samples (for procedures see 
Isaksson et al., 2014). 
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Safety for laboratory personnel: Precautions must be strictly followed when using this diagnostic test 
when using samples coming from definitive hosts (feces, eggs, worms). Samples have to be frozen at 
−80°C for 7 days in order to achieve thorough deep-freezing and inactivate the eggs. 
 
 
 
